var title_f20_33_21008="Figure of eight splint";
var content_f20_33_21008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Figure-of-eight splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For a figure-of-eight splint to be applied properly, the patient must be erect with hands on his iliac crests and shoulders in abduction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21008=[""].join("\n");
var outline_f20_33_21008=null;
var title_f20_33_21009="Elbow radiograph position";
var content_f20_33_21009=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Elbow radiograph position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiographic positioning. The correct method of taking a lateral view is with the upper extremity directed anteriorly rather than externally rotated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21009=[""].join("\n");
var outline_f20_33_21009=null;
var title_f20_33_21010="ECT stimulating electrodes";
var content_f20_33_21010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F77514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F77514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Electrode placement for electroconvulsive therapy (ECT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21010=[""].join("\n");
var outline_f20_33_21010=null;
var title_f20_33_21011="Diagnosis and treatment";
var content_f20_33_21011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Resistant hypertension: Diagnostic and treatment recommendations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 790px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagnostic and treatment recommendations for resistant hypertension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Calhoun DA, Jones D, Textor S, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21011=[""].join("\n");
var outline_f20_33_21011=null;
var title_f20_33_21012="Activated charcoal: Patient drug information";
var content_f20_33_21012=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Activated charcoal: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     see \"Activated charcoal: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     see \"Activated charcoal: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Actidose&reg; with Sorbitol [OTC];",
"     </li>",
"     <li>",
"      Actidose&reg;-Aqua [OTC];",
"     </li>",
"     <li>",
"      Charcoal Plus&reg; DS [OTC];",
"     </li>",
"     <li>",
"      CharcoCaps&reg; [OTC];",
"     </li>",
"     <li>",
"      EZ-Char&reg; [OTC];",
"     </li>",
"     <li>",
"      Kerr Insta-Char&reg; in Aqueous Base [OTC];",
"     </li>",
"     <li>",
"      Kerr Insta-Char&reg; in Sorbitol Base [OTC];",
"     </li>",
"     <li>",
"      Requa&reg; Activated Charcoal [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Charac-25 [OTC];",
"     </li>",
"     <li>",
"      Charac-50 [OTC];",
"     </li>",
"     <li>",
"      Charactol-25 [OTC];",
"     </li>",
"     <li>",
"      Charactol-50 [OTC];",
"     </li>",
"     <li>",
"      Charcodote Susp [OTC];",
"     </li>",
"     <li>",
"      Charcodote TFS [OTC];",
"     </li>",
"     <li>",
"      Charcodote-Aqueous Sus;",
"     </li>",
"     <li>",
"      Premium Activated Charcoal [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10086662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some poisonings.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691593",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease too much gas in the stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10086661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2717185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to charcoal or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2717150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: GI (gastrointestinal) bleeding or intestinal block.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10095140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10095424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10095426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10095136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2719642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Poisoning:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2719641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gas:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet or capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix powder with water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2722643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with chocolate, cola, or fruit juice to make it taste better.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10095139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it, after a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10095427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10113354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11566 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21012=[""].join("\n");
var outline_f20_33_21012=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149199\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149200\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10086662\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10086661\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10095140\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10095424\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10095426\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10095136\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10095139\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10095427\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113354\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=related_link\">",
"      Activated charcoal: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=related_link\">",
"      Activated charcoal: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_33_21013="Enfuvirtide: Patient drug information";
var content_f20_33_21013=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Enfuvirtide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     see \"Enfuvirtide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/39/6774?source=see_link\">",
"     see \"Enfuvirtide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fuzeon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fuzeon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to enfuvirtide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698303",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pneumonia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritated pancreas may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698687",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If anyone other than you is stuck with the needle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If solution is foamy or jelly-like, wait before using.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695220",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give this drug into clean, dry, healthy skin on the belly, upper leg, or upper arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11174 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-3918385851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21013=[""].join("\n");
var outline_f20_33_21013=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165005\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165006\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025367\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025366\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025371\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025372\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025374\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025369\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025370\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025375\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025376\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=related_link\">",
"      Enfuvirtide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/39/6774?source=related_link\">",
"      Enfuvirtide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_33_21014="Management of anticoagulants in patients undergoing endoscopic procedures";
var content_f20_33_21014=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of anticoagulants in patients undergoing endoscopic procedures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21014/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21014/contributors\">",
"     Patrick S Kamath, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21014/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21014/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21014/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21014/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/33/21014/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroenterologic procedures are commonly performed in patients taking anticoagulants. However, there are limited data assessing the bleeding risk of specific procedures in these settings.",
"   </p>",
"   <p>",
"    This topic will review the periprocedural management of patients taking anticoagulants. The management of patients taking antiplatelet agents, as well as patients with von Willebrand's disease, hemophilia, renal failure, liver failure, and thrombocytopenia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society for Gastrointestinal Endoscopy (ASGE) has issued official",
"    <a class=\"external\" href=\"file://www.asge.org/PublicationsProductsindex.aspx?id=352\">",
"     guidelines",
"    </a>",
"    regarding the management of patients taking anticoagulants based upon the available evidence and consensus opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/1\">",
"     1",
"    </a>",
"    ]. The recommendations in this topic review are consistent with the ASGE guidelines. This topic is also addressed in reviews and guidelines from the American College of Gastroenterology, the American College of Chest Physicians, and the American College of Cardiology, which make similar recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROCEDURE-RELATED BLEEDING RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, diagnostic endoscopic procedures are lower-risk for bleeding than are therapeutic procedures (",
"    <a class=\"graphic graphic_table graphicRef50700 \" href=\"UTD.htm?43/43/44731\">",
"     table 1",
"    </a>",
"    ). The procedure-related bleeding risk of various endoscopic procedures is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H3#H3\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Procedure-related bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK OF THROMBOEMBOLIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probability of a thromboembolic complication following reversal or discontinuation of anticoagulation depends upon the preexisting condition for which the medication was prescribed (",
"    <a class=\"graphic graphic_table graphicRef77634 \" href=\"UTD.htm?40/0/40971\">",
"     table 2",
"    </a>",
"    ). This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H4#H4\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Risk of thromboembolic complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ELECTIVE PROCEDURES IN ANTICOAGULATED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ASGE guidelines take into account the procedure-related risk of bleeding (",
"    <a class=\"graphic graphic_table graphicRef50700 \" href=\"UTD.htm?43/43/44731\">",
"     table 1",
"    </a>",
"    ) and the patient's risk for thromboembolic complications (",
"    <a class=\"graphic graphic_table graphicRef77634 \" href=\"UTD.htm?40/0/40971\">",
"     table 2",
"    </a>",
"    ). The guidelines are general recommendations and may need to be adjusted based upon the patient's stability and the estimated risk of bleeding related to the specific procedure performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H3#H3\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Procedure-related bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The guidelines recommend that elective procedures be delayed when possible if the indication for anticoagulation is temporary (such as deep vein thrombosis). The administration of vitamin K should be avoided since it delays therapeutic anticoagulation once anticoagulation is resumed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Low-risk procedures, high or low-risk conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;No change in anticoagulation is recommended for low-risk procedures, though we suggest that elective procedures be delayed in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    if the INR or prothrombin time is in the supratherapeutic range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     High-risk procedures, low-risk conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients at low risk for thromboembolism undergoing high-risk endoscopic procedures,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be discontinued five days before the procedure. The INR should be confirmed to be below 1.4 before the procedure. Warfarin can usually be reinstituted on the night of the procedure.",
"   </p>",
"   <p>",
"    Patients with normal renal function taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , an orally active thrombin inhibitor with a rapid onset of action (two to three hours), typically discontinue the drug one to two days prior to the procedure. Dabigatran can usually be reinstituted following the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H4559905#H4559905\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients in whom a sphincterotomy has been performed, the risk of bleeding persists for three to five days, and when sessile polyps are resected, the risk of bleeding may persist for more than two weeks. It is reasonable to delay attaining therapeutic levels of anticoagulation in these situations until five days or two weeks postprocedure, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     High-risk procedures, high-risk conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients at high risk for thromboembolism undergoing high-risk procedures,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be discontinued five days before the procedure, and bridge therapy should be considered. Similarly, patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    should have the drug stopped one to two days prior to the procedure, assuming normal renal function. We suggest consulting the clinician prescribing the anticoagulant to discuss the options for bridge therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H4559905#H4559905\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bridge therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bridge therapy may be indicated in the periendoscopic period in patients on anticoagulants who are at high risk for thromboembolic complications. The American Heart Association and the American College of Cardiology recommend the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial fibrillation &mdash; Bridge therapy is not required for a patient with isolated atrial fibrillation, but is recommended for a patient with atrial fibrillation and a mechanical valve, a history of a cerebrovascular accident or transient ischemic attack, or a history of systemic embolism.",
"      <br/>",
"      <br/>",
"      Patients with atrial fibrillation and a bileaflet aortic valve do not require bridge therapy, but should have their anticoagulant restarted within 24 hours.",
"     </li>",
"     <li>",
"      Valvular heart disease &mdash; Bridge therapy is recommended for patients with a mechanical mitral valve or a mechanical aortic valve with any of the following: atrial fibrillation, previous thromboembolic event, left ventricular dysfunction, hypercoagulable condition, mechanical tricuspid valve, or more than one mechanical valve.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    who require bridge therapy, warfarin should be held and unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    started once the INR is less than two. The heparin should be stopped four to six hours prior to the procedure and resumed following the procedure. Warfarin usually can be resumed the evening of the procedure. Once the INR is therapeutic, the heparin can be stopped. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link&amp;anchor=H19#H19\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\", section on 'Interruption of warfarin for surgical procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An advantage of standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is its short half-life, which permits temporary discontinuation should patients develop a bleeding complication.",
"   </p>",
"   <p>",
"    Alternatives to unfractionated intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    include therapeutic doses of subcutaneous unfractionated heparin and low molecular weight heparin. If low molecular weight heparin is used, the last dose should be given 24 hours prior to the procedure (",
"    <a class=\"graphic graphic_table graphicRef71508 \" href=\"UTD.htm?43/10/44204\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Low molecular weight heparin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An approach to bridging therapy for patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H4559905#H4559905\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low molecular weight derivatives of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    have a number of advantages over unfractionated heparin. In particular, they have greater bioavailability when given by subcutaneous injection, have a longer duration of action, and can be given in a fixed dose based upon body weight. Low molecular weight heparins (LMWHs) are at least as effective as unfractionated heparin for the treatment and prevention of venous thromboembolism and are also effective for patients with unstable angina. Patients receiving bridging therapy with LMWH should receive their last dose of LMWH 24 hours prior to the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/4\">",
"     4",
"    </a>",
"    ]. This recommendation is from the 2012 American College of Chest Physicians guideline regarding the perioperative management of antithrombotic therapy, and it differs from the ASGE guideline that recommends stopping LMWH eight hours prior to the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the expense and inconvenience of admitting patients to the hospital for intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , there is interest in using low molecular weight heparin on an outpatient basis for high-risk patients (",
"    <a class=\"graphic graphic_table graphicRef71508 \" href=\"UTD.htm?43/10/44204\">",
"     table 3",
"    </a>",
"    ). A decision analysis, for example, suggested that strategies involving low molecular weight heparin may provide a convenient and economical solution to the problem of anticoagulation in the setting of elective colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/5\">",
"     5",
"    </a>",
"    ]. At present, there are limited data supporting this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a therapeutic procedure, unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be restarted two to six hours later. The optimal time to restart LMWH after endoscopy has not been determined. However, for patients undergoing surgical procedures that have a high risk of bleeding, it is recommended to resume the LMWH 48 to 72 hours after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/4\">",
"     4",
"    </a>",
"    ]. The benefits of immediate anticoagulation in preventing thromboembolic events should be weighed against the risk of hemorrhage.",
"   </p>",
"   <p>",
"    While the use of low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the short-term appears safe, controversy exists over its use in patients with mechanical heart valves [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/1\">",
"     1",
"    </a>",
"    ]. The controversy is based upon the observation that fatal thrombosis of mechanical valves has been reported in patients receiving low molecular weight heparin for thromboprophylaxis. It has been seen in both men and women (pregnant and nonpregnant).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Alternative to bridge therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to bridge therapy in patients with high-risk conditions where the need for a therapeutic procedure is uncertain (eg, a screening colonoscopy that may result in a polypectomy) is to perform an initial diagnostic endoscopy with the patient on anticoagulation. If a lesion requiring therapy is encountered, the patient can be brought back for another procedure while the anticoagulation is held or reversed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     URGENT PROCEDURES IN ANTICOAGULATED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ASGE guidelines recommend that the risk of reversing anticoagulation should be weighed against the risk of continued bleeding without reversal and thus needs to be individualized [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reversing anticoagulation in acute hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fresh frozen plasma can be used to correct a supratherapeutic INR. In one report, successful hemostasis was achieved with endoscopic therapy in 91 percent of 52 patients with acute upper gastrointestinal bleeding after correcting the INR to 1.5 to 2.5, a success rate comparable to a control population of patients who were not anticoagulated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/8\">",
"     8",
"    </a>",
"    ]. Vitamin K is less useful than fresh frozen plasma in the acute setting because of its delayed onset of action (12 to 24 hours) and the prolonged time required to reestablish therapeutic anticoagulation after its use.",
"   </p>",
"   <p>",
"    There is no reversal agent for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Efficacy of endoscopic therapy in anticoagulated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from observational studies suggest that the success rates of endoscopic therapy for gastrointestinal bleeding in patients who are mildly to moderately anticoagulated (INRs of 1.3 to 2.7) are comparable to the success rates in patients who are not anticoagulated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Therefore, we suggest that endoscopic therapy not be withheld in these patients pending normalization of the INR. While data are lacking for patients with supratherapeutic INRs, we recommend that, whenever possible, attempts be made to lower the INR to 2.5 or less prior to endoscopic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Resumption of anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited with regard to the appropriate timing for resuming anticoagulation following endoscopic hemostasis, but they suggest that patients who resume anticoagulation have better overall outcomes than those who do not. If rapid resumption of anticoagulation is required in a patient at high risk for recurrent bleeding, initial anticoagulation with intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is preferable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    of low molecular weight heparin due to its relatively short half-life and the ability to reverse anticoagulation with fresh frozen plasma if bleeding recurs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H97407782#H97407782\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Risk factors for persistent or recurrent bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H1230806#H1230806\">",
"     \"Therapeutic use of warfarin\", section on 'Resumption of warfarin after bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study with 442 patients who had been on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and suffered a gastrointestinal bleed looked at the safety of resuming anticoagulation during the 90 days following the bleed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21014/abstract/11\">",
"     11",
"    </a>",
"    ]. After a median of four days, 260 patients (59 percent) resumed warfarin. Recurrent bleeding occurred in 26 of the patients who resumed warfarin (10 percent) and in 10 of those who did not (6 percent). On multivariable analysis, patients on warfarin were not more likely than those not on warfarin to have recurrent bleeding (hazard ratio 1.3; 95% confidence interval 0.5-3.6). In addition, patients who resumed warfarin were less likely to have thrombotic events (0.4 versus 6 percent) or to die (6 versus 20 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of bleeding from endoscopic procedures can be classified as high or low. In general, diagnostic procedures are low-risk, whereas therapeutic procedures are high-risk (",
"      <a class=\"graphic graphic_table graphicRef50700 \" href=\"UTD.htm?43/43/44731\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H3#H3\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Procedure-related bleeding risk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The probability of a thromboembolic complication following reversal or discontinuation of anticoagulation or antiplatelet agents depends upon the preexisting condition for which the medication was prescribed (",
"      <a class=\"graphic graphic_table graphicRef77634 \" href=\"UTD.htm?40/0/40971\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H4#H4\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Risk of thromboembolic complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For low-risk procedures, the American Society of Gastrointestinal Endoscopy (ASGE) guidelines suggest making no changes in anticoagulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest that elective procedures be delayed if the INR or prothrombin time is in the supratherapeutic range (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Low-risk procedures, high or low-risk conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients undergoing high-risk endoscopic procedures, we suggest discontinuing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      five days before the procedure and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      one to two days before the procedure in patients with normal renal function (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'High-risk procedures, low-risk conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bridge therapy is not required for patients at low-risk for thromboembolism. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'High-risk procedures, low-risk conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients at high-risk for thromboembolism, we suggest bridge therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'High-risk procedures, high-risk conditions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Bridge therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of patients taking antiplatelet agents is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=see_link\">",
"       \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other disorders of hemostasis that may require treatment prior to gastrointestinal procedures, including von Willebrand's disease, hemophilia A and B, renal failure, liver failure, and thrombocytopenia, are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21014/abstract/1\">",
"      ASGE Standards of Practice Committee, Anderson MA, Ben-Menachem T, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21014/abstract/2\">",
"      Kwok A, Faigel DO. Management of anticoagulation before and after gastrointestinal endoscopy. Am J Gastroenterol 2009; 104:3085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21014/abstract/3\">",
"      Becker RC, Scheiman J, Dauerman HL, et al. Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J Am Coll Cardiol 2009; 54:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21014/abstract/4\">",
"      Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e326S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21014/abstract/5\">",
"      Goldstein JL, Larson LR, Yamashita BD, et al. Low molecular weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: a cost modeling study. Am J Gastroenterol 2001; 96:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21014/abstract/6\">",
"      Johnson J, Turpie AG. Temporary discontinuation of oral anticoagulant: Role of low molecular weight heparin (Dalteparin) (abstract). Thromb Haemost (Suppl) 1999; 82:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21014/abstract/7\">",
"      Constans M, Santamaria A, Mateo J, et al. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int J Clin Pract 2007; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21014/abstract/8\">",
"      Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 1994; 35:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21014/abstract/9\">",
"      Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc 2003; 58:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21014/abstract/10\">",
"      Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol 2007; 102:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21014/abstract/11\">",
"      Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 172:1484.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2609 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21014=[""].join("\n");
var outline_f20_33_21014=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROCEDURE-RELATED BLEEDING RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK OF THROMBOEMBOLIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ELECTIVE PROCEDURES IN ANTICOAGULATED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Low-risk procedures, high or low-risk conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      High-risk procedures, low-risk conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      High-risk procedures, high-risk conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bridge therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Alternative to bridge therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      URGENT PROCEDURES IN ANTICOAGULATED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reversing anticoagulation in acute hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Efficacy of endoscopic therapy in anticoagulated patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Resumption of anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2609\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2609|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/43/44731\" title=\"table 1\">",
"      Bleeding risk GI procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/0/40971\" title=\"table 2\">",
"      Risk GI procedure conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/10/44204\" title=\"table 3\">",
"      LMWH ASGE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_33_21015="Clostridium difficile and probiotics";
var content_f20_33_21015=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clostridium difficile and probiotics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21015/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21015/contributors\">",
"     Lisa E Davidson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21015/contributors\">",
"     Patricia L Hibberd, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21015/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21015/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21015/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21015/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/33/21015/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clostridium difficile is an anaerobic, gram positive, spore-forming bacillus that colonizes the intestinal tract after alteration of the normal gastrointestinal flora, usually by antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/1\">",
"     1",
"    </a>",
"    ]. It causes a range of illness from mild diarrhea to pseudomembranous colitis and death. The frequency and severity of Clostridium difficile associated diarrhea (CDAD) are increasing, as are relapsed disease and infection refractory to standard antibiotic therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ). With increased morbidity and mortality associated with CDAD, new approaches for prevention and treatment are needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Probiotics are live, nonpathogenic bacteria capable of colonizing the colonic mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/2\">",
"     2",
"    </a>",
"    ]. Several probiotics are available over the counter and in health food stores. Most are sold in fermented foods or dairy products as formulations, including the bacteria species",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    or Bifidobacteria, which are part of the normal gastrointestinal microbiota [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/39/25203?source=see_link\">",
"     Saccharomyces boulardii",
"    </a>",
"    is a yeast (fungal) probiotic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/8\">",
"     8",
"    </a>",
"    ]. The role of intestinal commensal organisms in maintenance of the intestinal epithelium and immune system is an area of increasing interest [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/9\">",
"     9",
"    </a>",
"    ]. The alteration of gut microflora in the setting of CDAD has raised interest in a potential role for probiotics to restore a diverse intestinal microflora after disruption by antimicrobial therapy and CDAD.",
"   </p>",
"   <p>",
"    The role of probiotics for treatment and prevention of C. difficile will be reviewed here. The role of probiotics for antibiotic-associated diarrhea and other gastrointestinal diseases is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF PROBIOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics may be effective for prevention and treatment of Clostridium difficile associated diarrhea (CDAD) by means of several mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alteration of intestinal flora &mdash; The gastrointestinal tract is colonized by a complex balance of diverse microorganisms. Administration of antibiotics disrupts this balance and is a key factor in the pathogenesis of C. difficile colonization and disease. Patients with recurrent CDAD have markedly diminished bacterial diversity compared with controls [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/10\">",
"       10",
"      </a>",
"      ]. Most probiotics colonize the gut temporarily, producing bactericidal acids and peptides and promoting \"competition\" among microbes by competing for nutrients and epithelial adhesion. These effects appear to reduce the favorability of the environment for C. difficile [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. Both lactobacilli [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/14\">",
"       14",
"      </a>",
"      ] and S. boulardii [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/15\">",
"       15",
"      </a>",
"      ] have been shown to suppress the growth of C. difficile in hamsters.",
"     </li>",
"     <li>",
"      Antimicrobial activity &mdash; Bacteria in probiotic preparations produce acids that lower the pH of the local gut environment as well as toxins that inhibit the growth of other bacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/16\">",
"       16",
"      </a>",
"      ]. S. boulardii has been shown in vitro to secrete a protease that inhibits binding of enterotoxin A [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/17-19\">",
"       17-19",
"      </a>",
"      ], and Lactococcus lactis has been shown to secrete a cationic peptide that has antimicrobial activity against several strains of C. difficile in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intestinal barrier protection &mdash; The initial site of interaction between commensal and pathogenic bacteria in the human host is the gut epithelium. Probiotics may be capable of interfering with the binding of C. difficile toxins A and B to intestinal epithelial cells. In animal models and in vitro, probiotic strains have been shown to inhibit adhesion and decrease invasion of pathogenic organisms to the colonic epithelium [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/21-25\">",
"       21-25",
"      </a>",
"      ]. Specifically, Lactobacilli increase expression of intestinal mucins [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/26,27\">",
"       26,27",
"      </a>",
"      ] and decrease bacterial translocation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. Several probiotic preparations, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      rhamnosus GG [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/31\">",
"       31",
"      </a>",
"      ], Bifidobacterium breve [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/32\">",
"       32",
"      </a>",
"      ], and Streptococcus thermophilus [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/32\">",
"       32",
"      </a>",
"      ], have been shown in animal models to stabilize gut permeability. In vitro studies have also demonstrated the ability of S. boulardii to inhibit adherence of C. difficile [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunomodulation &mdash; Probiotics modulate both the innate and adaptive immune systems by stimulating toll like receptors (TLRs) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/34-36\">",
"       34-36",
"      </a>",
"      ] and upregulating cytokine expression in dendritic cells and peripheral blood monocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. Ingestion of Lactobacilli has been associated with enhanced phagocytic activity [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/39\">",
"       39",
"      </a>",
"      ]. In addition, several strains of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/40-42\">",
"       40-42",
"      </a>",
"      ], Bifidobacterium [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/43,44\">",
"       43,44",
"      </a>",
"      ], and Sacchromyces [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/45,46\">",
"       45,46",
"      </a>",
"      ] have been associated with increased IgA secretion in both stool and serum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     USE OF PROBIOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical role of probiotics for Clostridium difficile associated diarrhea (CDAD) treatment and prevention is an evolving area of study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/47-58\">",
"     47-58",
"    </a>",
"    ]. Probiotics vary in their capacity to resist gastric and bile acids, colonize the lower intestinal tract, and influence cytokine secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/24,35,59\">",
"     24,35,59",
"    </a>",
"    ]. Therefore, it is difficult to generalize findings observed with one probiotic species (eg, product, dose, duration) to other probiotic species or combinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevention of CDAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics may have a useful role for prevention of CDAD in some cases; their efficacy has been evaluated in three meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. In one meta-analysis including 20 randomized trials and 3818 patients, probiotics reduced the incidence of CDAD by 66 percent, which corresponded to a pooled relative risk of 0.34 (95% CI 0.24-0.49) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/62\">",
"     62",
"    </a>",
"    ]. These findings suggest that in a population with a 5 percent incidence of antibiotic-associated CDAD, administration of probiotic prophylaxis to patients receiving antibiotics would prevent 33 episodes of CDAD (CI 25-38 episodes) per 1000 people. However, the incidence of CDAD applied in this calculation is likely an overestimation; the risk is variable, but is likely closer to approximately 1 to 2 percent in some regions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The strain, dose, and duration of probiotic used in the above studies varied widely. Further studies comparing the different probiotic strains and standardized probiotic dosing are needed. In the meantime, if probiotics are used for prevention of CDAD, treatment should consist only of regimens with demonstrated efficacy (",
"    <a class=\"graphic graphic_table graphicRef50560 \" href=\"UTD.htm?19/44/20160\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12810765\">",
"    <span class=\"h2\">",
"     Treatment of CDAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics may also be useful for treatment of non-severe CDAD, particularly in the setting of recurrent disease, although data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Two meta-analyses published in 2012 evaluating the efficacy of probiotics for the treatment of antibiotic-associated diarrhea suggested a benefit of probiotics for treatment of CDAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], although few of the trials included were specifically powered to evaluate CDAD. Prior to these studies, the authors of a 2008 Cochrane review of probiotics for the treatment of CDAD including four randomized trials concluded that there was insufficient evidence to recommend probiotics as an adjunct to antimicrobial therapy for treatment of CDAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest that probiotics may be a useful adjunctive therapy to antimicrobial therapy for CDAD in patients with non-severe recurrent disease as long as there are no significant comorbidities. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus far, there are no data supporting a role for probiotics in treatment of severe CDAD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12811550\">",
"    <span class=\"h2\">",
"     Choice of probiotic agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of probiotics for prevention or treatment of CDAD should consist only of regimens with demonstrated efficacy (",
"    <a class=\"graphic graphic_table graphicRef50560 \" href=\"UTD.htm?19/44/20160\">",
"     table 1",
"    </a>",
"    ). Thus far, the cumulative data suggest that the most useful probiotic agents for prevention of CDAD include combination L. acidophilus and L. casei, other mixed species, S. boulardii, or L. rhamnosus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, a dosage of &gt;10 billion colony-forming units per day may be more effective than lower doses.",
"   </p>",
"   <p>",
"    Interest in the role of probiotics for treatment of recurrent disease was initially raised by a study of 124 patients with CDAD randomized to receive four weeks of S. boulardii or placebo (in addition to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/53\">",
"     53",
"    </a>",
"    ]. Patients with a history of recurrent CDAD had a lower rate of treatment failure with S. boulardii than with placebo (19.3 versus 64.7 percent). Among patients with an initial episode of CDAD, the failure rate was the same in both groups. Subsequently, a 2006 meta-analysis of probiotics for the treatment of CDAD including six randomized controlled trials involving 354 patients noted that S. boulardii was the only probiotic agent with efficacy for reducing recurrence of CDAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further evaluation is needed to fully evaluate the utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    for treatment of CDAD. Several small studies have evaluated Lactobacillus rhamnosus GG; although these studies did not demonstrate benefit, they were small in size and likely underpowered to detect an effect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/8,49-51,63,64\">",
"     8,49-51,63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics are regulated as a dietary supplement; unlike drugs or biological products, there has been no requirement to demonstrate safety or manufacturing consistencies of probiotics sold to consumers. Therefore, cases of probiotic-associated bacteremia or fungemia may be under-reported or difficult to assess from the literature.",
"   </p>",
"   <p>",
"    A small number of case reports describing bacteremia or fungemia attributed to probiotic administration have been reported, although none have been noted in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/65\">",
"     65",
"    </a>",
"    ]. The probiotics most frequently associated with adverse outcomes are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/39/25203?source=see_link\">",
"     Saccharomyces boulardii",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    rhamnosus GG [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. In most cases, patients who developed bacteremia or fungemia in the setting of probiotic administration had severe comorbidities, were on immunosuppressive medication, had recent surgical intervention, or had recent prolonged hospitalization. Of note, two cases of S. boulardii fungemia occurred in patients not receiving probiotics and were attributed to transmission by healthcare workers caring for patients who were taking S. boulardii [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of probiotics in the setting of pancreatitis has been noted to increase mortality due to bowel ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21015/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link&amp;anchor=H15#H15\">",
"     \"Probiotics for gastrointestinal diseases\", section on 'Pancreatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/47/28402?source=see_link\">",
"       \"Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=see_link\">",
"       \"Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Probiotics are live, nonpathogenic bacteria capable of colonizing the colonic mucosa. The alteration of gut microflora in the setting of Clostridium difficile associated diarrhea (CDAD) has raised interest in a potential role for use of probiotics to restore a diverse intestinal microflora after disruption by antimicrobial therapy and CDAD. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mechanisms of probiotics include alteration of intestinal flora, antimicrobial activity, intestinal barrier protection, and immunomodulation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of probiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients receiving antibiotics who are felt to be at increased risk for CDAD, we suggest coadministration of probiotics for prevention of CDAD (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Factors for consideration include prolonged duration of antibiotic therapy, local incidence of CDAD, and individual patient characteristics. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevention of CDAD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link&amp;anchor=H4#H4\">",
"       \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Further studies are needed to compare the probiotics strains and dosing. Regimens with demonstrated efficacy are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef50560 \" href=\"UTD.htm?19/44/20160\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12811550\">",
"       'Choice of probiotic agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT administering adjunctive probiotics for routine treatment of CDAD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Use of probiotics may be reasonable in patients with recurrent disease that is not severe, as long as there are no significant comorbidities. Regimens with demonstrated efficacy are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef50560 \" href=\"UTD.htm?19/44/20160\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12810765\">",
"       'Treatment of CDAD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A small number of case reports describing bacteremia or fungemia attributed to probiotics have been reported;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/39/25203?source=see_link\">",
"       Saccharomyces boulardii",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      rhamnosus GG are the most common organisms. In almost all cases, patients who developed bacteremia or fungemia in the setting of probiotic therapy had severe comorbidities, were on immunosuppressive medication, had recent surgical intervention, or had recent prolonged hospitalization. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/1\">",
"      Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008; 46 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Agriculture Organization of the United Nations and World Health Organization. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Available at: ftp://ftp.fao.org/es/esn/food/probio_report_en.pdf (Accessed on November 19, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/3\">",
"      Saarela M, Mogensen G, Fond&eacute;n R, et al. Probiotic bacteria: safety, functional and technological properties. J Biotechnol 2000; 84:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/4\">",
"      Heller KJ. Probiotic bacteria in fermented foods: product characteristics and starter organisms. Am J Clin Nutr 2001; 73:374S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/5\">",
"      Mattia A, Merker R. Regulation of probiotic substances as ingredients in foods: premarket approval or \"generally recognized as safe\" notification. Clin Infect Dis 2008; 46 Suppl 2:S115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/6\">",
"      Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr 2001; 73:465S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/7\">",
"      Tuohy KM, Probert HM, Smejkal CW, Gibson GR. Using probiotics and prebiotics to improve gut health. Drug Discov Today 2003; 8:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/8\">",
"      Edwards-Ingram L, Gitsham P, Burton N, et al. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol 2007; 73:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/9\">",
"      Surawicz CM. Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2008; 42 Suppl 2:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/10\">",
"      Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/11\">",
"      Orrhage K, Sj&ouml;stedt S, Nord CE. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother 2000; 46:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/12\">",
"      Hopkins MJ, Macfarlane GT. Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 2003; 69:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/13\">",
"      Wullt M, Johansson Hagsl&auml;tt ML, Odenholt I, Berggren A. Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea. Dig Dis Sci 2007; 52:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/14\">",
"      Naaber P, Mikelsaar M. Interactions between Lactobacilli and antibiotic-associated diarrhea. Adv Appl Microbiol 2004; 54:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/15\">",
"      Elmer GW, McFarland LV. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother 1987; 31:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/16\">",
"      Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003; 17:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/17\">",
"      Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/18\">",
"      Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/19\">",
"      Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996; 64:5225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/20\">",
"      Rea MC, Clayton E, O'Connor PM, et al. Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol 2007; 56:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/21\">",
"      Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/22\">",
"      Gopal PK, Prasad J, Smart J, Gill HS. In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. Int J Food Microbiol 2001; 67:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/23\">",
"      Bernet-Camard MF, Li&eacute;vin V, Brassart D, et al. The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo. Appl Environ Microbiol 1997; 63:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/24\">",
"      Kalliom&auml;ki MA, Walker WA. Physiologic and pathologic interactions of bacteria with gastrointestinal epithelium. Gastroenterol Clin North Am 2005; 34:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/25\">",
"      Hudault S, Li&eacute;vin V, Bernet-Camard MF, Servin AL. Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium C5 infection. Appl Environ Microbiol 1997; 63:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/26\">",
"      Mack DR, Michail S, Wei S, et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999; 276:G941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/27\">",
"      Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/28\">",
"      Dong MY, Chang TW, Gorbach SL. Effects of feeding lactobacillus GG on lethal irradiation in mice. Diagn Microbiol Infect Dis 1987; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/29\">",
"      Naaber P, Mikelsaar RH, Salminen S, Mikelsaar M. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J Med Microbiol 1998; 47:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/30\">",
"      Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004; 286:G613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/31\">",
"      Isolauri E, Majamaa H, Arvola T, et al. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 1993; 105:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/32\">",
"      Terpend K, Blaton MA, Candalh C, et al. Intestinal barrier function and cow's milk sensitization in guinea pigs fed milk or fermented milk. J Pediatr Gastroenterol Nutr 1999; 28:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/33\">",
"      Tasteyre A, Barc MC, Karjalainen T, et al. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathog 2002; 32:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/34\">",
"      Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/35\">",
"      Lan JG, Cruickshank SM, Singh JC, et al. Different cytokine response of primary colonic epithelial cells to commensal bacteria. World J Gastroenterol 2005; 11:3375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/36\">",
"      Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/37\">",
"      Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr 2001; 74:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/38\">",
"      Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006; 343:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/39\">",
"      Gill HS, Rutherfurd KJ, Cross ML. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J Clin Immunol 2001; 21:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/40\">",
"      Kaila M, Isolauri E, Soppi E, et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992; 32:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/41\">",
"      Link-Amster H, Rochat F, Saudan KY, et al. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 1994; 10:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/42\">",
"      Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995; 20:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/43\">",
"      Fukushima Y, Kawata Y, Hara H, et al. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol 1998; 42:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/44\">",
"      Yasui H, Shida K, Matsuzaki T, Yokokura T. Immunomodulatory function of lactic acid bacteria. Antonie Van Leeuwenhoek 1999; 76:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/45\">",
"      Buts JP, Bernasconi P, Van Craynest MP, et al. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 1986; 20:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/46\">",
"      Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/47\">",
"      McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/48\">",
"      Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008; :CD004611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/49\">",
"      Biller JA, Katz AJ, Flores AF, et al. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995; 21:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/50\">",
"      Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987; 2:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/51\">",
"      Bennett RG, Gorbach SL, Chang TW. Treatment of relapsing Clostridium difficile diarrhea with Lactobacillus GG. Nutr Today 1996; 31:35S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/52\">",
"      Schellenberg D, Bonington A, Champion CM, et al. Treatment of Clostridium difficile diarrhoea with brewer's yeast. Lancet 1994; 343:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/53\">",
"      McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/54\">",
"      Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/55\">",
"      Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005; 54:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/56\">",
"      Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc 2001; 76:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/57\">",
"      Wullt M, Hagsl&auml;tt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003; 35:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/58\">",
"      Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000; 95:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/59\">",
"      Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol 2000; 95:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/60\">",
"      Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012; 307:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/61\">",
"      Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 2012; 7:e34938.",
"     </a>",
"    </li>",
"    <li>",
"     Johnston BC, Ma SS, Goldenburg JZ, et al.  Probiotics for the prevention of clostridium difficile&ndash;associated diarrhea: A systematic review and meta-analysis. Ann Int Med 2012. https://annals.org/article.aspx?articleid=1390418 (Accessed on December 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/63\">",
"      Belet N, Dalgi&ccedil; N, Oncel S, et al. Catheter-related fungemia caused by Saccharomyces cerevisiae in a newborn. Pediatr Infect Dis J 2005; 24:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/64\">",
"      Graf C, Gavazzi G. Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation. J Infect 2007; 54:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/65\">",
"      Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/66\">",
"      Mu&ntilde;oz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21015/abstract/67\">",
"      Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:651.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2705 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-11633CD92E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21015=[""].join("\n");
var outline_f20_33_21015=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF PROBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      USE OF PROBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevention of CDAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12810765\">",
"      Treatment of CDAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12811550\">",
"      Choice of probiotic agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2705\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2705|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/44/20160\" title=\"table 1\">",
"      Probiotic regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/47/28402?source=related_link\">",
"      Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=related_link\">",
"      Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_33_21016="Acral erythema on the hands";
var content_f20_33_21016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79857%7EONC%2F77501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79857%7EONC%2F77501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Acral erythema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral erythema is present on the hands in this patient with acral erythema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acral erythema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 306px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEyAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDptoZDu46dsd+9QXFsy4JwFI4HYmiNtj7mOSfy7dfyq7NEGQOXPqccgda+fsmj7de6zCuLb5iyjA7kipY4Q6puO3ccZ9BWulogVhncT1HbvVMRGGYoF6/dBFRy2Lc+ZGYIntriZCd7HgE9qiB5bzOvc1fneN2Enlnco2+xPcfhWfMd7NnIOeMCmKEebcQTGNMqBk/qKfE7uAFxkdzgVUByzcZOf0qWNSMNg45IB9f8ilc6FCxqW5Dr88oA7AcnNTzJaKu+e7RSD/q40Ltj19M1mCPKbwyqAM884+lQ+fv+WQZx2HqO9VcORvVMvXF1ZKQsFq8hwFV5JOAe/AHSqk1y7cpDEgJIBC8dPXmoRIryM0nyr0wKC6btoyvAPB4FJsvkSOf8R20xK3UQ/eQEOD0J9qrQ3kOp3E89qoKyBOCejdCD75rtGiSSJogiNz83y9q83vbX+wfE8cgVjbXTZCA4w3rmnF9DGcrO5pLa+ddSMP8AVLLyQOvNTafaKqMzKOcNwPWrcPly2U0sDsEe5wp6Zxk/4VZtYisUoIwAoyfxFJo059C/b226FWSPeR1HOQa0YrQOGMluzqRyyPgqfyqKCPhtmWZdp9ODV21Z2RyEC8gYHemkc8myCa2tfLG+0uuf4hKD09eKz5IohKTDFIsY4O9ga6q2jkkTYDFGQv8AFux69vWle0kdHC2lpNg4LANn9DVKFyY1uV2Zyat2JdR13Z6VblSSa6QKGkRhldvpWvLaF18uK0WIgYIE27H5j/OKZDAr3MeYmAUHcBwd2OOlWoFyqXVzIntGZ/niILYClf51j6fA9vr8kbqoLAZ9Onv9K7m8gEWnxS+Wq8qWyxY/n269K53WrIWesRyspAkXkj1Bye/vVThZEQlzaEdxbZkQldqA5PY/5xSC3KmRWZcq2FB7rzzVicHeXHmH2A79qbcuZJ5WQOfM+YEjkHI7DpWFikmZ8VqsN0zxn55FBIUE5NdNpcDfI5WY7TjGB2z61mQrE7RCWZgfLGDnoQSP5Vu2Mg+UZJAUgADOR1rSklcqrJ8tjUhUGLJUDHTLklccjjjkY7dq0rBsrkkFdwJ64988dv61Qt2bzAYlxknBc7cHHB4q7bXax4V2VQRkqg4B9QfT1rsjY8yqm1YuatARJFclVUhTkr0HHY/XFQ3cKefbiNsqtsoyex3/AOJ/Wpr+5D6XcQE5Zh8h449v/r1gz36vawndu+QAg8HryKcmkznp05St5F+Y5trmONAu/bheu35jke3IIptkqyl2jf5+mF6g+oFZwu5BIWydjqAx7MR7e/X60k94Ez0Vv720YzS5lubqi9kbstwm1Yw6AlWUjGAcEcVXYLuDyeZIMDC7Q2PrWDPq2Vfg5AABAP8AjVdNRDvlCAVPQk9P8+1HtUCwzR0U0haIBECtuOD1wPrVR7pSGKPuUcMBjH+FZr6sWOAT93AUHGeaoSakGdUkH3DjB7Drwf8A9VKVVdC4Yd9TVkndpARtyOVB79hWa5MEzEYLvy3HBJqC5uY7gjYyjnJwOW+tRTXcaKVkUhTx15rGTudEYWKty4jYSOMFueO/sKr3DxpEVU4c/MSPXrRdXMIOBgt/ebn9azLqcIu5yvJ6E1izoXmV72XEbHjvj3rQ8Ay+V51w4wsknB/3axYobvW7hoNHtpLiVQWZh91QO5PStLQNNuLS3toheKjuWLBhjkHnqOlYzZjV9/3Uevad4n85SIoiTGduO3Suf1e9k1HXJLtcJcSBbZBnKPgYOPQ/Wsy0juTbyRsxidyEBU4Kp3fA/mK04ofKimudoJVRFDE3WU44YHufyrNzlJWbOOlhoUpOVtS5o7eRNKtyGe1yYEcHDRv15H1HWuk0OW2kju4LsN5sUe1wRhsk5yD61i2scURilkbbbw4wxO0SSnA2MRwcetbDwI3l2suCULTzNITuTP8ACfUH1pw01M69pCjTCsckcE4mjtYPOEcnO9iTwx7iqggHkwB91usoEtxIOVjHYE/3aEmktWxG5je4PzIzFhDGMAfQdeTU1nqIt3uRqCSqs8ZjRVXeir0HI7Ec807Rexn768yteyvdCBFVG8w7QAdwWEH72PQ+oqOe4VrqW4twkMShYLZVbMbyt3wOQfetHTrHfYTywrNFcquLORDlQvTgVXltnhskmdBNBZljuiI3CQdZAOuM9RT5Xuw5op2XT+v+B95Q1GRtNu3S6VS1mQJnByrzN93JHpx1pDbsY4LBy+45u75nPGByMnGG/GprSDdKgYmQLGb26Cr/AK/+6c9z7HNV1eeeER+Y4utTkyJQo/dRDqDzgD2GDSL/AK/r8X9xzcThYv3nIzgkj61q2crGMxkL7H86ptAW3NkMM5A/z9aktUKsqEjjnPJx0rVNpnpNqSNvyePvbc9QOc89qzNRj25mQcoMggHOa27dllI3sD0VsnpzUN1bKYyGBwB61rJXWhzQqcstTjrzdHPscEj72Cfuk9aqTbQ3yk881cvTElxh8IrcA9M56fjVGcMV2t9QR3rnZ6VMjK7mJB6dcdadAgcBMsBnBFMGd+Ao54FWElK5woJ78c0I2fkTCLbAQ/IHOCDz0qhO0pVUGEU8+lbds24gMQD/AAhRz+P51NJBBCd8kaTMuTtY/L+Jq+W5CqcrszEtLZBai5uZUhgztXAJdz14FPkvNPjRhb2ckjA8STyj/wBBH+NWJ43nk3OpJVem3hV9h2qGTT+8xjgGBtRjy30Aos+g3JPWTEjlZwzAiVjx8q8H0A78ent3Fcz4kg+1WquV3TRMJE9eDXTfZ2iiZAsi7vlVG5H1GKytSVidsrbnXBDeppWsQ0paHPaReNd2sYiZ2VrmQ7D6kcZH96umtxIlhJICDmVUOD2IzyPwrkbYpYXt5DuWPcwuIiV4JAIZfbsa6e3nHnvDj7pGTnkn3/xrRrqYRk/h7G1YDbHeHdhgFIz/AL31q5bGNogrqTICSD+NU7adXjuCQ6syImD3wR3/AA/Spot2Bg4XuRyfX86SQmbVtFCUDvGMKRkDcWP5fpVqOxh2vKrzop9ZCpx9KzEkYu2+YBQOSO31q7/aCOpzI95KuPkjBVMY6+ua2hbqYSUuhs26QxOEjjkZ2zhnZirfiehqleWLQ3hlRQQcl9nIIB6fX/Gq9tqjnasm3djjccHH0P8AnvV2W9jcOAN23AUDjA69fWuhOMkY8s4spTRMbKWJmbKtzwMAZ4P1ql4xiwlvcLtAhlC7eDkMoqe6uXMTEBdsqYLDnp0/EYqnd3yXVhMrIGYhSeR1FZykrNG9OMlJSM543yjxxkNt+UBssQO+KSMK8zsFlQngMA3BAyBj6EVE7KqKx+faeu7qPT9aWWW3gkjLNIm4EEr3IPGefT+Vc1jrRctwyrGJGlAQnB8voDz1I9q1Q5kWJh5hbaQGHY/y7iseGXCGNDKSwyB39hwKuWkzyEskbIFXJz15HP8AjVxdjKeuprQD/RgpIPqrZJ/Oni8aNV+ZAuMDnkflWfLIEHEoz0+9z+lUJbrC+XuG4HAJ5qnUaMOVPc15b790RuyG547VjPOqSMituA5H+FZd3emBXy/TqOoA+tYeo65bQBT5q7hkgA5qHJs1UYo61bxTg+YFPTnn6cUjajtAEmWGN2Ce3cVwVtfX1ygNhY3dwjSbVYRnBPpnpU5svEVysu6yS2SAhX8+UAjPTjrR7Swm4nQX+qWztIUUjc2QM9R+FZ/9psmRuAHoKY3g/U8ut3qFtGEALeUjP2/h6ZqWTwKJkKz6vO3l/eFvGqhiegUk81HOh+0tokLHrUAj+eQDjjJzVC5122STKyBVBzwetadv4C0m1jE11b3V/sIZ0acjK5xgAYye+K2rDwt4eaaWSPSYEhX52GNzKnYjdnvSdRMXtLanFW/iKEM+6ZQp5HNPfWFutwignmZV3sI42baPU8frXo8emxpZyGGC2CMSzMIlTzFXovA6094swRtLuhMqqWcHACZ4VvbrzU+08gdVs87h07XNQ2C3sfsyPH5qyXDhflHfHWtTTPCCXC251e8mmmlJYRRL5cWwdcnrn64rtGsRO7sBxchUH7zmJOu4e3Ap3lyTyyNHs82VhFEhGPMjXgt6596iUmyHVbKdgkkFgqWEaqjnEXlgRmNRxhsevr3rQW0iu9OC3iR+ZICuHAHlqP8AH1qzFCd0kiB9rstrGwTP1DAfzIq8lqzpJHAFOwCCEAglPU5H3hUownVRFaaFHc6e8lrI8cqkLagcgDp37davrpUiF3MJmishuEaDPzYxuXP8qiVFtnkmAljFoAkQjYAE45Zex59eanN9d2ahVV5k8rdOxIBcnkKB65qrROaU6jejv/X9feJZi3JhjeQvFAnnSnG3zpD04PccUiRyyTfvJJd7gzOxbIKL0jb0qy/2e7iigeQqJv3zwtjcG9M9uwqC/wBPuILko7rN5n7ycMdpwMbQD2P86bi0iFNN6uz/AK/r7iC5uC5hJXYl0dpkXDGFOu1+4X3qKSaZlAhjkZZh5cZLDECjqT6qfxq9f2s8VwTKltHNekIzKM74wOR6Aj6VTmlCI8kT7pJv3FmwjwxHcNnjPv8ApUNNFRadrf1/X6ElxM8QE9s8lqIiIrdC4KI/QuB3X+VW11KXSwi6jZFxBGDcSR42Ox6HHXHqazspA7mWUG30xfL5i+cTN29CD+FJA0ZnS2ldY3iH2i6jCnKE8jg/w47VcZNaoUoKS1X9f1+LNObTovsqtCQDfv58sqtjYRztA9MdKzr+CcW89zJEqpc4t3aE/NEB/EAf5dKZcTLMjRbzE9zkogYkQqf4xkcr+WKtyahfCyjt/siyopECSQkFpM8eYB6YofKxJTjb+v6/4BkNG00PEGVK4I9AMDP6VWmt2hIdQoC5BG7qOlaD5JXOQuZPkQ8gZHr9TST26Rou63cMDg45zyQSfTtXVKFzshOxFayMqrsyQ3PI6c1au42kt2iVipKHHtxxVOMgSjynkeNm+YY4x/kCtYfeUtkqUIxj8KUFpZiqOzuef38ZM8JkJO6IMMjoc/8A1qqyxkRkrkD0xWvPGd0TNGTmHHHoGYVSkwd6kYOSOO3sKwsepTloVrGLzQRtwT/eNXlsweSBnA3YYe3A96ppGzHgjk8j34rYs4pV2sScccEZz06VUY3KnJrVMrBAknCEZOMdewq3DHutdiOVLHbj04J4qygOVzw5Qc5wDwKu2qoI9zxliDgKTgE8jr37c1pGGpzzqaXKF1EwyApCrwxbg7jz27Dmsx4yX+dWVm+83t/kVvLAUKKxYlgDlm6k4/xNSLp5l2gYAzgknJ/zw1VyNkqqo7mJZRvE7bBuVhhWwCSM9v8AA9eOnWqWuwGeGOVQ3CnII68/ewf8fxrq73T9qhCh2EEBsfp/+qsJnb7TiVmeJuHHGSMY/OlKPKrMqE+d8yPMvF2meZZ+ZGB50RDJ74NWdJ1U31tHcwJGj7QsiqMbT0Jrptb0pow/OU6AnuPWvOr4yaDqvnpj7LPww7I3r+NKP8rHOy/eI73TrtCmx2y4PL/QHp61oW9w8kaCMRvnqNwU1ytoUkiSRQVZjubB4yf5Vd85SjdTjgHp/wDrqHoWoKWqN+ZxGrl4HBUkElc7fx6GqbTmVg0QfavUkggfSq0F7c2ygxXMiq+AQrlR+Iqw2pyXUXlSxwyqSTvEK7sn3HNFylFomhvJ45Qjqk6r82488Vpi8ZYSJMID/wAs/wCLnv7Csa1iKqGRcY6BuCPwNS7VBIQkyHjIPSmnYUkmaazjax3gHOOTWb9paKQqoZsZUgdMUJGxBzyAeQD0+lTBY1cH7pYYJPWncyk0iAySxKgidl9Co60yaSaVNjszOOQc9xTVlUkwnovA9x61FLcRw9NuQCQSaCfaLqXraZiN88s7YGdqnn8SagudTWHcT8kY6ZfP+FcnrHiRoZlgtiJZ3+VY4xlmPsBWtpngXW764s5/FLPaWcwytrA37w9/nP8ACMfU0basxlWV7Iin8XRQsI7cmR1/hQZJ/AUsEXiXWJYGtbNbKGRsCa6OwD8OT+leg6X4dtLBmGlQQ2p6RfulZgO+5jyc+uauJbSlv3Zky58iEvwIz3JHXBqHPsZubZxK+CCsv/E01ua8OcSJaR7EHtuOSf0rpY/Dvh2xu7aXRIIGZ02nzQXYN7k+/pXQ2lrIiO7AKbdzFGq7TwTjd7r7VLFpNuFmV413Q5bfEBkOe49V9u1Q25aE+0Sd7mfc2BivBDlZkQbiBwHc46j19xTBZKkYaQGR4Dw0w6sTwreo9639N08W9yTctJcFFDzlR3xwV9QPSrtm8bXM0V6F8sqXXgbXJH8wO1Cg2ZyxFvM5FbP7MGO1o4YZPObaMmOU9B/u+4qY2UsEoa4RJCoMs0YwBJJjqmK6XSbW1nhKrMIhCrSKWAPOeAx7jHapLPT2ltvMkihJtm85hEcHcehX0+nSkosmWISvc5eKwZ/IRidpBmkkJ+Vz6N3BA71NDaM80bsm1sF5DnlU6AN3IPrWzFDKYVkkYYndpJtyYR15wMfwtx1702ZGdYSrsqyAZkzjYg52MPehIHVb0MprLKNCkeY8GXacnygffuPepoVhGjTwTrtZlAR9u7co9ParSu4GxQ0X2l8srN88C+o/2SBSNNtG6MBZpMQwLnPyj+NfQ/zppdROTehDBFZTafK6kpKTsjZeCqgdvTJqzFpxNpcywNmS3wqow2g8csp9agkmR03sFdXYQQbQQJGH3j/snrSTrKsQFlcyKsJ8lFlJKu55O7uDn8KLLqS3LoyVo0hlDOHHyeWm5SVZj1b2b3pwKW0gkgVPNgUQW8rdS5HOe+fxqZbuGIR4ldYUOyUn5lRycE5pt6lsuo5Rmhgt4vlwMiRz0z70cttUTdt2ZVNzDC7Qq/nQWfNwBH86ytyCP/1VXEagujqwk/4+rhQoxJ/dx23e1W7rzLed7OVZJIsCVmLf6w9ge/41UcIJnhvJvJLv9plaXJ2jjCg+n51L3Ljtdf1/X+Q6aIvIhlkAklPnyYjwQo6L1yGqVbm/82NzOZlmdSnnIQQo5KnHQ1npdpMHVkRWuJA0oY5CRg8MOwz+FSTX0Vy00okUTyfuodrMPMTuw96a01Q+R7NGy99aahcIZImSZzsjLx4Awf8AGrWpWuVK227zo12+Xj5HkPT8hzmuaF7CsIkiH2k7fKgAkI8xu5GeAR6itjSNR+z36Kz7owpaWaRh94jpzyGHT3qlJS0l1MpUpQ1j06BEhSKJbkS77UnzUc585+3Pr9ahlt5Z7OARvKlxOxdpe4QH/Vk8EfhV1L2OeZwrIqzFpRLKMA44/A/Wl1ZLe53zadOs0lxiLaxwrY6k47ZxzQ46XQuZp6mNDJc7fNHnI88hgt0ZQfs4HUH2PvTgw3ySWzYVP9FhUxYCt3bryDV2/tzBcMXi3zGL7PHjdluOTkdCB34qKW0iQRSQJHL9lTybXL53k/eOeu4fn71NjTmT17/1/XzKMEuYt/l7jkHkHHzLjr9RUsUnnRgtxMRvd8/eOM4P4rUdqzgAAnhPT5SQcgg/SlZVimiaNt6ktu/Pt+ZrtN7K425t2GcKOcgjOD9cfhU2n3Idlt5sh1zhgc5q3E6ZUuq7WAUknhTgc1VvLB5VaWLO5+nHelODTvEXMmuWRz2pQuv+rG6NJ3QkHqGAYf1rOPVnbaGPtxjmtiKPzIri2dWS4DfMG7sD1H4ZrJuonMrjd8684Heud9z0aMrrlZWRwZsO3yEcBep+tbiMNi8Hd6E4yBzt/JTXMrIVlYOAMHt61taeC+MZAYc5PA7fhwaqEuhtVjpc2xEu/GVk2847tjbkfqaswQFipUq/lsgRV9d+SfyqKO4IikfAEhGBx975AP8A2U1bjUrFGqj5gw/g9wee9dKSvoefKTRGm3yztH7xeCHPX5SRgCtdbaEFJEYcyNlVOQcMOPyY1mGGIooSQxTFVCt0U/LjHPBHWp7aYStO7hRknDQkfebr+g6n1q46aMxqXauhHi3Kp2tk8AEYJAGOOMgcetYtzbkBi4YE9Pb2rpZFjEBZVTay52jJU/jgfTvWHeA7GL8seOvC59aioXQm7nPajEZYjuOWHHsa43XtKju7VoZFBDg9ewzXdvtlIVFJKn5mJAwKxdTtgzHPPfp0HpXM97noLVcrPLtIuLjT74WF6WLR/wCrcn76dsfSurtzG3LsSh5JHXP0qj4n0Zry2LwEJdREtGx459PxrH0XWjcQCKX5J0+VkbufStbc6ujCNX2T5ZHZGEOMrJuUHriljjWAkqPnHOAelY8mpRogVyB681Sn8R20DMS5J9SalU2XLFRS3OvjukGfMPysOo6mmNeptOQUX6DJ/GvPZvFEtwdtlFJKW+UeWhIJ9M1ai0vXdSLfbr+10+AJvOX8xvphejexNV7O25xTxqex0t54itbJGZ5l57Z5JrBuPG9vC4YyDJHQnNVV8MaRaSwvqr6hqnymSQxSiNQM8DGM/rXYWtp4Z0/S7ZbaxtImmO5ZVXdInfaS2TQ0kYe3c9mcavii+vw/9mWFzcmMbmZEOFHYk9hWlaeEtZ1W8gj1zU49OEqeb5UIMshj7nI+UfTNdvJa6g0kJVg0N0MsIxsaFB2HYipXsZLiby5JGiluuYl3nPlrgkr6j1GKlz7DSk9Ww8N6BoujREaVG0d5KP8Aj6mJeVk7uCRwD6DFdlbXUk0oE6SSJIu0Spk5U9WUVzkZbYfN2RLKQnyscpGP409RxzV9NUjUmJCN0z+XbeUxH7sdZE9yOorF3e5pbodhbfYr25jWPzWvYomjRnGAcjrj6Vf0+w84EW0qykDyljkA/dn+Injp2xXErqiPLDPaMGeRjFbsmQXIxkj0I5471etdauLK8ublbgzxPiNlJ2tIw64/2h3FCtfUynTk17rOhe2gVjJAVj+y/u4iy5y56/7w9qgmjNqrtcB3ihHmSGJAf3nXK+2e3tWfZ+Mbe2v1SeLyYYs5O3coZuhJFSWWq2TTw28UoNo8jysUOOe2fTvSsTyTW5bhk8uBQytM0KfaZQMKJGOcFT0yMdM0S3CITFOA0USiYqCF3yN0A9G/Sue1K8dZImW3lnXzWnZoyA2B04+v51TOoyLI0RHySH7TNEwCsT22+hz1GKVzRUG9Tp5Lq3WdhIASEPnuMruJ/hPocVXW6eMIIblCkoLSCTjjshPYiuWk1CdpRBLuWV8z3BzuV0U/cY9M/lVaTVPNVZpWNu1wS37wjKxj+Fh3HoaLstUUdzJ4iiFhNHN80k52vCRgoB0P0xUM0wItXScx/akwEOCvljsf1rzqXxJYbPMe/iSSVjHGTIN0SjjnrkVVn8YaSFIGoNhG2KIwWx/tDjp7U7t7jjQitj0q8acpBIhQvcgxROBkxxjsQeqkVmy3Zi8ySF3EccYigiXgLnq656j6c1wcnj+0O3Ek8iRIURhGRn3wfarVx490y6htI3W43W4+WQx4Oew60WZcaTWjOolvPs8krRl5HQCNIhLlZXPVwD6c96SXVWQM3nLKYVCpgEebIf4SK4+TxdpbCERpcpsBYqYgR5h7g5qP/hJbFtjXAkZIQXI2/wCsc98dsUrMv2aOzbVGjQQ7srbqHmDfeVj0RvUe/aoBcB/IWUvFOqmeQgkhR2B7Efyrh28QxhVSHzbkli7u64LDsp9ary+Ib2YSxwwBA7fKS2dg/uj29qfIxJI76bWr97dDNJHcA4csnyvGi8gnnmppNbi1e/TagaRwF2t8h2Dr19TXnT6nfyCcCNIy+BuXPyAdhz39Kka8vJtweGMnG1G6FB/s0cr6lKmt0jvvNXDSQTtG0x8hIZFyVQDB57+mKqyXKBXWLMBiTyrdAOIj3IHv61xUU2oRTRTLMwEfKqTkAnvV+PWrsXfnyW4l3Z3KGxmlylKDOna9WN9rndaWoCmNRk+b/eXv69alS4dQsE0m7colmQqCGXtj/a+lcZHqbQQwxJA4hRzIA2CSSemfSpF1TzI0Dbo90nmPgcg54HuD6UuUfId5FqDuhaMiV7nEaIyAExj1x/FjvVmHVUtAbmySFJSBbQZVsyeuV/vCuFXVo2eaYbvMuB5W3fjyh6g44/WrNvqkjMRDtkMICRq0mC5z98duOtK2uhLpLqj0vStd8y4eTVJoJEK+XFKTtbfgngetaOhwW2pm5eJmjEA4kDdH7nHrn+VeZW+sRyXKmSfetuCTsOD5ndh7ite0ui8ixxNKp8syzlTtMnPUeuPStYy/mRyVMNo+V2Nm1SMxbRuAYZKyDaRg8YPQnGfyqzHECZIguGX5tp9sflxzWJZ3/lLtuYzJESOUbofUg/55ratrtFLNZTmRfvKkq7WJHHB6dD0rqi0yqkZRHTLiVLf5WWM/Pt6M3Y/rVlLos+JMou0cHtVKCdHuAxBBXO4E4JboPy4qdkMi42Zzklff2ql5Gcl0kZd+YPNhnk+6Q2ecE5rP1JVjQHaG4yJP6GrOvBvs6iNOB/D/AIGqxf7RZRsi/MVBKk47Vzy1bR10lZKRz1ysbyn5drsOBnP5Va092QdeCMAE9fSrJtYJUYYAUN8wIwyE85//AFUxYPIUpJht54lx1PXp2NQk1qd7mmrG3YqJJlVQPLQ5weepP+Nalj8wgJ3HhTknuFP69KyLNBGUDshAxkqa07WTAAlXqAQQevyEdK6IdDz6z3sSfvY7ZcMrsyqvPHO30/H9Kn8qRFTcIRg8beCe39B+dV3kaJgrcMX6jOBwMfp/OrBuZJkAi3Pk5MfTLA8DPp/OrutjB3H3MhRQrBSpJI+uPx5/WqVxCJA7SDy4+yKcfme30HPvVto3Vf3hz2A6Djrj0UfrVeZf3REgCkDOSOMdiR/JeppO7CnpsY995UaoImjTjdtH+ev51nywM4jywbuuDk8+3+Sa0ruL5UUA7g2CPT8fX17Cs65jRW37OAPvdKxloztjLTQy7y2/dvsj3r03dxXjvxD0iTTZhqdkCkcrbZQPXsa9klmZPlflTwc9e3+fyrnfE1jBqNlNCRkMhGMdKdOXK7mWIhzwaPE4LqWdWZ7iTgdFrf0KwE0Etz5XneTgHcNz7vUDp+FRr4UeFyjhixPy46N7A+tXG8PG3QPHLcQlTuYK5GfyrqdnseO4Stqb2nWF0bYQwgyW9vmVowgUGU9Cp/pVw2s8eUvpFj/5b3BaRQJAPurn1rGj0CeeERpJO2/Dn94Tn0qGfwdGozKWLtlmGc4FQ4+YRpuXQ0m8Q6PZ2/l3t4ssk53zLbr5p2g8KTwA3uKoar41sroXUOnaK8/mMNk1y+whR0+Vf4vfNYt7pUUFyyxplfQCtfw/pIlIIB+YjnbnFZSlGJ2LCyS1L1r4v8ZyQFIpbWBCnl7jAGZV7AE1JNqXjS5S3im1mdFgUrF5USIQGHPIGa67RdNgaIk7crnjB65rYa1t1Hy3EKtjHQ5/lWfPfoJwa0uedQW/iWGIMuvajgDCgvwPwpqL4jhMflavcHYpVQSCFB68Yr0RtP2xDEkWAONpqlJahJT8oZcgdcU7k2fc4Jde8TaTEwS4WRANg8yMErnPI9+etX9K+IOogW0d5ZxzRRAh8MRvY/xn/a9619QtC28SR7QBgDGR+BrlHsjFcnYAAD1NNJPc2gpctzov+E+g+zRBoZpZd+Z16Bj6E9iOORVa58S6jqKPHBbQWxZt5kQndx0Gen6VnW2lFoLk7RjeST+NdRp2nxiLcFyAvXrVOnFChOcjOTxD4hluDCZ41VQrqwjGRjpilvbzXbw7rvUZNpbzBhQvzeoIFbENrHHPuIAby+PzqO6RNmTxg1HLFdDqipM5DVbjV5ZJFlvriR5OXy/X61jNb3DsyzM7t0I5Ndz5aNk44PGMdaqm3zIFhR8E7jyQD+VFkbRps56GwSQbZFVG6Bs4NKNPiiHV2bsAOP51vvZbvnESqV7ZBJqB4JOUxgDqSP0pGipohtLNpI8mIkDIHGM1JNaKF2qp47+lamnRk4TnPJ5zgfjVmW1ViFUjPUj6dqdx8iT1MqztI1YAYzjOD3qW+ssWxIA+fC4rShtZY+qgZ68Vae3MjRAJ0YcDrSIqJWM+3sFQIgQYIxnHpVlbTYylVHJ6Y/KtaCL5nJwuDnjtT1UOT/T602YQ3M0W6L1Ax3GKnSNQTxgE46VdNsQWJ27R1B7CpltgApwD7EZqLHRpYzpIUcE8KG7mlWy3MHCZ9zxWjJYtuVk4xzzxU8QchUwny/xBjQkTJq2hkTWXyZIzjnG3tVVrPzME4UdOMc1u3P7xWESnd3PJqlYx+UqCaUysF5Yjlvw/GhxEnoUFsEbCjqBySOlVZdLTqHYntit6SFWQEc8Z57VAIZAWJPyD0FS4lqRz8iTW7xEBGSF98e4dG9RU9rqbxyNFKy7ZDukblW9tuOD6EGr88ODhhn/Csq6t85UAeo4o5RSSe56jpMIL/MuRjpnjkf5/Spbi2MfzRgqnDE8lQMdR+dR2krQyGJl5XABPRvQ1sX0f2gQohZl/iXgFj/hzgVtD3onFKbUr9GYaTIWULv2jOSDlvx4rVt5tqBlLSIMAqQcj6Vm3FtIJHOCTyQQOQKjhv5bYAHcV7huOho5nF6lyhzr3TQun+0ojowxycdcj0qi8Ei2UexQcEqCOOBxzWmjx38PmW7lJB95e49KypNQu7bfFcouSSMlcZ96JNXuzOnzX5UUJIhLKC4SOXOMox3fjnt9as2sFyuWeGOZQAPkbnHuKyr28k8w7GCD0Udfxqkk0y/OZJdn+8euenFRzK56Hs5SidiuzkMjQocA+YuB2zhqkED4zC/ytkEnnOQOPY1zdnfFGX5UY5+beSf8AP/1q07e/h8z9+nlcZzHnr+dNTRyzpTizTcOdm9WL8EB+cZPGT+FW4pWi2oMbmOBkA49Tx7dKpw6jbkqBKxbkZA/x/GrEIXYuydM5BUkfgMitFNbmEr7SRpWzpKzKc789FXcBjpj1A/8Ar1FNbsHDsseD8wYjIx6j1+p69OlWbW1k27iUYAYJTkHj07dPypZpJFYDYA+QN/3c/wCR+QrXdHMpWl7pkvZ5aQbQG75PAH9f8azr2MJkFAH/AIse3+B4+grbZHff5WWAPbvj0/n9AKy9VBAfyx+7B4Ldcdv5H86wqbaHVTk27M5fU0VBxkgHr/Lj86wGLrc5YqUbhs88HvXS3SYifcwI75HfOP6VgyRbX2kEZP8AOsUzttdWL+p6DACIdgCsU5B5XgEn25rM1DSlmimSePLIuBIP4vqPX3rvNOjGoWSSylSzj5j3B6AfpUdzpZEZQA5xjJ6EciujXdHHHlektzirC28i3XI2npnHYZ4qK8hHkuFBLN3I7VvxWrRWaK/O5nyD26f41SuIRg5zgD6VPMdNOmkec39run+6dvOfaug0SyWLYFV9hxuOO+Kiv4AbhsEgHoD9a6TS9htyEGNwxwf1+tZT1OipG0dC7a26iJV3su45wOg/CpRbKXjHnQ7mbG5m2gD6mtKzthInM3lgDjCEn05NTQWEaggzqwY4IMZ6fT9alHmyaRUTSZk3L/ozIeCPOUFT19arPYyRkvJGxTGdwG4Vsvp6SKv+kwgnk/eyf05zVaS2VhhHAXaR5gVl6Hr0rVIwvdnNajbeYcjBPcg8HPpXF6nmKWXYOFBwff1FeialGkKtvZvMXl1x2x7/AENcPqVvvWUj5cqSpYZz70kdVJXRJpCu1mPNChQAx5zkk/zrWgdYwUHTB6GqttAqWli4LHKhmIA/z3rUW1CNyMsRjZn+uK1bLhFIhVR5oY9kbqevFUblC7Nszjr9a1XhMbupyoWM5APrxVbaXQR5ABTk/l3qGbw30M2SFnBDAq2O54FMgtHA5eMMeRk9MVrQRjoWB+nOf0rShiCuC20R4z93vS3Nuaxgi3ZXVHuECHnK54/IVIunLklGU54BI6/nW6IVmlJ2KFK8EA4zVtoII1wrdWJ3KAMU0hOpY52x01stukiyCR16Vu2uliNN7IgkbjLAkj8MfSiARpIE3LkOTtbOD9cAVpDbtbdKAM8tuOT68Z/yauKRjVkzLu7cqhUHOOhQdPxxVIQCOVHP3xyPf0FdHIBKWZCWcHj69v61Hd2sWBI7HcwBwOQD/nNU49Tn9o0rMorb/aHKINu8cnHQf5NOSy8uBSVzI0bNn144/rWlZWyF4mV8YXBye4waVVV1eNjwjnO3uD2z9DS5dLkKetkUYrGQSYxuw3J645/Xoa2UtofKyG3YXBxjn6/yptsgMwEzKQeTt59M1ZeOBMBQqsCV+X+v6VSgOdS7Mq+jRB8g3DsQvX04NUxunZQN2G4bI5Fb0NvCy75C7EEDaSc0w/Z0kk2lw6thQB0o9n1Y1V0sjItNNfdudiiEdzj9aYNOy2wJ8ykkZPTB6/T610Et0sMLiQqwfPQDnOPyNMSJIrfGzdLj746/Q03COwoVZbswJYGdSsa9Mgj1qksciqVGSrcYrflAeTLDb6jH6ZqBrcqwUg88hiOeaycToU7IxZ4lWHDhiR2rLuoQ4AUH24ro71AItx+83f8A+tWSylXKlQVx97Pv0xUtAnodhbuJIFcKHIOdxG6rtoZVmYgsCCeGGOPT27/pWL4fvIZwQAFBzmPPKsOmR+NdDCB5ak5Knvn1qorqjjk+X3WieVMrtcjJUE7uwrC1CNEDbSeOvvWzdMGkeVSTkjJHTjrioxbRXVvvZdpLYxu+b8P5VclzaDpy5NWc1BI0U4KErg9DUmt3twse5l34VSDnJGD3/Wrr6ficowGeSHxjHoMf4VnalEyoY3O2ViFBAwD/APXrBxcUzqvGU0zA1KcSFWikVB/GpHPT17frVB7ncwSNmWKMYUd29z9afdB3TEgJeM+WT71VjRQ/fPvzmsXc9WlFWNe0m8x0Un94e+c8f0rWjRmZdmGU8Agg8c1gWKqIpJJG/dgBeG5JPQD61atZGxHhzv6GRRgD04pp9zOpTu9DbEZ+XZw2Sf8A69SxXMqqQjnGeM9agt/OutuNg4OGPAPI6n1qaFGEhXaw7kkZBP8AnNU49Ucso9GaEWoyD72GPsMEitW01USYVvmxwA/XHvWG0cbcB+Ockd6hdWGSrdDnjqaFKUdjmlQhM7H7RbSbSFKsByAOP8+/uao6lCJ4Syyqx25JyOwP61z8F7PbkK8YePPRhx68GrEl7BInEvlPkjZIOBz6j61r7XmWpj9WlCV0U7mAPJIrsCSSRj6n/wCtWPdQDZx+HHpXQbkjjLM+R0xwR+FY9xnawZgT1AxjNYy0OqLZteEriIRRxIpaYDLnadg5ONx9T6VvXJSWTBBBUc7uxxnb/Oud8GZ2zuf9VuCk56H1rqri0ICtnfKOST/F6fpXVTfuHn1Go1HdnKGEunzArscrgjk5/wD1VQ1O2VBwThug9q6O62ukrIchZABnuSDn9Kx74ibABU/0rJqx30p31OO1CBdwOSoHrT9MdvM5b5gecen0q3fIAxBDEE4zVezTbNkJz+o96ykdr1idjp8qtApBOTw3atK0QMQWzu4I3DIHv0PP/wBesXTC7syoCoI+Y4HA/wAa37CNX2xiWbLEfKJSobAyBx6gEfjVU1dnkV42uXjFKIWEcY24OMwqcYPrVC9V44Q0fktgtkGMgDjnODW8IrUKzM0m1WGC0rYbvjr3U/mK53VZ0HyxscsfMRwxOcHrz1/+tXY42RxUvelZI5LWMRSmJEBY5HoD3/TNczcxiSN9/wDBnAHcY/8A1V0usxCS78wzq4B3HPY5x/LBrFuYnaSVnfdxj5TjHbGPwrn6nrRjaI21gC2+lMUyJY8jB4xmuhEfnvEEUbdxBOeARVKxgEujaa0bfMpljIAwBhxgn866CxiVbwQuhZVT7pHX5stW8UmYSk0ZepWj2907hd28KvPrk1Qe0IYHHG0fyyf5V0eswDzEK79hfKn25qKztxLbqxIUIdvzdCc4/qKiUfesXTnZXMv7OVVArlTxwG6Y6fTNTQ2zOWUKQcYxv5OOf8avFfLkOAq4I/A98+tW/IMQ3nLOQTgYz/nFCiaupYzfs5SYK64UkjOeD6nr61fh6LHFJg5YgFhjntTBCsStnOSem7qBzxzTvNQsN8WACeNucZXp16VSViZSuJbxsrKZvKJHO7I556fp+lXPOwQnnNtJ52IWDH1GPXr9RULeUFRNpHO4naCOvH8+ahlRVYyRhVABA5B/CrT5TOXvGhtikkw7tnjB27Sx/Hnrj86r3dn5kEg7xqxPOOhGMfnVV23ssiC2QjglST35/wA+9WGn82OQGZSw5zj73GO/sRVXTMJxa6jRIvloSSiqSfQkEVNp4RoLmZ1GZHbaB04Kn+WfyqhZ3CtYhZHLPGxz6jB6/jxU1vclIAUIwWLFR39f0NK/czS3SLlpDDCo81CRu57jH9OMflVuZ0j27HBGfToemR/OshbtHYlvl9AwwM+/4U2S7VFA3ZZegPTihSsi3Ft3NYbrpHeVEYrkZbqD14/z3rPnmPzwhU6lQyDPA69e9UJr+MAJDJyynOTwPpz61TN4qOCzFsY4Hf61MpGkIM143/dkYZiDzuA5FaEGyGEnzRnuvUCudW/jBXEqnJzgtyB+PWp47sOrMrqB1LLjPHpmlexbi2aFwC0jkqXVj1Hr9Karglg24HJx7VnzaipfylL7ScdcflUjXAA5YqoHryf0qC+V21EuphOVwQ2OOAP5/lWPfY2r8xDH261K9yqvgx5z04/Ssq8u0IYyHr/DjGPTNLVlJWNO6tJ7ST7RbFhKpGQP4h1roLPUpntxNnKgA4PXNIsQ+fkBcE81mRLNaXBt5Bi3kO8Er1rnu4bDklPc6bT7+JysciBWA3EuRtPtV61dDOfKlibBJyrcgHtj+vqK5p4ijH5gMAHIPc0qBl+YBCwHf/HqK0VRrRmToJ6pnTuuF25XJGRkZH+P/wBfNUbu3S5OydNs4OeeM/Q1WttaCKqSjY4GFJHT8e4FXi3mqpypUDk9s/571smprQycJQepxOo2kkd7Ik4BUncGIwTjj+X8qo21iJ71Y1K5LcHHb/8AUK6zxNGFs0uGCsY2Ug4PIPrXJatOFjkEZ2GTpjIIjz2+ua5pxUWephqjnHQo3iWtxfebbx4WIFFcEgsO59KvWjDzBE5WPbzub9B+tZIlA2pHEgXGc9Sau6e1tuYylgCduO1ZX1Oxq0ToLVXERC7jCxAKY6nHp27Vs6b5bFUkLbmygGB7j/2YGsu1jYBBb5ZMZDYx/niraaaktwWLtzzt3sOvvn64/CumCa1OGq0002dELZZAdi7WAHynjA9vzpkmjSbwWZhv/hI6c4I+tTWBRURJAOcgEHg+uc/5wfar5uUAbeS/UbXOCe3X3xj2I966OWMlqeW5zi7RMOfS1eAhVLLjlD16Vly2UgcsyHaDyuCcf17V2MkkMoZhtDHnA+n/AOvPoap30se6Z5Mb2YjL8c8c+g5ArOdKO5pTrz2Zw8vmIqhiwP3gT6f/AK6pTOXbDNlgPet7UQjqNg5z1zknNYl1E2SchlBrkasehF3VzR8DXaw395bEkCUKVHv0r0NpS+fLPfj3FeN2l+tjrtrcZIw2057AivU7O432SO5ZFODH23D1/wA9a3pSfLY8nGQtUuUr2PbDPGVzvlVifQ81gtC8asDncCcbvSuivB5MrAsCXQMCfzxisXUmBYshXcP1pM6KE9LHOX7neMgYznnrmqsT7ZckjP3enFWNVdNxZV5+tZtpOHnVSqls5GTxispHpJ+6dRYs4ViAVDKVOP8APtW3aSROCpj+UD5GA5BGCK5yzZo1LFt3bG6rKTHMrArkYIw3I9KIuxw1I8zOmlkV40ijUHYB1QH+LcOQPQkVzusTq164DhtgZOMYHJ7dqguNQBUvJIyJtChFP86w5buROPlIHfI7+prV1L6BQoWdzTvJIG4CE/PgHrkYA6elZci+bOGGME9B0NRm+VlxNIBgk8dCcf55pscgMQ4+bGBjsKLnVyWR0ejhIdH82XYF+2lWwOu5A34dKkgk3XszrkDLDGevPT+VZ27/AEUKuSrTK7DPGR3rYRVWaVkUFOgz6+9aqRySjZtmg7eeke9EwoJ9wSOKp2rxuLhSq/exnOME4/TIoimbATHOccVXSPDzZyNxolO7uKMEtCYFZ32lJcAjOOc/pQ15mIi48yMnIBPJ6cfyrLuJnV2y3A7gdR/nvUMU7mF8uFI4Cg9R+NLnNfZrqaqXMZ3EuxHTjCgfmarzTFpHIZSoHAC5P41kC4Kb1dcYIbcDjFSNdxKhZWAAHG5+PyxS57j5UmXzdy7WaVCIhwcRgeh9ajWZeoYCMsTtUEZP41jPMgYlnjwTxg9aryaiUJw6rjkAnp70XYnZG7cnYV8ucRs44BHB+mO9QeZICVaV2IPJPH1rlr7WEY4aXDKcn5sdfbvWde+KFhYESApn15p7mUqsUtWdoLgRxyMSxBPJJxWhBfRiELvGOw/+vXlV34zhYEbzyex6Gl/4TFXRCsFw7gdViY/yqkmjndSDZ6bc3KOjFSeuMbuDWfJK0akqzHj7p/8Ar1wsXia8kiaa3069eNereS2B9TUrzeJbmTFtol/8ybxujxlfXntSsuppGqktDpprgFmyQT3pxuF8oAn5+p7Y4/wrjo7LxVLHFKNNCCdsR+bMilj7DOSKSOw8RN5skkmngI3l8z5Dv/dXA5NKy7lOv5HUieJTlWG7Pc9KsrqoLBFcKB04rlZNE1+IFjd6Y+0fOBK3yn0Py9abFo3iKWdEjfTt5Tf/AK48f7J44PtR7vcFW8juYtRVlXdwRxwMA1J/aOFIUgHPArjLPTPEL2rSNcadGS3+rknKs3OMgY6VpL4a8UfZY5Hn01VkOVHmsTj6baLpdR+0v0NC7v8AOWfAbjHI69KwdQ1BYwzM2SxycnirI8NapsU6hqcVuXcJEEhLeZ34JPB9K0rPw5p9ldSTiI3jwKPKa7fInlP8IxwB9R+NLnSE5M9G8gSOME4X7oJAH6U3VLKK9tAsyfvkHytnqfpSwSwXAZU2qy9EJ2kY9PWtBYFkiDIxLHnBPOKhxvsEm4tM52QRy7NuDOIwwUEZXqMkDtwagkeeM4bZu7Muc8etOmElveyL/C4O3tjnkVn3V00Uu1zz1Jz0rG520otk8lzvUJIqkDnnnFLHqcsBAjkfYSflI4/+tWTNOewwx5GDmopLg49Wz1H8qXNY3dFNHXyatb3+n+W7Kkm3BB6nH865K/th9uSEMdjDcuV7dxiqMkrKNxyDn8qVrw3DBJJGSUD5Gzwceo9Ktz51Z7mcaXstY7Gvb6fEZ027hjkbSBWo9ksTf6FbojDn5pS7Z9f51V0a7S5gjZDgr8zAdc9K3rec+VugMUS5+aVl5/AfhUxitjCpWkmYMT3MdyqNF9nYHcrISue4PPFb+nT3TArcqkhwpHY4HvVXVYFuI1db53IfAdlZeBzwKzrKJMn5jJ647j8RVRk4uxrdVYXOwSXAB8tlJ4wRwOf/ANdXd4JDEDPp1J7Z/wA9axrW5ACGMOqhiMs4/l0rWE+6I74XORwytxjtXWnc8+pGzHGTB+4F5x/k1mXJAOQQSeOD+lWpWbbz8wJJytU5ZDEpR1IHXjkVEmVTVjKmG0s5zwfXg1nyjdkMRuA4xxWrM6mLIYt64PQ1l3EXm/MpPqT6VztHapaanLayP3QfjKNuwR6Gu/0S8+0WUGGJeXHOfSuK16AiyuX7bCRg+1SeBddgGkRrM+1lXueta043R52MqJTR6DeXeZI15dejHHX/AANYeo74rgDO5DyrAcVXfU0KsFYbWPBzjmqFzdJLDt80hgcFSeKHF9SIVVHYqatIAkikk8E/WsG0vo0kO8gN0V8VPqd4tur7ZA/GTu5Irjr3V40kLZyCfypOm2jvhiY2sehwaokcSB5FDdie9OfU1Zxh1bcCW5ryuXxAMEE71xgUn/CTYJznnjg9BUeyl2M/bQvc9Fu9XVY9zbd2MBazp9XB3FJAD1I/CuCn11ZRtXI/Gq66pJkEsCvpmmqMzWOJgjvINQViPM3SOT19K3bOdpAG5HPc9K8xtdRLEDOB25rqdN1aJdjTOoP1qlCXUqWJgz0GOXiFBySemfxq/DeiS1cMcFnPpwM1xkOrxbk2SqS2cbj09albVIVuY9pAQJyd3HrTsznnOO5102oJGeoBIzk0sN/HIxbKrxjcDXnuoeJrOIEyTqp7Dr+VUTr2rXsWzS9KupI3yVkKbFI9cnAo5WTKrDoz0qWVHZjxgevasm7v4I5mLlVUA5PWuN+y+JbtrcXM9rZpKpcbX8xtg6njj9alt/D8E0aNdXFzeGZi8ZaXYpQdQyr3/GnZGftpdDQv/EVjE2GugG6bVYEVh3GtLcyMmnW17clhkCOMkfpW3bWljDDHNY6fbRTXR8mAtF0QdQ+e/X5q0EUvBut3kixmC2cZBDZ5z/jSukLnm+pzAj8STpGU0vyYnO1HuJFUZqA6Fq828XeoWls/mGILGpck/Xjj3rsjHeWlwZFY3NsE+zrCVyVc8F+nStHSNMt5RK0sRQw/IFI+8cdc9+aTm1sHIpfE2eejwpbrLI97eXd1GiiPg+XiY9B7r+Valn4d0SyfbeWEcv2WMGd3ZmLuw425ODj0rutN8LSXEMrw+Y4s+Rk5H5dxmmf8I+5topJElRFcvJtQlRL6H1FS6j6gqMehzttawQSeTb2tsqgfaZVjjVd/Hy7Tjgj0rR067v4HE1rN5c82d6gZTZ6j+6w9K1T4fZAkLLujUfabt1Ykl8/KF9vpViTSmZfJaORZLj95dKX2hYwPvKR6e9TzJlpW0M7TtV2TXBuYHliuF2xn7ytjjkdqSHyL3S7iXTblobhT5cTJzjnGPx9KtppkzRhrXe8s6iO2XzMB4hyWx2PvUMmnQQbrpWijjj/cwt5ioHfvnnG4HPNK6K36lK7tpks3uBFGYEbyozFyYGzy2PfmqL26ZEoEbQRDDRhesh6SDv8Azq2/iHRtGSeG81mymiVQ+2Jt0jyehC5HFPn8a+C5rG3jfVm86BwUlFrICB6ZC8iqSfRESkupjfZGjmeBn3lAJp2QfLPnoAT/ABD8KbG4WNEuSsct0DJI2TgxDopHY+9aX/CT+ETDbLHrsTKzmWVHhkR1f67cYNSx3/hy/MrtrGnOkuJJ4nlACsOgUHt9KevVEpJ7MoRJ5roGG77UCFOTkRj19G9+9OWe6FqEsGDbCY7VZGOZB3JP9KuyWlpfQTvBdWwuLlNspW5RxFEp4I56mrPkhS8+EeRwILaNZMnaB/rPrznNJMu3cj+2o9nbx3QBMXy5JyC44wD0rRXTzDJHJZbo1EQdoWbIMp6EehqmsCogjjEdzHG2xcYPnSE/eH0qzaRSWE6/YpAHtMyOGOVkOMcA9x6UXTBJrYlumUSDaDtfnOPetnRL8hhFO25D9055rmnnZyCoJHfPWrFtJvUEcEnkHvUKTi7o9GpR5o2ZueK9ptkuVTa0bDLD0PY1yeoEGUAZ5AJJrX1WQy6fsneQnHysvTPoawDJI8CMSGJGDiqm76k4dcisxYF3DIUk+taEdusShuHJ6imW0YEQznd/Fg1pQjcclck/w9BWJVWqZ1xZrIAqpgHj61g6tpZQBlOHHTBrtHQBgAp/2gBmqN/AHVwQMgZpNEU6rvY5XRb4WFyDLuUN97Hc/Wu0s7mKZPNWQbzyAev/AOquQe2SV3VwCM81KlzPaSpHIc2xOMqAAOMVonfcqpRu7o9Hs3W5hKkKXOcDHc9x2z7d81l28X2eVlkbGfl29c+/Hf8Az6is3T5ysiMUbn7oPzZGODit1SkwBhBjZ+dpGdv447//AK/WtY66mSh7P0Y+PylC/NnjG4D8s1YFzsX5Hz3yeh/z/n1rP8uWNl3ZkAGAAOn+f8+tILoFDkn5sjBHP19a057CdPm8zQTUzuCO/wAzfdbjt6/5/wAaLh1eNmZgTgZHQCsqRwx3Fy2cheMkfgP8/Q1F58iZ7LjJUd6lzvuHsFugupTFyyAKeA3rVGe7VSCuVbkDaeMVJPiaHeAxyMhcY4PoD/kcjtWVMxCv1Gflwfx4/Ais27HRCCaKOs3JkglU43bSMDtXjVl4kexleMMSisRz6Zr1xt0rOhywC5/H0rzHU/DXnXDtDCeT82Rz/wDrrpw80r8x5WZUJSa5ESy+PcIBFG5OPWq0njXUbmbMMDNI/HQmrVl4cjhYFo1dT09a6GXSbaNYnhiCupGRjmtZVYdEeesFNayOXRNf1DmTEKHn5j0/KrkHhO6mAee6dgeu0YrudPjR4EOOeR04rTSMbQAhC9DtHOa5pV5dDqhhrI4W38DxbUMrs27nk9KuxeDLEsoMBYjk+hrv7Kyjx5gBLEYq6lmoX7nUcVi60u5p7GJ5yvg2xJKi2XJ9c8VDceBLRuUGzPYE16c9tG2Rzx/EO9L9iOPkXP6UKrLuWqUex4vfeEFt2G2R/m6HnrVSLw6XJAnmQjnGe/1r2m5012Vy6qBjaQ1c7qFgkNwGKkocdq1VWXVm0aFOXQ4X/hEZ5IQ9tqcyMeQrjI/Os+/0rV7Bh/aE0k1vg/NGSQ2O3qK9GhthnKkYznBPaiVY9xRwMAcZGc1qqjMquEVro830+xf93LaBGMeZG3c7vRR716XpF5dC2hi1aX7BJIm9ZJyFjCjkKCeh+tckml6kVuJLS6a3tZ3DJHGoyCP4gT0/CtCw0H7YgudTkkubhvmZp3LFm/GiVnuctGlO+h1k03hua5a8TXrWKObajwicHaR1YL1HPpVa41Dw+08yi5nuI32xGaCB/u9yDgYP061QtNDsotQ+0C1RXSI4XGeSa6COyjQDACKOQKysjrjSk9yhP4h0iPzHey1SdmAhQiJVHl+vJ61SuvHV7DcBdL0FDGiiOMXUu78SFAFa95FHtLbVI9KxrqJC52/KTkgjpijQ2jh2+pTs/EviuVoPs62FoIt20JAX+91yWJq5E/iSS3ijm1mVVhcmMRIgIJ684z+dEcXlsFDPkDLDNaWnxbyC5JUZ7Z/Gi67FvDWW5mWmlausW06zqirIclVuHUZ98GrkXhy4CYN7qJ35Zj9qc5Pr1rp7WDzcMSMZ9QTV5LVBnO8knnOKoydNI4mXw66KVN7e5YcnznyefrVGfw6zFnW7vc7SuftD9PTrXeyRAqTggj8v88VEkCM2HQZH60XM5U+p5nJZazYXcP2HWdQt0U7Ridjt9sGp4vDZvLmR9Qmlu2Y5BlYsBn0H1rs7uzH2yMKgYgcitC0tlFxEzKACpAJ4xVc1tUZRpX3OTh8JWkOALZBxnGPenJ4dtgceSpB7MK7d0Dx5XBXO33qsYUWUA555yB0qXNnRClF9DkJvC8EgBEaqce1Vj4NtuGaJSM+nWu6ggWR9oXv1FXo7TG3IwTxmhTbKlSijz8eDtNwCbVFP070kngywKbkjIHbHb8K9FW3iQlpF68cev0qKVYnGFX68ind9yHFdjzdfCcMco8otGccMjMuPfg8UHRb+1CJaapeIA+5V84kA+o5rvpokCDK7UPJJHXFQS28btwNo64PSkUoRKqwHggHBpVQpwdxTr9PpWgLcPBvUkScHNVLq1k8wAvkgevBHtXO0ejGfMWI38y3aNhlADgd65qKBolaMnkS8ZPQYJroLIkPtYEg98dKzdZR11eIcZcjPGPpj8KfQhK0rFuFDvG4DkZJH6Vq2AZ28pucDhjxiqtsmVLMD0zkenSr9mm1d5YIw4AznNYnNUehPIP3Oxjk469Md6ztSRVgYsXyeckVrSqvkjcQp3Y6Z/WsrUsCNssVTPQ9Kq5NHVo5+OLJJA5xV2DTzMg8xQytxz2qFCI8cZBPGBWxAvmRjAzu9O1OKuejUbSMeGOTTXaMlmtfvBsZKH/Cuo0t47mNGtJkwTyrYHTngk1B5KtGAwznoSKpR2z2FyskPMJbc0Y7/AErSMnF6nNO015nZSQNNGHdcgAnA7g+mP8+orI1CweFA6EBcck56+5/Hqf8A61T6fqO9Gmhy6khSNvQ+/pWhMqTH+6yKcZY9P6j9D39a6mozRxKUqctTlgxW4UlCnHJOP8/gf0qByxbdnqSct3P1/wAn+uhqkBQyq6bAMDb7dsZ/9BP4GsaN3VXUfOvQE/l/k9R3rma5XZndF8yugeT51yjAZznOcnPp/ntVC8k8wMRxIeoxgHpj/PvV2edFLFwSy5yMAY9/89/rWTcs7srBgWbnriky47lOEMhmdsfKefamvYZI+U5ZRLVmQ7bOUsOW6lea0r4ec0aqqggKuEHByOn6VUSJ6yOQmgInBb5e+0VcuoxNartyMEEEnkVZMChmMu4YzgbeT/8AWp5tgbZgVIDAkKO1QmXOmpIr6ON8Y2ZVl4OTnNdDYgZ27sZ5Ax19ay9MURwL2x7e1b1mpyrR7Av+0KkwlCyLUNu8jFYx6Cr0OlXrglU4HOdw5/WmI8gOSyEtnOF5NPjRZsFotwxgAMeKOVHK0+hOPD2pkZNjOxwD8uDio20+7iWXzEkiQjBDL0rQhQRJvEblV+bcnOBT11eZEMUd24mIwI3fjHbOeMj07g1oqcTK9R7Wf9fM57GE2uWOeWXGaytTgVoxghix6Hp7V0F7qhlA3KjOCcgoMnjnBHsPy+lYt0ouhLIkJiuATkbsqD7eueo/Gi3Y6qcZJ3aOcnj8vGzHX5Tj+dZl95iid0P3Vzmtq7jIZlUsX6DPSqBjVhMhPJXknvQnY65RvEdY2kgtLMSCQ7lJ5+lakFvsTlfxrXSzVPsmwHAwuO+NvarZswu3aFOP4Tz+laPU5INI5+SJVF0QeBGP502aUugZPuY7VpX9rttrryyDwOlZRUvAv8OVHB9alm9Oz1K0jEg7SSfXrVdl3cuFz2zVmVOoHp1qtk7VJ3bRwcVNzqUbl22i25ObUEDnrV5YgXULNGpHJZVP+FV7HZswsau55wTn+ta9rGS7qET5ccBc546dcU0Zz0LFkUGM3MwwMbVTA+vWrwfau5LllUHIyMg+9VYtkYO5BuHTagORWjZ/vAowmCeD5a5x+VapXOSppqMJknUrmHaoxuEQB4PqO5qsINszAnj1x+f6V0CJ++G2G3kjVgTiPbnsenHpVe4swN7DIXkZH+f0pyizk9qloc9Pb4uXMcYIC4BPp0/wqaLyzbYYchSPoanu4JIbxIyC3UYJxj1z6cVApja1dhyCp5U8c9MVDTNISTQ+3DMvc7gOfyp8cG4MQQPqM/561JbSR+WFVQo2gjJ64xUkbkkgfI2MdOOD/hikkaczJ7aJAxw+MjsuP896uJBHk5bJHqMA/wCcVWji2gsxBwOp743VYs4ZBhGnK5B6jkZPpWqiZTfW5RuISsmEZTnGBjJwRkVRniaObMIJAwA/TPGfyrdMKxMre/Oc9OgPsB/+qknREeV5I8qozlVzx7DtxwB2zmn7MqNWxm21s8oUu2fT0H1pLuBUZlwoUd+2f8mr0GowqWVtkcm0SAMp6Ek9hj+uB71VmuYlOA7bm68H2/Pp+tU4pInmk2VNNkYwlX4KjAz1NLexs0gLr24BHb1q5Dao1pDIrHzNgI4xT0t3kQsBhh1DdvauVJtWOmM1e5kSRMTkkDb6HqKy9WA8kSZw6EbD7V0Lqd+1mXIOcelYmtRYgkKgbXGcN3Pt6VLRvB3Za08FrRQDuAwQc8Vegm2LtZB35xyT7VnaRKptIHjBDbelWY5Y5H+ZuGyTlTnNYGE43bNT5VVEUZUjp1//AFVka5lkyFAUDoOtaDyKI+QMFcnB5B/oaxr6dHZlcneOwpsMPF81zLB8zHHTvW1Zjaikk8jkVlQocDDD5jznmtezjKJhsnA9OM/5zVQO+q1Y3bMQ3EKrKpMn3QqDP+fp/KmSWoEZwhVgcLzT7HfGy7YxhuuRyMeg/I1fMZljVkTBPIB4I98V0Wujy5S5ZeRzzRXFjN59qQCTl4mPyv8AWtvTrq2vEAVnF2hxjGNo9D7/AE4pkihsq7F35OAORx61jyQY2zQ7opFO5HAwQaUZOn6DaVRa6M3NVhikhYh1GFGWA4x2GSOn14+lcmRKsjiRkKrx8hz7D6/Q/hXTwaj9thIkRY7hMM23GGHqB/MVR1CDe+EiQBu0Rwv1B/p+laztP3kTRm4e7I5K9DCU5BORyfX8agZNylgMhRkcdDWtNbv5abtqDOQrdqrLCwDZHHQ9qw5Tr50UUXEceUG4zqcHkHkcVq6hA8WpXSlW4dCm0gAcdP1qrEeF2KQRKh5HHXJ/lXQakr3Wo3UgZlaSQBWC4zgf/Wq0vdM5TtIwJoAJHCMpO7aGwce+KaYAkMoY5Kruxn8q3Y7WSXDsNwPHCjjHc/rUeo2qhHfDMzqF6c5J9PSs2upXtlsYltAxbpt+cofUd+lbEMQCpsIB5UcE4osLZARuRhiRh164OK2VtAq8rGWxnHI6CkotmdSqkUbcNCwRkzxnB5J/GtnT4h5YkVJAW4GwdqjhtnRkI3gKcAA9PWut0aCUuhWaVRtyOAR09/xP/wCqtacbuxwYivyq5yupFViIU3cYxyWiJwfqD/SsBJColUlZQTkZJz+v1/KvQtVsLhoH8u9h2YJPmRAH8cfzrk/KzhXtoEdeBncAcH7wIrSVNpm+ErRlE5+e2YyqN20sAWYkDI+vYg1HtlQ5wPMAPzoOCOuPqOoFbV1CXiWRghOwEsvsT1B6/wBearIAxRioUrkAKM4IIIH4ZyPbNRy6nap6GDNasyqY1baTgnsM5IrMkjUeaWXtnP64rsZYYwm5NyjdkAc/LnkfgTkexrG1S0H79URt+D1Pf1qZRsNVLqxr27bxbEgDPHTg/LV4MxfbEpOV4zkbelZ9lk2NkXwV2bx3yRxV22/eXACAthsEk/59K0ijjdinewHbdjDBlUZ4x261htD+6jGOccg11eoxAvd7sY2g1lQ2zOAOSQvOP8/SplHWxtSnpcwzB/rFB3ZIqpJCvlsQ3KsNuB1roPsyLNkK2AwC7gPWoZLcRoFdWGQQDtAwAc/0qHHQ641ClpqNgLjKrznYCfpnFbYSSRSSsqrtHzk4zxxgZrNRVDh0mb5SNnOM5+nStBIoGCbpA5dQFVWbIPP6j+tOJE5XLFvbqZEV4ZGwTuUnB9x1/KuitbON7dWZI1PUDc3TGeue46e/FYKWmnmAM85RygIzKT83cHnp/I1p6dBbvCqgzMMfMqyt0z3+nf8AOuimjkrO60bNGKOOJG2K52j7wbAbjPOPapTC4L+Zu9GBOQAeP8/UVCgtbVtkbyAORwXyc9uO3p+OakuJAeNzL3BI+6vbr+H/AHzWnKjgndsztYgZ4vOa7ZXUKHXYpDY4B6e/6VSkhSJDEUyUOwttHofSl1W6yYQpzGq4IK9s5HPfvSQ3S3F9MxYgSfdx0JHP+IrJ2bNqcWlqR2WVhh+RBGQDkDn5sr+WcVbhtTNLG78KVw4IBGcFSf8Ax2nafLC+nxFVw4jaPaeeo3A/mDV1WaQB4gSOhHXrz/7NTjG6KlNpsgFvIZAFZVYcElBtPAx+pNJBLGWYFnEhAUbgcdOO3uPzqrdyO0pEkrgMSMD055qrCwkYFZpSjMSFdv046d/1ob10NFG61NaKTzJV8+XLLyp5XPbk/wCfwptzHNtXy2iTJJIIbp245FVIlSQefLEhIBK4ODikt08mdGt90QmG4gsG4+hoQnDszSiKPFiV1jjPGSc49gT2/KqkqqZCS6EYy5KnHT/P/wBapHmk+VV8o9hj5Q3vUE97HJtSYvsHPHTPpVuSM+WV9CxpodooohIZGYDLFQoPH3sdvpTDFDCwigcLEhIzyQ+c5OT+OK1Cpsrd4MZllAJc9QnpVCaPbCwXADHIHce2KwSsi4Su79CtcRoSTHgxg5G7qeeoqpqEYe0bKDhSee9TeYGYrhvm5yF7iopncwsv1H168ewqZWOlJowdH2R2/wC8+Uo3XOOauidVIkLFnxgAdqrEEzToVG1X/hHFU2dfMBOMA9Cf0xXLLQ6vZ87ua8lyGiLByp9AcgfjWXITI2B1P61N5zyxkHOxTnHQGmLy6s3IU5Jqdy6cOUt2kLGZcnIB54/z61u28WXiViQWzjjv7+/+NZunhXkyV5zwAc/nXTQQAjzGw2OQwHSuunHQ5cRUsS2yLGokK/MxwRjoK1I0jkV2QhSwJLbefp71BDGXIaXO3uD/AC+n+FStMsStjKqG4UcgH3/x4+tbrQ8qbcnoUHXL/ImBgDPf6VRv7ZQjEkBsfnWxJtaJZOA54z1x6VlXeScbs4x05yRWMjam22YbQ7RkLnBHfkVYWZpIlRlBVRj2x7VaaPcjM6/lWRcF43zG2GHK/wCfSsk+Q6GucgvSS2ACAD3FU5Ttyp6kcDscVYub1GiYOSr9x2rk9S1Yfa1jWQsckAdcCrSvqTz20Zv2EygyO204B+XdgA4wD/Ot0Tl5FKkpNJJkKRnGep/AdK5mwi86KOJWUGQhmPt/n+da4njtb/A2siJt3tyCe1O7SG1dnQWyoZGjjBOAcjHXjp/jUurIDbjqWLZbjnHOB/Ksy0mYkNkoyDBPJxWu7xy26gKQygsx/vA9KIyurHJUbjJMqafEzxokgyA2R8vTI7fpWhbQkIvmmXBOM8A4/wA5qrpkp8pTu5VF57ZGR/StFZxtATBOOO/NCaInN3HxQ7YpI8sqhgwG7npycVsaXDK8Ra2uvJYMOWGeO35dawnlJgYqpYKvOOxpYLx4cBbmYehEYbFUppO5jOEprQ0Nbk1ry3QT206HOSqgAev1GPSue+0aokbJLFbOPulzIASMVtz6lJdWcatO5J+8FUAk45Nctdh3nLwsyheAxViT/wDW5rRzV7ps6sJHTlkl9xPeXvmLEJdowu0orAnt781XVSjKDkMOB8wJY9qrhpSA7FQ5J2qnftk8etSWgCTDdgdCMHpxUuV3c7+XlVkWFhYHCkHjG5V646fp/Si+t0kZiE+RRtAA544Bz+Iq1E/nKxQFVXO3HPPX+VW7SJDKfvE7T8pGPof60aPQwnO2rMiwgRLOJJAdypLGOnGMkVsWaCG7/dY+YsenuAPwwPrVWKOSG5MeN+35+Tz83B/rV0KnmKHJQCMPkdyD0FVTlY55O5S1dEXUXjwHMsDLk8dBxVG1hcWjT7GDMoC/QDDE/QitPVctI04ALomBnkD8vqarXUyxW8R3FYwCUGMn5sbvwzz+NNpOTbNacnypIz7mECJJVAXj5e5OAe3+etUrlBPOBDk4dWx2AKnPP6VJeagjwKvngGNvl4Bx2qSzmMZ+UqI5GHDd8HPPX1rOVm7Gzk4q5etLVE6JGxSMSY55wckA49qtx3toZ/swUkjCkhVxyCBj3z3qrMoAWQGAjOOAOe3H51CbopEjI4OxlO3jOBVp8pxuTkyxNGI1dEVioYuCwySc9fyPIrPTUCkpA4OeMgfN7D+n5VJd3ckpDkkgDBypIFYN1O8Fw6gxFGG8Yj5APrxScrbHTRd9JHUzXskcIXzMqRgY4H04/wAg1TmvyqH5yWJyc4rmk1RSxDsGb6HipHvgwOD8nU8YpObZp7FLQu6ncGW33ISGiHLHsM4A+tMsrzy5I5o2zswy9s+v+feq5mQ2r7fmc9j0NU4blHiUDG4NtI/SpuybJaG42pJDIxiSRoy2NijPBbP6bjVk6qqNGu9io6H04A6fhWAvXKZBXnHSqryNuyTnJx1pqbRXLFnS3lyTJ8sgAHXv19KqQXRRApZcY5yc5NZa3uf9YQTjgf5+tWDdW2wBUyBxz3FDbY04pWZprdmVtiEqGPzE1JAwaRliCjouX7Ac1lR3kYffswq9Mcc96bJq/lM2wAd/ehX3YOa6GyJIopmNy0megKnI/wDr1K17bwyiOAswVc5c9u+M1zD6zu3FpOQeSDz9KzbjVVIKsI3XsFBGKtO2xjJ33Papo8webLhrhjuKjsOgFY9wrYZnJOT2/kK2iS10Jfuo6fTbjOKzrtRNL+7BMa8IpOcA9fxppXRjRdjI2h7gfMMN1IbHPtU0cAMbMoBYdR27VM9qiu4UBVUYdifuj0qaHaINgDYJHUckY71HL3OqU9NDk7lHE14yYDlhkdOKzgzM2No4/iFa17FuvbkkNuXnAOQapR27KNxXIOSCv/165Jq+x6VNqxCSQEEhGP7q85qRFMpPB2g9B296eLdQcqAD7nmnsoaVWT5eOnSpSLuuhpaRG24bT27CuktwwGMhQpwSx/z61i6YQHDDJ9MDnPrWzAWZeQME9fXjFdUFZHl4h3kXRMS2wdGOSfWnTIT8xAG3gA8Ec/y9qZDAXIcZHJ3en0q35AaNgGHOCQ5rRHFJpPQoLv5TGB+WP1qB0MfzMFIIwW6mt2SBREpVwzcbscdKzJog0jHlUPr3qWhwqJlOaRSqlVwRzk96y7hEKsCAMHGD3rTVVbK8lRnBxVO7jCjgDuaxlrudMNNDivFUZFrLsykgUkSLxt4ryfw/fyXOpvLeMWdG2jnrzXqXj3UFstKnm4Xg4WvH9DBK7wVBJyckVtRjdMwxUlFo9Otr9ltSsSnzWAbAHYHI+nrmrek3TT3LPLIpZ/mbPA9645tUS0sZlSQF5gFdjyQO2DUmj64kUhUkENyD3FKcTVVly3PVbJyUAD7wecqeQfXHce9a8bsInYshY8YBOCe2f/rV5xp2uDecSASdOuOP6Vsx6zG7je4C5x1qErHJOXMdHBP5RdcMrAkHHpnIp1teiI/6O6FRyUIwf14rlH1fLARsSGOcZ/zzTBfqgby8jkD5sGpcWhppnapqUouW85EEbAbSD3pXuRksjA+ynpXInU1VQS5Ddlz0HuKcdVaRgxbOepAxS1Gkuh1fnMI/3LOCq4wrcj6Vn3E0joPOlk2g8gNjIrKi1eJHGx8knI55zUFzq6ZbccMoPXk07m0HZk0t4wlK26EIcDGWJzmr9hMJY03Hb0BBPSuJ1LVQwXyycMcHrnFWNF1J3kfcdwGeM00d6kpRPS7OFXYh5QqAjj3xWpvhVFWNjGB8xbPP+eRXIWN/NNCiKUXaexw3Pr1rTtZWTJmLBc7sAdfbn2Fa8yWyOKrG+7NC8lVUaYsQ0jpGufpk/oRVee52y5cnpx6DnqP1qhf3m+JgDliRt3c4PeqH2pijOW+bcF6/hUX10M4w11N+4u18qVMptMTAe/Fczqt8MrslPlpyAD09efyqU3QGTkBk6fSuZ1a+SMOFJKdQPeqcmzopqMWLNqLi7LBtoBz61rpqUZZZcog3gnIAHIx0rgJ9SMs4QJ1XPuKitNZWIiGf5lDZXd0qbMqrKLR6WbsPny2CZ53eoqIas8URjeQ7SCAa4c6/bgE7o0YDjHQCqkniK3KAmRNvUimjickd1PqfmAo0zsvoSfyrOutQjwxJC8H5ientXCXXieIb9kmSeuBWXNqk164VBIV6kLyWNOzCM0jpjqLLOQu4jOQR/OtCPUjDGW3A+/SuctrHWmt2eDTJlijI3STfIFz0zntWjF4R1iedhe3trBHEA8wRi5jU98cZo0XU2+sStZI2Ydbi2bndcjpg9DWbd6vGlws0ciKoyCQep+lLb+DkzbLez3UrSkuygiIpCP48cmtrTvDGlsgmtbKNlnQuBON5RAfvgE/nReKMOepLyMI+LbZcq7g+4psnieGVMR7iB8zYUniuxNhbmyuLZbAKj7fLkSIYG3jJwOAfWrr6PHFELixCMzBbdAxyrqMbh9DS50O0+558usSMVWG1uZXY5AEbZI/KnJqt85UR2N2dzFFymMt6V3UthPDtWRRDLOfLgIbKLF6FqellmWLyGJEym2jRiMqB94tn+Ljg96OcLS7nDm41iRNwsZFj3BF3MBz+dJJba4PPZ4o4lhOJGMobA9eP6V3iWRESTwJuaANb2queJVxyfXP1zUa6f5KxgFxDAu9Wdhl5T/yy/wBrmj2gKL7nHyeHdTIic3tqyyJvJQMdox0NRtoF5DdxwXc5RZIzKJFjJTH19a7CHS2JMeXidT5txIGGI26+Wa0JmmublWuYCA3JK8lEHPIPSl7RlKCPR79vKg8gDljhu21ccc1nrIkKEyEDA2MV7dOnqTU14xeJ5X+ZCxRh9BWXbyb8SkKzZ2gMOFH+e9dFx0oe6X1jjnjAlO0j7sa84+vqfap4EXaoznnvwcYqrbDYm1cmQEKoBxngVtQoIbbOVZweS4zkY7fjmrSuTUfKc1qFrGplBIJZGwOnfvWKkYMj7tzKDgcdu3/6q39SRd7yv1VSQg7nPT2qhaxB5mM24nksE+X5uwz7Vzyhqd1GdoXZntaksNwOSc46j6UwW7ebu2uewz6100Nq4U7GyQcYAz3HSqIVIyWkG5+oGP1/lQ6RSxF72JdOjaK3JO4b8/w98VeEO0kjBAAyF6mo4SxCYPJHbotWIshtp+XHGSffrWlklY5JybdyxChLxkE7UXj24q7KvksocEh1zyB0PeoomJdfKO8uOMDtWhHEj2/y53JyPpSSOOpKz1KzFAqqi7cHPXrWbdS+YM7cnnrwa1XaNFII3Z5z3BrEvy8LEoCQe/rUy2Loq7IDJtwxGM+tU7+UMT3bH5USy5QHHygd+1YOtXX2aymlcsDtIUA9655Ox6FOndnj3xl8QLcamujWR3CA75yvqei15+k08GG2yLjvivYNO8IW0Vo01yu64kbe7yfM2489e9VJPDkd7rCxJEBbxEFxjhjXTCrGEbWOSthZ1JubZxOm6JqupxiRFWMPwGkJrXTwXqisX+3W4K/7LV6na6ckaoqIAoHGKsnT/MjAjPTOeOtYSxDew44dJas8ph8Na3E2Y761Y+4bmiXQ/FEA3KIJcc7lf9Oa9UXT1VwoGPrxirqaayxeYPnjzg1KqvsU6Ee54lLe67ZD/TbCcKucsi5/lUMXiooSJWIbsGX+ea90ktEbG9F56ZFY+p+GdOvVYXNjE5/vbRz/AIVaqJ7oh4d9GebQeK4SuSVz3yeasL4kidTtlUAcgg4Oa1NR+G2mzOBbebat3KnI/I1xuseCNV0xWlh8q7gH91sPj6f4VquSXUxlTqR6Gw+uqIy5lCknPDc1VuvFAZAIizSZzluefWuPMvkSbZoSjj+GRcVct9VSIACJMD261fsTNVEjWOpX9wVZUdipyGK1saPqn2dw0+8scAgj3rDTxDGUG93BHvxTZNehYHchYnphaPZ9kWsTbQ9T07V1Bz5q4fHQ9K1W11CjRlxjsS2a8Rk1tiwRUdDjgEYph1Kdsf6/D9No/lS9kL6w2ezXWuxsRhkAJGMHpzWbca+gN0RMgTPY968k86eQp5SznedqljjPtUkVteTbgzbPm2YJzlv896PZ2D2zbO+vfFke3KvuyPXpWHd+JY5HIduvp2qlZ+HHuBMHdv3WEyT8pfsv/wBeuo0Xw/HaTgy2cBkgG4OoPMn9w1LsilOctjmoL+R932W0nlYMCSIycZ6Zq6dH1jUpRG1ikBILbpXChQPX0r0S30eK/L3MMs6GJVlnVQMMR0Qj0/rVvT9CvL1hFOimW5zIQ2U3Jn5R7dOtZupbY0UG1eTPM7LwZLcra/ar+O1ad2Hl43Mqr1br0rd0/wCHelspa4mvZWdtsXRQMd2AzwfrXbHSDMyvCqh2XymymHWJTyp960LaC5aWCKK3WFpm8uBX6LEPvbuxz6dal1W9i1TitzD0nwno2myyT2+kRTKSIU89N7CTufm4xXT6VaWUWqEL9njt4yUO5Ah3Yyfz5xVqC22FZU3eXExtrdH43P6EenucVaGnQlRHerFLDaAlt43Hzic7CD/D71F31B8qTSM6PQpGvFit5hFC+6UpIu4Y7Kfr1xWf9kKkxT7raYuXLBcjylP3Mngqe2a62zsVh/0ZpmRA32i4DPuMLY4XPXaRVu+lhKo9/CyALmfABVY+q49v8aFtcj2lnY4+fSftDiNofKM6klnjyIYx1iJzwG7EVXl0y6dJGt0EMs22GENHj7PEvUZ64Pv+ddlPBbT2MMNuUN1LIVkRW3bkxnB9sVR1CAW8cV0yxySXCC3EoYjbHkZU+/vRdoFNNnOCGTez28Uu0sbaFTEV2KD87dTkGkWJI5CbUFAJhDbDnYHA5PTp71viUlZ1tyrRXJEFt85AMY67s9+Dg1VuERYQLBHKohtrSEy/eJHzEnqCPfii6K5n1MrzzGyC/Vfs8TGKNg2WZjx0HYc+1acelxaleXMNjdeRGyhAdodSRzkemaYYmiSFYA06Iv2a1DurCbu7E9fl/wAinJvtLuG4sj5TbvKhxjbN6tjI5GO+KezJbutCParI8nlsskDCCKLBZc45YHseKc2kxfZmiki863jcOgZc+dMP4h647itPS7ptL+1veReeWDYkUfKZD1wOvAFWdLtIpdOkuomCz2q74l3ZUMeckevNSNy5d9jGk0xWaUOiyhh5uouxPP8AdVT29s1I1lObgwMUN/dJukUjlYB09s/nW7bwMLSOW5Tybb/W3LhshpSM/kfQ1KsbSxhRhZ7vpIBlYoh2Ht9OlMzdRooajcj7UYrdT9lADqq+p6/XkVTiYqZFboT9z/GozL9pgSSPKvDCCBnqOcge9Vg6ySgRBuH9P61036nfTh7tjqLNA5hwwxxwP4hx1/KtERLxghgDgex57fjWFZ3KoE2qM5+XjgfX61tW825FCANu6dsn/wCtXVFpo4q0WmZOoI81zsAUKE8sn+6cZzTYI/JeRZD8r9G6k+9W7wMJL4AFwQnzEdD6/wCfWqyyPGxV1XhgoIPJz/SoS1uzRSbjZEzRSsxaI7C5BLj+EdOB3pr28dvBKwXLKASSdxf7p/8Ar1czE37t2yqkhWPHqahuIN2CGwGOcD0HFW0ZqbvYhjKedsQHlM5Iwp9s+vSrc0EYbKkknsBwOw/r+VLC6BeuCuSMryT/AJ/lVqzeMqWYDIOSCc8D/IqWkTKTWotnGrInl8MF+Y+vP6elaMCExHb2ydx/pVKN2+WOJTmYbiB/d/zk1etpnjikyQoH3QefzqbHNUuyheQ5d3KMO+DWVeyK4JZCmRwe1at9dAhQD+8b0/lisW4KEFQSTjJPYVlPQ6KKfUxbiRskKSUAwM8Vh30Qub2NCF8uL5mB4B7Ctu+YxhmZuo6DtVGGIyqJyhRWy248ZHYVyfEz1YOyuZeueWiskXBPyg+p74qnpFksFooHEpPzfWptQHnzZjYMinanGM+tWNPcxSJHNgqfQdKmTuzb2doFiKNOVGd69c/zrShgJi3mOTA6HaeabEqZ5wvfK/pzirhvHVViimcZ+Zjkj86FFdTlnd6Iz5kWFS8kWD1AIxmqI1SUFkjGzqdhHBqbVZrqWQQNdloz2EoqO2ildhulbA45Oc07a6HTTprlvMheWWSPc2RnOMnpTY4Z5CMkhcda2nt1aM4IBxjAUHn6VCsDxgIuGwO3y546mtOSw+ePRGLc2cyqSSxzx1rNmsZNmZSDgYJrrGGQwKkjPU9s1BNChLjBHeiwKXkef3+g2t/GwubVJOwJHK/jXH654CNvA9zYylVUbmRzkfQGvXbhQGKxoBtP3j3qtLbpdRBZB8u/BX6c/wCFVCbhszLEUIVVdo8AtNPeeREI6k7v9kDt9a0bTR7h3j2RyZPIR0P3R1Br1ux0mzWeV0jjDO7NkDnrzV65t1jSVkT5hGQOPWtXiGzhjlrW7PNrPR/tdzCZbWaKOVgDI6ZCKP8A69ah8Ko165tpok899oDn5UQDqfTJ6V3sUQSGNXwpwDtPenmxjkPTcCc/KM1m6rZosvjHqcVB4eMskiLbK8pUxIsLbsLnBfPr1rRt/B00RjuLWNZYoV8mHHymUnhj9R+ddGdMQqcR9TgmmHSUjGEV129lYgVLlLoH1SKILHwu+mtGMK9tbDar7s+fKf4Tjrj6Vs2ulQxDymIVIDulLHgzHpGx747EcisxdOJWMLJOFD+YmJG+Vx/Fj196m/syU+a89zKS773/AHp+ZvU+9S7sfseXqb1vZpCroqOJJBvuWj5wD0DehH61e043Fjd+dbCK6klJRfNO1o4wMZ9M8cVzSWF2Gl2X92ryqFciQncBwAc054tQUMwvbjd5fl/MFOV9M4pcrE6d9DtLSWzksTdzbYhds0IiYANGPX60XUN1EU2RxSRTL5aJJkMsQ9/WuAvpdakzvuopMqFLPCCcfUd6G8YeKrpzG8Onjyf3fmGJvnGOpGaOQzdOSeh3W+WFo7xUVBtMFvG+MMx9fRveqom8gRRyNKFsQZWYjes8h4EbfT6VxNzdeJdQjQXOqvEqNvWOCJYwD6jjNUn06/mX9/qd/KM5P79uvrxRys0VBtanpEUk4ji+2RMjSqbi4ZsERJjKxsc9DzSrdCe2WWV40Rh5rk7SAv8ADH16HtXmQ8NxSmQTS3Ds4+ctKSW+vPNRnw5ZxceWuT1yTT5Bewdz0N2jZ1uLV4Yb26YEseAFX+Bh/WiTWVhnRrt7cQzSkIm7hH7lvbHIrz5fDUO5iIOB3yaUeFrWQZaEE9gRTUBuh5noNjd2mp3sixlM7hEuJByDxkAfnSXNvKby8Me9vKAjTCjjuWBPcfrXnsvh6zUHbBtP+yMEUDT7u0y2nahe25PaOVsc+oNPkRLoyWx3Mcxd2liQNIoEcYCAEj+JwB0PqKiU/vd0Yj8uLKwx4bBkP8YHoO5Ga4ZNa8R6bE0ZNpfp82DNHtkUnqQy45/OtLT/ABjYyLHHfQS6bdqu2JpCWjVj1bcOgPoRU8rE4NHUR3j20r7/AC0W0whADEPM38Q9uff6VOLwWazwP5cbrCslyQSULk8bW9/SoxJCtvBPbzK9rAAsTCTIeVh0OeqnPXNRRk275LSr9nJmuNwGGkPSM+350rEW6HQrql0YjaXse1JSsshiwyqPw7e9aVleWd9DObQqzsAlsckHHQmuOSaWDKyu0NxeHzpHALLAnpgnjNXY5YdwkWDZP/q4niOdkY6nI7H3p+plKmnsZFlvVnGGBbJwDgZ71dtvLiAywxnIGOB7UkwTzRGjKsbgEFuuf8moo2ZGYMoUdCW5rR6Hq09Uasc5KA/KMZ5Pet7SJd20xkrtX5hnHHc1xY3eeAWLAdvQVs2l1JGx2EjK4xitadSz1M69G8dDVlnL3TuF3IGC7AevHSmJLiUAjb2ww6jtVS8XF2xQsobDDJ5z/kVLBHufcj5Xrn09RWqk7nNyKxdYfMu4BV+vNT/LJbr52T9DyajyrHAZAp598inRjzpBk5BGMZwPzq76mLROUQLuUjZjpmorVDIRG2Q7fMzDqF9Px/rSxndIYywZB1Jp28hjtJLngsOoNJ6is9i75wDNGpAYkgbTnHt/IfnVOR3RDGJM4Y5OeM/1Azj60QQiMbd2WJLbgcH0zn26VHdzLFFshCj1CjHPYZ/z3o82Soa2RSuLnO4dWHTtxUG9pOWBzjLVFcSAKm/Jxznuc9/89qaHaMOC42gZY+lc02dahZaFGdJbyR4IBkpyzE/dFSXSGKBic4jQeXn+dXNLtGjLSMjBXbLc8Y7VNdWzzyXTMDgKAAeo49KiEG1c09olK3RHJvAiKowqgjJx3Pf+dKbZ1RnUhQBkHPv/AJ/KtpbCRWyYyzp2FSSaY7qCZI98gwoDkgD0o9i30Ol14rqUotjQgshGV4LHqaki8iQtGd6IBljjv+dX30yZwhLI23GBux/MYzViOxdHCypCwXBIJVsDnuKtUe6OeVWO6ZhG0iflLmM7OnI5p0NuybmRw8mMkFdv61tNaFZBjeke4E9CKljt4fn2AqoGDzj/APXTVIbxGhjRygONg7Z+Ye1OlCStJiIAjldmQPyrS+zeZITGE5IBcuAQfYUSRyKB+6XHcsCafI7C9or6GUUjwCN5HX3NVJow5BYncvPSr65UlgIzwduQev8A9aq16hYb1BUDhjj/AD2rNx0NovUxpyB5jMRxyarJZymCFmx87M2T7+lSyRO52c5Zhn6V0CQr8iIgOwkKH4xx1zisUrm85chz0FrxnPQYwO9QXe4W1wQDyOv0rqGsWihkkdkG0fMBIOfwrOuYVGmSbgCWAAx15yapxaCNVSZUtIg8at8udowD9OtWkjCjheD1IqSxj8yJMg7sYx71sQ2QU7ThiT8uCAB7YpxjcyqVFHRmPEn7oEAFjk0S2smVKg44PGSK15bNkYZwM/7QoFp5yBQiknsGzgetXydDH2q3KMVlMWGYW5GfersNk0jKHQ5UinLbKjqHZM4ydw5JqZbdXT5pFCNjohJzT5DOc79Q+wy7iRGTnpkgZrNuLdgpYA/eIrYgt487RNGD2yrDP6U6eJIwQ3lnbnkfypNaGKnZ2Of+zPtJI5IPBpkNlHDCu9Budg2Sf0961flWLKcknBHpk0nkh2iQHODkZ/xpJFXdzKljVyRt7dB3pkUYG7euPwreuoQSwwA2AOT7VFHalm5PHTr71XL2NIzVjGWIEnLDv7e1RixRzglfX3+tbVxbxqWWNN3HL+nHWoRbnzVYJjPGF7e1JR6MrnvqjMMDxFTGoIPBHXipkG5sqFy4/u4rYgiQttaNl4+81Mmtk3sY1CYxk4rXktsRz62Zm3NoyEAohJ+9jgCqz20TE5G3vhR0rYWMmbMy/mOoq1NYo0fABZu/p/hRyXD2nLozlbjTsB/k3DPBxzWDf6ZG5beuQ/ByOldwqiNiucIehz3qhfQpJjJ465A61LiWpX3OGsftOg3EZtWaSxU7mtWPyknuB2Ndkt1aXsFtJbzCa2bMrnHOR/BJ7+9Zd/aAI3BZB36/SsGK5l0PVkl84pZynbOmARjsfwPes5QuZ1FZXR2cDm6mm+YN9oOXZuixj+Bv6U+3Z5HeSB/LuLg+XG2T+7gHVSD36/Wq1i0OrTTNK0UUs/Vo2wCg/wATUkcVxK0pAeUH77xn5kjHAP1+lK1jnumUzqcc9nDMgYsp5x2Bq7ayeZy7A8fUEV5PHq15pLNZXoKkZAbHDfSut0HXUurUASfvF61rOmb0cRZWeh2cwCfNuUrjC4zmp7N2u5WUyrkdDzn8a5trtzjDE9Tn1qTSLx1nb7w5wT61Cdmdq96N0doZQYcHDEDcD60xJnEm1gdjdSBwazXuvNRGJ2gcdasRzYUgDI7k96tyuZKFkabzqZFZGA4zye30p8MzqxVyTk5UdjWfC6HBYj06Uq3ixueuQMDHSjm6kOF9DaZtm1UJJ6k+uetWIp0JUsq9MKuefr9a5/7Sq8Bsljgg8flVmO7UwoPMUEnAHRq1jMylR0Nd5m3s65AA444IHQH+lU5nAU7mBPTgc1XadYwv71CT2BIP4fyqGe4IJBQAkZ3Buuf8/lRNihTsRTybY2G5izdPlx361b02zkmkiSRcb2LDd/EB1P8ASs2OVTcyPOWKIMswPb29z2FdHpbsIZZpl2zSDYFJ/wBWnZf896xjHmZVeThGyJBEJrpPKBCgYHOaa8Cx3c6OuN0fysPrgn6Vq2sYS2SQfM44B7jp+lULiRHhilG3OXRwBk4zn+ldXLY4ozbdkRw2ilQzjCngccf56mrhg8po0jCh2ywJJ4Hp7Z61EkhBjZmMiYB2r3IB61fjVIox8jfMBk4+6fxq1oTOb6lJvtKBwViZkJXaex681Kkc0cTSi2t2DcDI4OevP8zT22Ftqx4GWDbn5I/KkB8vDRQKAh67i3HoB3/rRclyuhEgO/zAkO45G1DyPoO31p12AFYiOTLgcFSFOPT2q6k6OhRWhbA3YQ8n15/nSXV1CiAFMndySwPOOAfb2o6GXO77GLKY2VnCDaigkEck1VuYN8YIyADuwpxg1oXNy0iMGhQ5XIYnoc5x+lQJGjIZF4O4YC5yc8AD3NQ1c6oza1MuOFl3FnwTgNj/AD0FVr6AraEhc4U7mHft+orfu7YrHGFIM8p28noR1/DpVO8gAs5VbGWQEcd8ccfQVDp6G0K92mcW6/6XE0W4Y5xjHb/69bUMbBHcsw3Nj5uT+VVLaIreKjrkt69uQP8AGuiSKNw4xtHmY4GS2B0/PFctKF2zrrVrWRm3kKpZAtFwQW/DGT71i6koS1iXoCoOM9a6/wAUwxxWcrxPvKxANt6HgDr9T+lc3qECS/ZznaoRQqjg/wCeK0rQtoLDVeZKTJbABDHvGCBs6dB/nAroIbT+LJZT8xbHU468/wAvesnSIGDtIVLKMEY9eg9feumRGC5Z95wVXsFwcD9cn8K1pU/d1ObFVLS0KMkaMhVY4Q+CDzk/Q88VE1uNoRfLzt5bGPwzWmoWFZF5OVBJ6ZGev6fpULfZvJQtICCuTuHAbPA/LFVyo5lUZmXqTOZMSpuAzyFA3YwBwKq21vJhPPmgNwEBOxtq7iOSM9uvWtYhWkdpfnGSN3Qe5z644x70XBV93m7Y0PA56EDn8un40OCepuqjSsVYrc5JhKb8cHzQQPTvUYhlEbZzI3GQDnHf+orQtYRHHhzGEPIzjk4yf14rQhjgRxgJjHAQe/8A9ap9mmYzrcrOcEASAYX+Lv3H/wCqliZYyq7ScAfn6E/56VrTxxoURQpBJYc9OAP6VC6KJjEwXJY5weOBUqnYarc25TjjL3VwzEhWPGa0YLHz5X2AEKM56fU4qlZlLj7QXJGxto2j0xVtrgW7hV5U88np9fWqgkOo5XtHcrXVi8Mm9F+QkAlunUD+hqpJC20tuQAAnajdgcHp7VdnUy53ZcD5gwOeOf8A69V3ltUMYaSNU3YA3D1yePTgU+RGkJSD7IFhyRg7sjj3xUsFuWXAkPPAz3qxDPG8UmSrE85AzwTk8+vSqv26NXGRswWJBHRicn8B/Or5YoXNKV0MubddwYZyDn04/wAmo5ztMa4G5ugzxnNWtyOh8plYL6nJ/wAis+aMhmZeC3Y84PWhoqLvuZd4rLMc5Bzk8darMr7CV++TwAatSIcEEnbjqOef8/zqpNnJB3HjP69M1gzqW1ivO5Ik2D73t25rjfE0J8t1bqVxXVyOSmM4XHPbt/OuT1pyQ2CSNuOetJK5EnYl0TT31fQBPCPKntcGSRW5dB1GPXFaPh/VXsZZZJF+WdDHEycgAdz6d6s/BW4L3dzb/L5Ox94PIYemKzDEYdRuowwRllO84yqRAkAge/em1ZJnlU5805Q7F7xH4cg1S2khkUK45VgOleQXgvPDWrG3uN23PyuOjCvoeUKxwcZHUZ6+9ct4x8PWus2JhnQB8ZV+6miEuXR7Hq16HtFzR3OY0HXYri3jLON68/WugFym4ssi5PPHSvE9QjvfD+pNazlhtPyN2Za29I8SEHa8hHuTVypXOGGKlTdmeti+2AAOSCccVbg1IE43H5ewrgLPX4AApIYngt6VrWmrRSvtU4I5yO9ZOmzpjjEzuYr0t8qnknI9hQ0wkYkAEg9Aa5+LUrZ8guxyOq/yq9a6hAihUIUAZxUuLNo109jV3bcbh7YJ6VHcXEkUseA7BvvMMDBx3/8ArVSmv7diCDuIqC41EMreY5Y8Y/wpNGsZ3NVdQAO5nIB6sOT9KfPdb2QoW3MCRk569/xrlftgRgRwM9+9T2t6F3SB/lXgHPOT0x60r9DZpbna6VJEl5FCTm4kUlGf7sZwfnx7dvetaGaKG3+VmwVILucknvXHaDd+REbhjmdjyzjJ/CpZdaO0rlWTGCx61tCfKrnNKk5yOr/try3Cli+TyAcD9Kq/b9kjjc25ZSQe/JP+NcZJqZBLx988fSm3upG4kMrMVyASUHtSdZstYaKZ6FbXnnFfvDDc7OOcHGf0rRhnK9XdAcE7sYzXm9rq22PyiFGBkkHk/rW7FqCyRxHcxyu3JxzWsKia1OerhrHWLd+RJud15OfmcHjHWp5NTjS3ZwEjwvPy+vrXHSXM2T5kmFZRnLY/DioReyRwna7sCMbS/Sm6ljH6qpHWPq4hR97IhlGEMeeuP5URXryRgSMkPIwQuSSf51yyzAxq11hmQgEHGfoDjJq9FqEckqrDGScqMoM7Rj+Lil7QcsOktEbyYID793GPu9B7571aiiA2FDtIAB4B4HOPx/lWaJNp5L7sZJC4AHoasPetHsA37ScEs479f89qvY5JJvYsTyFZo5Ao355wMBVPU/jVVULLI5Ixgsx9+uD/AOO1IZkmJz8y5xzyWz/j29qSWZYUVUUtgHOB8pOfX0z/ACoJTtoYjQLHdq27OwKgA43Ef49a0NMZnvVgjHzYZgSegzj8+BiqF/N5drZwSrtmaYu3PQlRgZ9hj86j0y7VdTmOAOm3J7g1hH3ZWOltzizofFihrbZGyk+YNw2/hjjtndXN3Sedd2gQAbYy+MVt6gS8UCkuwUMeW6hRwT+JrKimj3pkgb4U25Hp2z9SfyrSouaWpOHk4wNm3RLWEo/zDbvAx1AAx+pFPwE8wIpDqm3c2SABxwPUnP4VnNqBE4AD/OAx24GB1/Tio21KPypwQT8m0cjpj/P4k1q5JIlwk9TcmVvLBEmQ0S7j7Ec49uwrMjlKboW+Zcndk9s/4/yFSR3Hn2sZD8nHBPUY6fpVSZxHIygDCqo3D6ZP86mT6kU9PdZZgijnO8qWQ+jcdM/0J/Knw2Nq8yiIFXzwA5PXH/16pQ30bpjzEIzk4OBz19uAAKlS/i3ZBVWAzjfnnHp+NNWKbmr2NSHT4gWK72XCkc8jJzTpFW3Py8NjJGeQMdPrzVb+0FSPAK5J4UY5IGO31qld6jkkowDNwQ34cfpVOyRzpTk9SS+aH7ZEySnO/HHoBzUdtIst5EWcFRyc9cHJP9OaxppGnLGP723cFxjOOv8AOpba6ZYsYBZ4ioHoTgE1Cs2bqDS3Ltk8mQkRIDtvA6cct/hUk0QkjyVUOARuB6EKDz+Jqk9393ACsp4I9NpA/pRLeKNyqpDjcNueBkgU0klZmy5r3Rfjinh2qdsqIzFh34IGKeDCzKqwqrZxkLg+9ZcuoFlYrubAOce7frVB9S+fccb+2DyOf/rVXNGJapykdS0qQw7QwAAycnqaqz3kKuAx5PTjjp/n865Ca/nYmMPz7Gp7d3wHnJBHTHOfc1DrX2RX1bl1bOlZIhllCN354xn/AArLctNIw3KYowckDrUL6gnl4Jyx4GeccYqKO5CKzPgB+OPalKSZUYNasnLrscDHy857E+3+e1U7qPbC5YYGCMk8/T9KllZNuVJwORjp/n2qjeT7wjEjcf4f5VDQ+axlXjHAG7GepxxXNeIZFW2dm7da6K/njGSnJHfI5Nef+JrzzwYI3VSSQC7dT6fjRGJz169kV/APivU9MtdVu9KslndGMe6UgJtY9cdT+FdzpMIn0e2LSbp3CzyzKoB55Ke/tXIX+iS2Gl6LZLMoTInuRESxgBPOMHkkHH1rutCtrW7spIrR/KYKZJCOOP4eD7CrrJJJI8vB3c5TezOjkH75P90Ul8AYSSMnFFFYPqfT9UeNfGFF+y2b7Rv3fexzXmaEjoaKK6qXwHh4v+Oy/auwxhm/P3rorSWQGPDt931ooqWYm1pztu+8eTzzWqrtgHc2T70UVlLY6aW4JI+U+duuOtW1ZsfePGe9FFZs76exHcMxliBJIPXn2qxbczrnsmR7cUUVJutjYLtvA3HHPGfaqzs24fMeRzzRRQzSOw1idh5qduLSDHHXpRRUsgi/5YKe/mYz7VdsHYFRubB7ZoooibP4DWVm8vG443HjNWYnbIG5sbc4zRRWyMGMiY7wMnox/lVhJZI40WN3VTnIU4zRRSRMi7pUsjWrEyOTnuT6VbkJEwUE7SoBHaiitFsc0viZdEjrBFtdh8jHg1LL/wAeaHvhef8AgJooq3ucc9zJ1onz35PDPj2+asnTSTeQgkkeTn8cmiisJ/GdFH4GdVdk+bjPAh49uTWLCSYrYk5IJx7cUUVvP4iKGxJqDst4m1iMqw4PuaqsB/ZsTYG4hsnueTRRUVOpvD4UaOnEjZyf9Wf5Vbu+UlB6YAooql8JyT+MzbZFN1cAqCAuACPcVvadbw/ZUbyo84PO0f7NFFFM1rbFvVQIoFEYCDcw+Xj0rlJBm9weRuxj8aKK1q9Dnw/Ufbk/bI/aE/yNZ87FY0Kkg47UUVmzen8Rdj/49R/vY/Ss26ZtqfMfvEdf9qiiiRtT3KwY+aOT0/rTz9+b2BoorM60Vo/4v97FaGSLWIA4B3Ej1NFFERVOhnyMwjmwT8qgjnpUbMdw5PT196KKTLLtpzG6nlQBwaqXnD3OOPkc/wAv8aKKuOyOSp1OY1cny2OTkGuKlRZNas1dQy72OCMjpRRV9UebidmbOjc29uT1eYBv9oZPWuktWZNRvWVirMnzEHBPHeiipluyKfwI/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acral erythema of the hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Payne AS, Jones WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 2006; 33:86. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21016=[""].join("\n");
var outline_f20_33_21016=null;
var title_f20_33_21017="Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth";
var content_f20_33_21017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21017/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21017/contributors\">",
"     Vincenzo Berghella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21017/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21017/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21017/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21017/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21017/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/33/21017/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonographic imaging of the cervix across gestation has enhanced our understanding of cervical performance during pregnancy. Cervical effacement is one of the first steps in the parturition process, preceding labor by at least four to eight weeks. Effacement begins at the internal cervical os and proceeds caudally in a sequential pattern, thus it can be seen by ultrasound, but is not always appreciated by digital or visual examination. As cervical length decreases in the second trimester, the risk of spontaneous preterm birth increases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/1-5\">",
"     1-5",
"    </a>",
"    ], especially when effacement occurs early in the second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a short cervix can be viewed as evidence that the process of parturition has begun, the cause of preterm cervical shortening is often unclear. It has been attributed to biological variation, occult uterine activity, uterine overdistention, congenital or acquired cervical insufficiency, decidual hemorrhage, and infection or inflammation. Risk factors for short cervix and cervical insufficiency are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"     \"Cervical insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transvaginal ultrasound (TVU) examination is the most reproducible and reliable technique for cervical assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/7\">",
"     7",
"    </a>",
"    ]. When a short cervix is suspected by transabdominal sonography before 25 weeks, TVU examination should be performed to obtain the best estimate of cervical length. Transabdominal images of the cervix are less reproducible; thus, they should not be used for clinical management [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transperineal sonography is more difficult, less reproducible and less valid than transvaginal sonography [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H921489\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical length measurements before 14 weeks of gestation have limited clinical value [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, in some particularly high-risk pregnancies, such as those with prior second trimester losses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    large (or multiple) cone biopsies, cervical shortening has been seen as early as 10 to 13 weeks of gestation and is abnormal and associated with a high risk of second trimester loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/13\">",
"     13",
"    </a>",
"    ]. Reproducible measurement of cervical length becomes possible at about 14 weeks of gestation, when the cervix normally becomes distinct from the lower uterine segment.",
"   </p>",
"   <p>",
"    No test performed in nonpregnant women reliably predicts cervical insufficiency in a future pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should empty her bladder prior to the TVU examination.",
"     </li>",
"     <li>",
"      Ultrasound gel is placed on a transvaginal probe before covering it with a condom (or specialized probe cover) and then more ultrasound gel is placed on top of the cover. If the membranes are ruptured, both the cover and the gel should be sterile.",
"     </li>",
"     <li>",
"      With the real-time image in view, the transducer is gently inserted into the anterior fornix until the cervix is visualized, while avoiding excessive pressure on the anterior cervical lip. The image of the cervix is enlarged to fill at least one-half of the ultrasound screen and oriented so that cephalad is to the left of the screen. Fetal membranes in the cervical canal or beyond the cervix should be noted, if present.",
"     </li>",
"     <li>",
"      The amniotic fluid in the lower uterine segment is assessed and then the lowest edge of the empty maternal bladder. The cervical internal os is then located, often just below this edge.",
"     </li>",
"     <li>",
"      The appropriate sagittal long-axis view for measuring cervical length includes the usually V-shaped notch at the internal os, the triangular area of echodensity at the external os, and the endocervical canal, which appears as a faint line of echodensity or echolucency between the two (",
"      <a class=\"graphic graphic_figure graphicRef82336 \" href=\"UTD.htm?31/58/32673\">",
"       figure 1",
"      </a>",
"      ). Excess pressure on the cervix can artificially increase its apparent length. This can be avoided by first obtaining an apparently satisfactory image, withdrawing the probe until the image blurs, and then reapplying only enough pressure to restore the image (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72281 \" href=\"UTD.htm?7/44/7874\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cervical length is represented by the line made by the interface of the mucosal surfaces (the closed portion of the cervix). It is usually the distance between calipers placed at the notches made by the internal os and external os. If the internal os is open (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62467 \" href=\"UTD.htm?2/11/2227\">",
"       image 2",
"      </a>",
"      ), cervical length is measured from the tip of the funnel to the external os (",
"      <a class=\"graphic graphic_figure graphicRef82336 \" href=\"UTD.htm?31/58/32673\">",
"       figure 1",
"      </a>",
"      ). Cervical length should only be determined from images in which the lower-most edge of the empty maternal bladder and the internal and external os are visible, and when the anterior and posterior lips of the cervix are of about equal thickness. If the cervix appears asymmetric, thin anteriorly and thicker posteriorly, this suggests excessive probe pressure.",
"     </li>",
"     <li>",
"      At times, the cervical canal is curved. In these cases, the length of the cervix can be measured in two ways. In one, the length of a single straight line from the internal to external os is measured. In the other, the sum of two separate straight lines joined at an angle along the curved length of cervix is determined: this sum is used for the cervical length if the distance between the angle and a straight line from the internal to external os is &gt;5 mm (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61433 \" href=\"UTD.htm?32/6/32870\">",
"       image 3",
"      </a>",
"      ), as it may provide a more accurate measurement [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/16\">",
"       16",
"      </a>",
"      ]. Usually a curved cervix means a long cervix, and thus at low risk for preterm birth, while a short cervix is usually straight. We avoid tracing the cervical canal because it introduces unpredictable operator variation.",
"     </li>",
"     <li>",
"      When three measurements have been obtained that satisfy measurement criteria and vary by less than 10 percent, the shortest of these is chosen and recorded as the \"shortest best.\" Choosing the shortest of three excellent images reduces inter-observer variation. We do not determine the best measurement by image quality because this introduces an unpredictable variable.",
"     </li>",
"     <li>",
"      Abdominal pressure applied to the fundus for 15 seconds can aid the examination by revealing a &ldquo;dynamic&rdquo; cervix, ie, the development of short cervical length in a cervix seemingly initially of normal length [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. It is important to allow at least five minutes for the total examination, and a couple of minutes between the gentle application of fundal pressure and recording the presence of a short cervix, as it takes time for development of dynamic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      &ldquo;transfundal pressure elicited&rdquo; changes in the cervix.",
"      <br/>",
"      <br/>",
"      If a short (or shorter) cervical length is seen after application of fundal pressure, the length of the residual closed portion of the cervix is taken three times, with the shortest length recorded in millimeters as the best estimate of the true length of the cervix. This length best correlates with duration of pregnancy. Only one measurement should be reported: the shortest best cervical length (mm) of all measurements taken.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cervix may be easier to locate sonographically if a digital examination is performed first, as gel from the examiner's glove left in the cervical canal makes the external os more echogenic. In addition, digital examination aids in the assessment of risk of premature delivery by determining dilation, position, and consistency, features not optimally assessed by ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following pitfalls can lead to suboptimal measurement of cervical length, typically resulting in over-estimation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Excessive pressure",
"      </strong>",
"      - Putting excess pressure on the cervix during the examination is a common mistake in performing transvaginal ultrasound. This creates an artificially longer cervix due to compression of the anterior cervical lip and lower uterine segment. As discussed above, this may be avoided by withdrawing the probe when the internal and external os are visualized until slight blurring occurs, and then the probe is inserted slightly until a clear image returns. The anterior and posterior lips of the cervix should be of approximately equal thickness (",
"      <a class=\"graphic graphic_figure graphicRef82336 \" href=\"UTD.htm?31/58/32673\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Not allowing enough time to view dynamic changes",
"      </strong>",
"      - A common problem is measuring the cervical length too quickly, without allowing adequate time (about five minutes) for any effects of transient pressure on the cervix to resolve.",
"     </li>",
"     <li>",
"      <strong>",
"       Uterine contractions",
"      </strong>",
"      - Contractions during the examination can cause a false impression of a long cervix. If the internal os is not clearly visualized, and a contraction is present, the sonographer needs to wait until the contraction resolves before the cervical length can be measured accurately.",
"     </li>",
"     <li>",
"      <strong>",
"       Underdevelopment of the lower uterine segment",
"      </strong>",
"      - As discussed above, before 14 weeks it is particularly difficult to differentiate between the lower uterine segment and true cervix, as the pregnancy has not yet expanded to the whole uterus. Placenta previa may also create this same phenomenon, resulting in an artificially increased cervical length.",
"      <br/>",
"      <br/>",
"      If the lower uterine segment is underdeveloped, it can be difficult to identify the true internal os and some myometrium may be included in the cervical length measurement. This should be suspected when the cervix appears longer than 50 mm or the internal os is cephalad above the bladder reflection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/18\">",
"       18",
"      </a>",
"      ]. A difference in echotexture between myometrium and true cervical stroma often can be appreciated during real time scanning, and provides a means for differentiating between the two structures.",
"      <br/>",
"     </li>",
"     <li>",
"      <strong>",
"       Prior cervical surgery",
"      </strong>",
"      - Prior cervical surgery may alter the appearance of the cervix, making the identification of measurement landmarks difficult.",
"     </li>",
"     <li>",
"      <strong>",
"       Air bubbles",
"      </strong>",
"      - Hasty placement of lubricant into the transducer cover may generate small air bubbles that create a poor image.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7011682\">",
"    <span class=\"h2\">",
"     Quality assurance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to obtain adequate measurements of cervical length, transvaginal ultrasound should be performed in accordance with all of the technical steps described above. With proper technique, the intra- and inter-observer variabilities are &lt;10 percent. We suggest performing at least 20 TVU cervical length examinations under supervision before generating clinical reports of TVU cervical length independently.",
"   </p>",
"   <p>",
"    An online tutorial is available from the Fetal Medicine Foundation (UK) at",
"    <span class=\"nowrap\">",
"     file://www.fetalmedicine.com/fmf/online-education/05-cervical-assessment/.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13942792\">",
"    <span class=\"h1\">",
"     SIGNIFICANT SONOGRAPHIC FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12424584\">",
"    <span class=\"h2\">",
"     Findings predictive of preterm birth",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7011713\">",
"    <span class=\"h3\">",
"     Short cervical length",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical length is normally stable between 14 and 28 weeks, and declines substantially after 28 to 32 weeks. Between about 14 and 28 weeks of gestation, the length of the cervix is described by a normal bell-shaped curve [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      2nd centile at 15 mm",
"     </li>",
"     <li>",
"      5th centile at 20 mm",
"     </li>",
"     <li>",
"      10th centile at 25 mm",
"     </li>",
"     <li>",
"      50th centile at 35 mm",
"     </li>",
"     <li>",
"      90th centile at 45 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The median cervical length is 40 mm before 22 weeks, 35 mm at 22 to 32 weeks, and 30 mm after 32 weeks. Cervical length is not significantly affected by parity,",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    or maternal height [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/1-3,20-24\">",
"     1-3,20-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increasing risk of preterm birth as cervical length decreases has been consistently observed in all populations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Short cervical length at 16 to 28 weeks is the cervical change best related to the risk of preterm birth, with a particularly strong relationship when it occurs before 24 weeks or in women with a prior preterm birth, especially before 32 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/1-6,18,25,26\">",
"     1-6,18,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Short cervix has been variably defined. A cervical length below the 10th percentile (25 mm) is consistently associated with an increased risk of spontaneous preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/2,4,18,27-29\">",
"     2,4,18,27-29",
"    </a>",
"    ]. However, there is no threshold value below which the patient always delivers preterm. This was illustrated in a study where providers were unaware of their patients&rsquo; cervical ultrasound measurement: only 18 percent of women with cervical length below the 10th percentile (25 mm) at about 24 weeks of gestation delivered at &lt;35 weeks and only about 50 percent of those whose cervical length was below the first percentile (13 mm) at about 24 weeks delivered at &lt;35 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/1\">",
"     1",
"    </a>",
"    ]. In another study, 75 percent of women with no measurable cervical length at 14 to 28 weeks of gestation delivered &lt;32 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound studies of the cervix in women with normal and complicated pregnancies show that cervical shortening usually occurs slowly and precedes labor by several weeks in most cases. Thus, a short cervix performs best for predicting preterm birth risk over the next eight weeks, rather than imminent preterm delivery. Conversely, a normal (ie, &ge;25 mm) cervix after 22 weeks indicates a low risk of imminent preterm birth.",
"   </p>",
"   <p>",
"    Among women diagnosed with a short cervix (&lt;25 mm) between 20 and 28 weeks, the rate of change in cervical length on subsequent ultrasound examinations also appears to impact the risk of preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/31\">",
"     31",
"    </a>",
"    ]. A stable or increased cervical length at a subsequent examination appears to lower the risk for spontaneous preterm birth while a shorter cervical length appears to increase the risk.",
"   </p>",
"   <p>",
"    The significance of differences in the rate of cervical change (eg, 30 mm to 20 mm versus 20 mm to 15 mm over two weeks) for prediction of preterm birth is unclear, and no rate of cervical change has been defined as an indication for intervention to decrease preterm birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H571942\">",
"    <span class=\"h4\">",
"     Contributing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several non-sonographic variables, such as gestational age at the time of the ultrasound, affect risk of preterm birth in women with a short cervix.",
"   </p>",
"   <p>",
"    The risk of spontaneous preterm birth is highest when short cervical length is diagnosed between approximately 16 and 28 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/6\">",
"     6",
"    </a>",
"    ]. TVU cervical length is usually not informative before 14 weeks of gestation, unless the patient has had a prior second trimester loss, or multiple or large volume cervical excisional procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/13\">",
"     13",
"    </a>",
"    ]. It is also less useful for predicting preterm birth when measured after 30 weeks, because the cervix physiologically starts to shorten at this time, even in women destined to deliver at term. &nbsp;",
"   </p>",
"   <p>",
"    Other factors that affect performance of TVU short cervical length for prediction of preterm birth include singleton versus multiple gestation, past obstetrical history (prior versus no prior history of preterm birth), whether the patient is symptomatic, prior dilation and",
"    <span class=\"nowrap\">",
"     evacuation/cervical",
"    </span>",
"    excisional",
"    <span class=\"nowrap\">",
"     procedure/uterine",
"    </span>",
"    anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/1,16,32-39\">",
"     1,16,32-39",
"    </a>",
"    ]. As an example, in women without a prior preterm birth and a singleton gestation, the sensitivity of short cervix for subsequent preterm birth is about 35 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]; the positive predictive value is about 20 to 30 percent, which means that the majority of women with a short cervical length will deliver at &ge;35 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/12,40\">",
"     12,40",
"    </a>",
"    ]. In women with a prior preterm birth, sensitivity increases to 70 percent, and is highest in women with early",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repeated preterm births [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/16\">",
"     16",
"    </a>",
"    ]. Women carrying twins are approximately twice as likely to have a short cervix at 24 to 28 weeks of gestation as women carrying singletons [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/33\">",
"     33",
"    </a>",
"    ]. Forty to 50 percent of twin pregnancies with cervical length &le;25 mm at 24 to 28 weeks deliver at &lt;35 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13942523\">",
"    <span class=\"h3\">",
"     Separation of the membranes and debris",
"    </span>",
"    &nbsp;&mdash;&nbsp;Separation of the membranes from the decidua and debris or sludge (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70493 \" href=\"UTD.htm?19/54/20322\">",
"     image 4",
"    </a>",
"    ) within the amniotic fluid suggest subclinical infection and are poor prognostic signs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Intraamniotic debris (&lsquo;sludge&rsquo;) refers to the sonographic finding of hyperechoic matter in the amniotic fluid close to the internal cervical os. The composition of the debris is unclear; it may be blood clot, meconium, vernix, or cellular material related to",
"    <span class=\"nowrap\">",
"     infection/inflammation",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/43\">",
"     43",
"    </a>",
"    ]. Subclinical infection is probably more common in women with very short cervical length (&lt;10 mm).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12425025\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Funneling",
"      </strong>",
"      &mdash; Funneling is the protrusion of the amniotic membranes into the cervical canal. Funneling has been variably defined according to the depth of protrusion [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/1\">",
"       1",
"      </a>",
"      ]",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the ratio of the funnel depth to the length of funnel plus the remaining closed cervix [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Premature cervical effacement begins at the internal cervical os and proceeds caudad, usually over a period of weeks. During this time, the relationship between the lower uterine segment and the axis of the cervical canal also changes and is described according to the shape of the letters T, Y, V, and U (mnemonic: Trust Your Vaginal Ultrasound) (",
"      <a class=\"graphic graphic_figure graphicRef72366 \" href=\"UTD.htm?35/11/36016\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/23\">",
"       23",
"      </a>",
"      ]. 'T' represents the normal relationship of the area where the endocervical canal meets the uterine cavity, whereas 'U' represents almost complete effacement, and signifies the highest risk for preterm birth. Representative endovaginal ultrasound images that display these changes are shown in the following ultrasounds (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77352 graphicRef66107 graphicRef52234 \" href=\"UTD.htm?24/16/24842\">",
"       image 5A-C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The length of the funnel is often uncertain because landmarks, such as the shoulder of the internal os, may not be distinct; therefore, we do not measure funnel length or use it for clinical management. In fact, while funneling is associated with a short cervix, it is not an independent predictor of preterm labor risk when the closed length of the cervical canal is considered [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. When funneling is present with a normal residual cervical length, it is usually related to a contraction of the lower uterine segment, and has little to no clinical significance.",
"     </li>",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"      &mdash; Sonographic measurement of other cervical attributes, such as tissue density, cervical axis relative to the uterine corpus, and others, does not significantly improve predictive value for preterm birth over cervical length alone [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/16,17,44\">",
"       16,17,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies of various designs have evaluated cervical length measurement to predict preterm birth in a variety of populations. These data should be interpreted according to the a priori risk in the population studied, and whether or not patients were symptomatic. The most helpful predictive data come from studies in which information on cervical length was not available to the obstetrician caring for the patient. The most clinically helpful prognostic values are sensitivity (the percent of women destined to deliver preterm who develop a short cervix in the second trimester) and the positive predictive value (the percent of women with a second trimester short cervix who deliver preterm without intervention).",
"   </p>",
"   <p>",
"    Although a 2013 Cochrane review did not find sufficient evidence to recommend routine cervical length screening of all pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/45\">",
"     45",
"    </a>",
"    ], the trials did not have a clear protocol for management of women based on cervical length and included heterogeneous populations (eg, singletons, twins, symptomatic, asymptomatic, intact membranes, ruptured membranes). Based on a meta-analysis of five trials of progesterone treatment of women with asymptomatic midtrimester cervical shortening, cervical length screening for all singleton pregnancies in the midtrimester coupled with treatment of women found to have a short cervix is a reasonable approach [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/46\">",
"     46",
"    </a>",
"    ]. Available data are insufficient to determine the optimum threshold between 10 and 25 mm for diagnosis of, and subsequent intervention for, short cervical length [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/46\">",
"     46",
"    </a>",
"    ]. Our approach to diagnosis and treatment of short cervical length differentiates women with versus without a prior preterm delivery. Based on the bulk of available evidence, we make the diagnosis of short cervix when the TVU cervical length at 16 to 28 weeks of gestation is &le;20 mm in women with no prior preterm delivery, as this finding is associated with an increased risk of spontaneous preterm birth &lt;35 weeks, and &lt;25 mm in women with a prior preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/19,25,32\">",
"     19,25,32",
"    </a>",
"    ]. We treat women with a short cervix &le;20 mm and no prior preterm delivery with vaginal progesterone to decrease the risk of preterm birth. We treat women with a prior preterm birth with 17-alpha-hydroxyprogesterone caproate, and perform cerclage if a short cervix &lt;25 mm is identified. This approach is consistent with guidelines of the Society for Maternal-Fetal Medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/47\">",
"     47",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7012163\">",
"    <span class=\"h2\">",
"     Asymptomatic women",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7012170\">",
"    <span class=\"h3\">",
"     Singleton, no prior preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only about 30 percent of low-risk women (singleton gestations without prior preterm birth) with short cervix at 24 weeks of gestation will deliver before 35 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/48\">",
"     48",
"    </a>",
"    ]. Although most of these women deliver at or near term, evidence from randomized trials shows that performing a TVU cervical length measurement at 18 to 24 weeks and treating women with a short cervix (&le;20 mm) with vaginal progesterone supplementation significantly reduces preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/19,32\">",
"     19,32",
"    </a>",
"    ] and composite neonatal morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/32\">",
"     32",
"    </a>",
"    ], and appears to be cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. By comparison, 17-alpha-hydroxyprogesterone caproate treatment of nulliparous women with cervical length &lt;30 mm did not reduce the rate of preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these randomized trials, in our practice, we screen pregnancies at low risk of preterm birth for short cervix (",
"    <a class=\"graphic graphic_table graphicRef70801 \" href=\"UTD.htm?19/33/19995\">",
"     table 1",
"    </a>",
"    ) and suggest vaginal progesterone supplementation for women with singleton gestations at the detection of a short cervix, which we define as &le;20 mm before 25 weeks. We then continue progesterone daily until 36 weeks. Vaginal progesterone treatment in this population reduces the rate of preterm birth &lt;35 weeks by over 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/19,32\">",
"     19,32",
"    </a>",
"    ]. Doses of 90 to 200 mg have been effective in randomized trials. Cost and availability should determine choice of dose and vehicle (gel versus suppository). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link&amp;anchor=H14419366#H14419366\">",
"     \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\", section on 'Short cervix in current pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of a pessary to prolong pregnancy in women with a short cervical length may be an effective, inexpensive, and easy to implement intervention. In 2012, a multicenter trial randomly assigned 385 pregnant women with cervical length &le;25 mm at 20 to 23 weeks to use of a cervical pessary or expectant management (no pessary) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/52\">",
"     52",
"    </a>",
"    ]. The majority of these patients (89 percent) had no history of previous preterm birth and none were treated with progesterone or cerclage. The pessary group had a lower rate of spontaneous preterm birth than the expectant management group:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delivery &lt;28 weeks",
"      <span class=\"nowrap\">",
"       (4/190",
"      </span>",
"      [2 percent] versus",
"      <span class=\"nowrap\">",
"       16/190",
"      </span>",
"      [8 percent]; OR 0.23, 95% CI 0.06-0.74)",
"     </li>",
"     <li>",
"      Delivery &lt;34 weeks",
"      <span class=\"nowrap\">",
"       (12/190",
"      </span>",
"      [6 percent] versus",
"      <span class=\"nowrap\">",
"       51/190",
"      </span>",
"      [27 percent]; OR 0.18, 95% CI 0.08-0.37)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No adverse effects were noted, other than vaginal discharge and mild discomfort upon insertion. The authors postulated the pessary was effective because it changed the angle of cervix in relation to the uterus, thereby reducing both pressure on the cervix and contact between the fetal membranes and vaginal bacteria. Use of a pessary to prolong pregnancy in women with a short cervical length may be an effective, inexpensive, and easy to implement intervention; however, given the open-label design of this trial with lack of a placebo control and the relatively small number of preterm births accounting for the dramatic results, we do not recommend implementation of this approach instead of vaginal progestins until these data are confirmed by additional randomized and placebo-controlled trials.",
"   </p>",
"   <p>",
"    Cervical cerclage is not recommended for women with singleton gestations without a prior preterm birth, but with a short cervical length before 24 weeks. The lack of benefit of cerclage in these patients was supported by a meta-analysis of four randomized trials in which singleton pregnancies were screened with cervical ultrasound examination and randomly assigned to cerclage or no cerclage if the cervix was short [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/48\">",
"     48",
"    </a>",
"    ]. Cerclage did not lead to a significant reduction in preterm birth &lt;35 weeks if the patients had no risk factors for preterm birth (risk of preterm birth &lt;35 weeks: 26 versus 33 percent without cerclage: RR 0.76, 95% CI 0.52-1.15). In twin gestations with short cervix, cerclage increased the risk of preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7012300\">",
"    <span class=\"h3\">",
"     Singleton, prior preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;These women may have cervical insufficiency. The management of their pregnancies is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link&amp;anchor=H25211294#H25211294\">",
"     \"Cervical insufficiency\", section on 'Women with prior pregnancy losses or preterm births'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7012331\">",
"    <span class=\"h3\">",
"     Singleton, no prior birth, but risk factors for cervical insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;These women may have cervical insufficiency. The management of their pregnancies is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link&amp;anchor=H7414928#H7414928\">",
"     \"Cervical insufficiency\", section on 'Women with singleton pregnancy, no prior birth, but risk factors for cervical insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7012410\">",
"    <span class=\"h3\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;TVU cervical length measurement is not a sensitive screening test for prediction of preterm birth in multiple gestations. No intervention (eg, progesterone supplementation, cerclage) has been proven beneficial in preventing preterm birth in women with multiple gestation and short cervical length. For these reasons, we do not perform TVU cervical length screening in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link&amp;anchor=H26#H26\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Preterm birth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Symptomatic women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of cervical length is useful in assessing women with threatened preterm labor when the diagnosis of true preterm labor is uncertain (the cervix is &lt;3 cm dilated and 80 percent effaced on digital examination) (",
"    <a class=\"graphic graphic_algorithm graphicRef78336 \" href=\"UTD.htm?15/38/15983\">",
"     algorithm 1",
"    </a>",
"    ). As a general guideline, preterm birth is highly unlikely in symptomatic women if the cervix is longer than 30 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/53-55\">",
"     53-55",
"    </a>",
"    ], unless abruption is the cause of their symptoms, and most likely in those with cervices &lt;15 to 20 mm in length [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/53,56-59\">",
"     53,56-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When cervical length is neither very long nor very short, knowledge of both TVU cervical length and fetal fibronectin can be helpful in management of the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/54\">",
"     54",
"    </a>",
"    ]. The evaluation and management of symptomatic women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5608?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of preterm labor and birth\", section on 'Triage based upon cervical length'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27415117\">",
"    <span class=\"h1\">",
"     GUIDELINES FROM NATIONAL ORGANIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a 2012 practice bulletin, the American College of Obstetricians and Gynecologists (ACOG) neither mandated universal routine cervical length screening in women without a prior preterm birth nor recommended against such screening [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/60\">",
"     60",
"    </a>",
"    ]. However, in women undergoing obstetrical ultrasound examination, ACOG has recommended that the cervix be examined when clinically appropriate and technically feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/61\">",
"     61",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In 2011, the Society of Obstetricians and Gynaecologists of Canada (SOGC) concluded that routine transvaginal cervical length assessment was not indicated in women at low risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21017/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of spontaneous preterm birth increases as cervical length decreases. The risk is highest when a short cervix is detected before 24 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H7011713\">",
"       'Short cervical length'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical length is best measured by transvaginal ultrasound (TVU) examination between 16 and 28 weeks of gestation. A cervical length below the 10th percentile (25 mm) at these gestational ages is consistently associated with an increased risk of spontaneous preterm birth. (See",
"      <a class=\"local\" href=\"#H7011713\">",
"       'Short cervical length'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical length is measured by determining the distance between the internal os and external os. It should only be determined from images in which the lower-most edge of the empty maternal bladder and the internal and external os are visible, and when the anterior and posterior lips of the cervix are of equal thickness (",
"      <a class=\"graphic graphic_figure graphicRef82336 \" href=\"UTD.htm?31/58/32673\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of preterm delivery based on TVU examination varies according to cervical length, gestational age at which cervical length is measured, singleton versus multiple gestation, low-risk versus high-risk (ie, prior preterm birth) status, and other risk factors. All of these factors should be taken into account in counseling. (See",
"      <a class=\"local\" href=\"#H7011713\">",
"       'Short cervical length'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H571942\">",
"       'Contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest routine ultrasound screening for short cervix in singleton pregnancies. (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7012170\">",
"       'Singleton, no prior preterm birth'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link&amp;anchor=H14004837#H14004837\">",
"       \"Cervical insufficiency\", section on 'Candidates for ultrasound surveillance and possible ultrasound indicated cerclage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H573547\">",
"    <span class=\"h2\">",
"     Asymptomatic women",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We screen women with singleton pregnancies at low risk of preterm birth for short cervix. (See",
"      <a class=\"local\" href=\"#H7012170\">",
"       'Singleton, no prior preterm birth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For a woman with a singleton gestation, no prior preterm birth, and a short cervical length &le;20 mm before 25 weeks, we recommend vaginal progesterone supplementation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Cost and availability should determine choice of dose (90 to 200 mg) and vehicle (gel versus suppository). Cerclage does not prevent preterm birth in this population. The benefit of placing a pessary has not been adequately studied. (See",
"      <a class=\"local\" href=\"#H7012170\">",
"       'Singleton, no prior preterm birth'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link&amp;anchor=H14419366#H14419366\">",
"       \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\", section on 'Short cervix in current pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      No intervention has been proven beneficial in multiple gestations with a short cervical length; therefore, monitoring TVU cervical length is not recommended in this population. (See",
"      <a class=\"local\" href=\"#H7012410\">",
"       'Multiple gestation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with prior pregnancy",
"      <span class=\"nowrap\">",
"       losses/preterm",
"      </span>",
"      deliveries or with other risk factors for preterm",
"      <span class=\"nowrap\">",
"       loss/birth",
"      </span>",
"      may have cervical insufficiency and should be managed accordingly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link&amp;anchor=H25211294#H25211294\">",
"       \"Cervical insufficiency\", section on 'Women with prior pregnancy losses or preterm births'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link&amp;anchor=H7414928#H7414928\">",
"       \"Cervical insufficiency\", section on 'Women with singleton pregnancy, no prior birth, but risk factors for cervical insufficiency'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H573555\">",
"    <span class=\"h2\">",
"     Symptomatic women",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TVU cervical length is helpful in managing women with symptoms of preterm labor (",
"      <a class=\"graphic graphic_algorithm graphicRef78336 \" href=\"UTD.htm?15/38/15983\">",
"       algorithm 1",
"      </a>",
"      ). Cervical length &ge;30 mm has been consistently reported to exclude the diagnosis of preterm labor. There is no threshold of cervical length that establishes the diagnosis of preterm labor. In women with contractions and cervical length less than 20 mm, risk of preterm birth is high, and interventions (eg, corticosteroids for fetal maturation, tocolysis, hospitalization) should be considered. In women with cervical length 20 to 29 mm, additional testing (such as fetal fibronectin) can help predict the patient's risk of preterm delivery within the next several days. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Symptomatic women'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5608?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of preterm labor and birth\", section on 'Triage based upon cervical length'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/1\">",
"      Iams JD, Goldenberg RL, Meis PJ, et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med 1996; 334:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/2\">",
"      Taipale P, Hiilesmaa V. Sonographic measurement of uterine cervix at 18-22 weeks' gestation and the risk of preterm delivery. Obstet Gynecol 1998; 92:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/3\">",
"      Hibbard JU, Tart M, Moawad AH. Cervical length at 16-22 weeks' gestation and risk for preterm delivery. Obstet Gynecol 2000; 96:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/4\">",
"      Heath VC, Southall TR, Souka AP, et al. Cervical length at 23 weeks of gestation: prediction of spontaneous preterm delivery. Ultrasound Obstet Gynecol 1998; 12:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/5\">",
"      Owen J, Yost N, Berghella V, et al. Can shortened midtrimester cervical length predict very early spontaneous preterm birth? Am J Obstet Gynecol 2004; 191:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/6\">",
"      Berghella V, Roman A, Daskalakis C, et al. Gestational age at cervical length measurement and incidence of preterm birth. Obstet Gynecol 2007; 110:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/7\">",
"      Glanc P, Andreotti RF, Lee SI, et al. ACR Appropriateness Criteria&reg; assessment of gravid cervix. Ultrasound Q 2011; 27:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/8\">",
"      Mason GC, Maresh MJ. Alterations in bladder volume and the ultrasound appearance of the cervix. Br J Obstet Gynaecol 1990; 97:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/9\">",
"      Hernandez-Andrade E, Romero R, Ahn H, et al. Transabdominal evaluation of uterine cervical length during pregnancy fails to identify a substantial number of women with a short cervix. J Matern Fetal Neonatal Med 2012; 25:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/10\">",
"      To MS, Skentou C, Cicero S, Nicolaides KH. Cervical assessment at the routine 23-weeks' scan: problems with transabdominal sonography. Ultrasound Obstet Gynecol 2000; 15:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/11\">",
"      Owen J, Neely C, Northen A. Transperineal versus endovaginal ultrasonographic examination of the cervix in the midtrimester: a blinded comparison. Am J Obstet Gynecol 1999; 181:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/12\">",
"      Mella MT, Berghella V. Prediction of preterm birth: cervical sonography. Semin Perinatol 2009; 33:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/13\">",
"      Berghella V, Talucci M, Desai A. Does transvaginal sonographic measurement of cervical length before 14 weeks predict preterm delivery in high-risk pregnancies? Ultrasound Obstet Gynecol 2003; 21:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/14\">",
"      Conoscenti G, Meir YJ, D'Ottavio G, et al. Does cervical length at 13-15 weeks' gestation predict preterm delivery in an unselected population? Ultrasound Obstet Gynecol 2003; 21:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/15\">",
"      Ludmir J. Sonographic detection of cervical incompetence. Clin Obstet Gynecol 1988; 31:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/16\">",
"      Owen J, Yost N, Berghella V, et al. Mid-trimester endovaginal sonography in women at high risk for spontaneous preterm birth. JAMA 2001; 286:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/17\">",
"      Berghella V, Owen J, MacPherson C, et al. Natural history of cervical funneling in women at high risk for spontaneous preterm birth. Obstet Gynecol 2007; 109:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/18\">",
"      Iams JD, Johnson FF, Sonek J, et al. Cervical competence as a continuum: a study of ultrasonographic cervical length and obstetric performance. Am J Obstet Gynecol 1995; 172:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/19\">",
"      Fonseca EB, Celik E, Parra M, et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007; 357:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/20\">",
"      Kushnir O, Vigil DA, Izquierdo L, et al. Vaginal ultrasonographic assessment of cervical length changes during normal pregnancy. Am J Obstet Gynecol 1990; 162:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/21\">",
"      Andersen HF, Nugent CE, Wanty SD, Hayashi RH. Prediction of risk for preterm delivery by ultrasonographic measurement of cervical length. Am J Obstet Gynecol 1990; 163:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/22\">",
"      Zorzoli A, Soliani A, Perra M, et al. Cervical changes throughout pregnancy as assessed by transvaginal sonography. Obstet Gynecol 1994; 84:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/23\">",
"      Zilianti M, Azuaga A, Calderon F, et al. Monitoring the effacement of the uterine cervix by transperineal sonography: a new perspective. J Ultrasound Med 1995; 14:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/24\">",
"      Gramellini D, Fieni S, Molina E, et al. Transvaginal sonographic cervical length changes during normal pregnancy. J Ultrasound Med 2002; 21:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/25\">",
"      Crane JM, Hutchens D. Transvaginal sonographic measurement of cervical length to predict preterm birth in asymptomatic women at increased risk: a systematic review. Ultrasound Obstet Gynecol 2008; 31:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/26\">",
"      Goldenberg RL, Iams JD, Mercer BM, et al. The preterm prediction study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births. NICHD MFMU Network. Am J Public Health 1998; 88:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/27\">",
"      Berghella V, Kuhlman K, Weiner S, et al. Cervical funneling: sonographic criteria predictive of preterm delivery. Ultrasound Obstet Gynecol 1997; 10:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/28\">",
"      Hassan SS, Romero R, Berry SM, et al. Patients with an ultrasonographic cervical length &lt; or =15 mm have nearly a 50% risk of early spontaneous preterm delivery. Am J Obstet Gynecol 2000; 182:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/29\">",
"      Rust OA, Atlas RO, Kimmel S, et al. Does the presence of a funnel increase the risk of adverse perinatal outcome in a patient with a short cervix? Am J Obstet Gynecol 2005; 192:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/30\">",
"      Vaisbuch E, Romero R, Mazaki-Tovi S, et al. The risk of impending preterm delivery in asymptomatic patients with a nonmeasurable cervical length in the second trimester. Am J Obstet Gynecol 2010; 203:446.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/31\">",
"      Moroz LA, Simhan HN. Rate of sonographic cervical shortening and the risk of spontaneous preterm birth. Am J Obstet Gynecol 2012; 206:234.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/32\">",
"      Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011; 38:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/33\">",
"      Goldenberg RL, Iams JD, Miodovnik M, et al. The preterm prediction study: risk factors in twin gestations. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1996; 175:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/34\">",
"      Vendittelli F, Mamelle N, Munoz F, Janky E. Transvaginal ultrasonography of the uterine cervix in hospitalized women with preterm labor. Int J Gynaecol Obstet 2001; 72:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/35\">",
"      Visintine J, Berghella V, Henning D, Baxter J. Cervical length for prediction of preterm birth in women with multiple prior induced abortions. Ultrasound Obstet Gynecol 2008; 31:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/36\">",
"      Airoldi J, Berghella V, Sehdev H, Ludmir J. Transvaginal ultrasonography of the cervix to predict preterm birth in women with uterine anomalies. Obstet Gynecol 2005; 106:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/37\">",
"      Berghella V, Pereira L, Gariepy A, Simonazzi G. Prior cone biopsy: prediction of preterm birth by cervical ultrasound. Am J Obstet Gynecol 2004; 191:1393.",
"     </a>",
"    </li>",
"    <li>",
"     Rafael TJ. Short Cervical Length. In: Preterm Birth: Prevention and Management, Berghella V.  (Ed), Wiley-Blackwell, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/39\">",
"      Guzman ER, Walters C, O'reilly-Green C, et al. Use of cervical ultrasonography in prediction of spontaneous preterm birth in triplet gestations. Am J Obstet Gynecol 2000; 183:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/40\">",
"      Iams JD, Goldenberg RL, Mercer BM, et al. The preterm prediction study: can low-risk women destined for spontaneous preterm birth be identified? Am J Obstet Gynecol 2001; 184:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/41\">",
"      Kusanovic JP, Espinoza J, Romero R, et al. Clinical significance of the presence of amniotic fluid 'sludge' in asymptomatic patients at high risk for spontaneous preterm delivery. Ultrasound Obstet Gynecol 2007; 30:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/42\">",
"      Bujold E, Pasquier JC, Simoneau J, et al. Intra-amniotic sludge, short cervix, and risk of preterm delivery. J Obstet Gynaecol Can 2006; 28:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/43\">",
"      Romero R, Schaudinn C, Kusanovic JP, et al. Detection of a microbial biofilm in intraamniotic infection. Am J Obstet Gynecol 2008; 198:135.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/44\">",
"      Yost NP, Owen J, Berghella V, et al. Second-trimester cervical sonography: features other than cervical length to predict spontaneous preterm birth. Obstet Gynecol 2004; 103:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/45\">",
"      Berghella V, Baxter JK, Hendrix NW. Cervical assessment by ultrasound for preventing preterm delivery. Cochrane Database Syst Rev 2013; 1:CD007235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/46\">",
"      Romero R, Nicolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 2012; 206:124.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/47\">",
"      Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 2012; 206:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/48\">",
"      Berghella V, Odibo AO, To MS, et al. Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data. Obstet Gynecol 2005; 106:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/49\">",
"      Cahill AG, Odibo AO, Caughey AB, et al. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol 2010; 202:548.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/50\">",
"      Werner EF, Han CS, Pettker CM, et al. Universal cervical-length screening to prevent preterm birth: a cost-effectiveness analysis. Ultrasound Obstet Gynecol 2011; 38:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/51\">",
"      Grobman WA, Thom EA, Spong CY, et al. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet Gynecol 2012; 207:390.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/52\">",
"      Goya M, Pratcorona L, Merced C, et al. Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomised controlled trial. Lancet 2012; 379:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/53\">",
"      Tsoi E, Fuchs IB, Rane S, et al. Sonographic measurement of cervical length in threatened preterm labor in singleton pregnancies with intact membranes. Ultrasound Obstet Gynecol 2005; 25:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/54\">",
"      Ness A, Visintine J, Ricci E, Berghella V. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. Am J Obstet Gynecol 2007; 197:426.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/55\">",
"      Murakawa H, Utumi T, Hasegawa I, et al. Evaluation of threatened preterm delivery by transvaginal ultrasonographic measurement of cervical length. Obstet Gynecol 1993; 82:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/56\">",
"      Iams JD. Prediction and early detection of preterm labor. Obstet Gynecol 2003; 101:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/57\">",
"      Tsoi E, Akmal S, Rane S, et al. Ultrasound assessment of cervical length in threatened preterm labor. Ultrasound Obstet Gynecol 2003; 21:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/58\">",
"      Fuchs I, Tsoi E, Henrich W, et al. Sonographic measurement of cervical length in twin pregnancies in threatened preterm labor. Ultrasound Obstet Gynecol 2004; 23:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/59\">",
"      Sotiriadis A, Papatheodorou S, Kavvadias A, Makrydimas G. Transvaginal cervical length measurement for prediction of preterm birth in women with threatened preterm labor: a meta-analysis. Ultrasound Obstet Gynecol 2010; 35:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/60\">",
"      Committee on Practice Bulletins&mdash;Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol 2012; 120:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/61\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 101: Ultrasonography in pregnancy. Obstet Gynecol 2009; 113:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21017/abstract/62\">",
"      Lim K, Butt K, Crane JM. SOGC Clinical Practice Guideline. Ultrasonographic cervical length assessment in predicting preterm birth in singleton pregnancies. J Obstet Gynaecol Can 2011; 33:486.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 450 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-109.224.62.197-08224556E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21017=[""].join("\n");
var outline_f20_33_21017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H921489\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pitfalls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7011682\">",
"      Quality assurance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13942792\">",
"      SIGNIFICANT SONOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12424584\">",
"      Findings predictive of preterm birth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7011713\">",
"      - Short cervical length",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H571942\">",
"      Contributing factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13942523\">",
"      - Separation of the membranes and debris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12425025\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7012163\">",
"      Asymptomatic women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7012170\">",
"      - Singleton, no prior preterm birth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7012300\">",
"      - Singleton, prior preterm birth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7012331\">",
"      - Singleton, no prior birth, but risk factors for cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7012410\">",
"      - Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Symptomatic women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27415117\">",
"      GUIDELINES FROM NATIONAL ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H573547\">",
"      Asymptomatic women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H573555\">",
"      Symptomatic women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/450\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/450|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?15/38/15983\" title=\"algorithm 1\">",
"      Management of suspected preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/450|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/44/7874\" title=\"diagnostic image 1\">",
"      Normal cervix on ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/11/2227\" title=\"diagnostic image 2\">",
"      U-S cervix in PTL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/6/32870\" title=\"diagnostic image 3\">",
"      Cervical length in a curved cervix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/54/20322\" title=\"diagnostic image 4\">",
"      Ultrasound image of membrane separation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/13/12501\" title=\"diagnostic image 5A\">",
"      US normal T cervix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/55/33651\" title=\"diagnostic image 5B\">",
"      US Y funnel cervix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/13/5331\" title=\"diagnostic image 5C\">",
"      US U funnel cervix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/450|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/58/32673\" title=\"figure 1\">",
"      Measurement of cervix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/11/36016\" title=\"figure 2\">",
"      Diagram cervical effacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/450|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/33/19995\" title=\"table 1\">",
"      Protocol for cervical length screening",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5608?source=related_link\">",
"      Overview of preterm labor and birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=related_link\">",
"      Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_33_21018="Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia";
var content_f20_33_21018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21018/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21018/contributors\">",
"     Thierry Lamy, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21018/contributors\">",
"     Thomas P Loughran, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21018/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21018/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/33/21018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/33/21018/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/33/21018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H458739477\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large granular lymphocyte (LGL) leukemia is a clonal disease of the large granular lymphocyte characterized by peripheral blood and marrow lymphocytic infiltration with LGLs, splenomegaly, and cytopenias, most commonly neutropenia.",
"   </p>",
"   <p>",
"    The LGL is a morphologically distinct lymphoid subtype that is larger than most circulating lymphocytes, and has characteristic azurophilic granules containing acid hydrolases (",
"    <a class=\"graphic graphic_picture graphicRef69027 \" href=\"UTD.htm?0/1/28\">",
"     picture 1",
"    </a>",
"    ). LGLs comprise 10 to 15 percent of normal peripheral blood mononuclear cells. The absolute number of LGLs in the peripheral blood of normal subjects is 200 to",
"    <span class=\"nowrap\">",
"     400/microL.",
"    </span>",
"   </p>",
"   <p>",
"    LGLs arise from two major lineages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 85 percent are CD3 positive, CD57 positive, CD56 negative T cells, representing in vivo antigen-activated effector-memory cytotoxic T cells (see",
"      <a class=\"local\" href=\"#H458750948\">",
"       'Pathogenesis'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      The remaining 15 percent are CD3-, CD56+ natural killer (NK) cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A syndrome characterized by the proliferation of LGLs associated with neutropenia was initially reported in 1977 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/3\">",
"     3",
"    </a>",
"    ]. The term LGL leukemia was proposed for this disorder based upon demonstration of invasion of bone marrow, spleen, and liver by LGLs and the first proof that such LGLs were clonally expanded [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/4\">",
"     4",
"    </a>",
"    ]. A subsequent French-American-British (FAB) classification recognized LGL leukemia as one of four subgroups of chronic T cell lymphoid leukemias, and in 1993 it was proposed that LGL leukemias could be classified into T cell and NK cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The revised European-American classification of lymphoid neoplasms (REAL) recommended that LGL leukemia be a distinct entity classified under peripheral T cell and NK cell neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/5\">",
"     5",
"    </a>",
"    ]. The 2008 World Health Organization classification of mature T and NK cell neoplasms continues to distinguish T cell LGL leukemia (T-LGL leukemia) from aggressive NK cell leukemia based on their unique molecular and clinical features. A new provisional entity of chronic lymphoproliferative disorder of NK cells (also known as chronic NK cell lymphocytosis) was created to distinguish it from the much more aggressive NK cell leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology, clinical features, diagnosis, and differential diagnosis of T cell LGL leukemia will be discussed here. The treatment of T cell LGL leukemia, the diagnosis of T cell LGL leukemia in the setting of rheumatoid arthritis, and the diagnosis of NK cell LGL leukemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=see_link\">",
"     \"Treatment of large granular lymphocyte leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=see_link\">",
"     \"Natural killer (NK) cell large granular lymphocyte leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=see_link\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113797895\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell LGL leukemia accounts for approximately 2 to 5 percent of the chronic lymphoproliferative disorders in North America and up to 6 percent of the chronic lymphoproliferative disorders in Asia. The incidence in the United States has been estimated at approximately one in 10 million people [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The median age of onset of T-LGL leukemia is 60 years (range 4 to 88) without a male or female predilection. Only 10 percent of patients are younger than 40 years old; the disease is rare in children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113797902\">",
"    <span class=\"h2\">",
"     Associated disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prominent feature of LGL leukemia is an association with other diseases in 40 percent of cases, particularly rheumatoid arthritis and other hematologic disorders (",
"    <a class=\"graphic graphic_table graphicRef64762 \" href=\"UTD.htm?4/2/4141\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113797909\">",
"    <span class=\"h3\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;LGL leukemia has also been reported in patients with autoimmune disorders such as rheumatoid arthritis (RA), hemolytic anemia, pure red cell aplasia, immune thrombocytopenia, and Sj&ouml;gren's syndrome. Rheumatoid arthritis (RA) is the most commonly associated disease, occurring in approximately 25 percent of patients with T-LGL leukemia. The onset of RA as compared with that of LGL leukemia is variable; in some cases, the clonal LGL proliferation may precede the development of RA by several years, whereas the two diseases are simultaneously diagnosed in other cases. Conversely, LGL proliferation is much less common in patients with RA, occurring in less than 1 percent of patients. Patients with both T-LGL leukemia and RA resemble patients with Felty's syndrome (ie, the combination of neutropenia, RA, and splenomegaly) and the articular manifestations of typical Felty's syndrome and RA-associated T-LGL leukemia are not distinguishable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=see_link&amp;anchor=H8862694#H8862694\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\", section on 'Felty's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113797941\">",
"    <span class=\"h3\">",
"     Other hematologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;LGL leukemia can coexist with other lymphoid or myeloid clonal hematologic malignancies including chronic lymphocytic leukemia, follicular lymphoma, hairy cell leukemia, mantle cell lymphoma, and Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/11\">",
"     11",
"    </a>",
"    ]. Clonal B-cell dyscrasias may be seen in approximately 25 percent of patients with LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma have been described in association with LGL leukemia, without an understandable relationship between these diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/14-16\">",
"       14-16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several cases of myelodysplasia have been reported, based upon morphological evidence of trilineage dysplasia on bone marrow examination, associated in some cases with a deletion 5q cytogenetic abnormality [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H359933#H359933\">",
"       \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'MDS with isolated del(5q)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Expansion of",
"      <span class=\"nowrap\">",
"       CD3+/CD57+",
"      </span>",
"      lymphocytes is frequently observed after hematopoietic cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. This may reflect differentiation steps during reconstitution of the immune system, an activation process due to graft-versus-host disease, or CMV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/20\">",
"       20",
"      </a>",
"      ]. However, clonal CD3+ LGL proliferation has also been observed following solid organ transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H458740796\">",
"       'Post-transplant T cell lymphoproliferative disorders'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458750948\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of T cell LGL leukemia (T-LGL leukemia) is not known. The proposed cell of origin is a mature post-thymic T cell. It is hypothesized that expansion of CD3+CD8+ leukemic cells requires several steps [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/23\">",
"     23",
"    </a>",
"    ]. These leukemic cells show all the characteristics of antigen-activated T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/24\">",
"     24",
"    </a>",
"    ], suggesting that an initial step in LGL expansion is an antigen-driven mechanism:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      T-LGL expresses a T cell effector-memory cytotoxic phenotype.",
"     </li>",
"     <li>",
"      T-LGL can be activated via the",
"      <span class=\"nowrap\">",
"       CD3/CD16",
"      </span>",
"      pathway.",
"     </li>",
"     <li>",
"      In some cases, T-LGL cells use a restricted T cell receptor variable beta (Vb) repertoire, possibly driven by a common antigen [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clonal drift in T cell repertoire with a change in the dominant clone may be seen in approximately one-third of cases over the disease course [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gene expression profiling differs from normal cytotoxic T cells by the overexpression of chemokine receptors typically associated with viral infections [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial studies have implicated activating point mutations of the signal transducer and activator of transcription 3 gene (STAT3) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. When phosphorylated, STAT3 forms dimers that translocate to the cell nucleus and act as transcription factors that enhance antiapoptotic pathways. In one study, whole exome and targeted sequencing of T-LGL cells identified a STAT3 mutation in 31 of 77 patients (40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/29\">",
"     29",
"    </a>",
"    ]. The most common recurrent mutations were Y640F (13 patients), D661V (seven patients), D661Y (seven patients), and N647I (three patients). These changes in the amino acid sequence resulted in modifications to the protein that enhanced phosphorylation and dimerization, potentially resulting in ligand-independent signaling and stimulation of Bcl-2 independent anti-apoptotic pathways. These findings suggest that mutations in STAT3 play a role in the pathogenesis of subset of T-LGL.",
"   </p>",
"   <p>",
"    The mechanism for neutropenia in these patients is not fully known [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/31\">",
"     31",
"    </a>",
"    ]. A direct effect of abnormal LGLs on granulocyte-macrophage colony forming units (CFU-GM) has rarely been demonstrated. Although diffuse bone marrow infiltration by LGLs is present in about 90 percent of patients, there is no correlation between the degree of neutropenia and marrow infiltration. Splenomegaly may contribute to an autoimmune process. Antineutrophil antibodies are frequently present.",
"   </p>",
"   <p>",
"    Another possible mechanism is increased apoptosis of neutrophils. The demonstration of constitutive expression and excretion by leukemic LGLs of Fas ligand, an inducer of apoptosis in neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/32\">",
"     32",
"    </a>",
"    ], implicates Fas ligand as a possible pathogenetic mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In one study, as an example, high levels of circulating Fas ligand were noted in 39 of 44 samples from patients with LGL leukemia and in none of 10 normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, resolution of neutropenia was associated with disappearance or marked reduction in Fas ligand in 10 of 11 treated patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link&amp;anchor=H20#H20\">",
"     \"Normal neutrophil development and kinetics\", section on 'Apoptosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of interest, pregnancy appears to have a beneficial effect on the neutrophil count in T-LGL leukemia, possibly mediated through the action of progesterone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3154436\">",
"    <span class=\"h2\">",
"     Role of human T-lymphotropic virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial serological studies in patients with LGL leukemia were suggestive of infection with the human T-lymphotropic virus (HTLV) and a possible role for this virus in the pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. However, subsequent studies have shown that most patients are not infected with prototypical HTLV I-II [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], nor are they infected with the related viruses primate T cell",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    virus or bovine leukemia virus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/43\">",
"     43",
"    </a>",
"    ]. As such, it is unclear whether viral infection plays a role in the pathogenesis of LGL leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3154444\">",
"    <span class=\"h2\">",
"     Role of cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The persistence and proliferation of LGLs could be due to the stimulatory effect of various cytokines, or to genetic polymorphisms in genes involved in the regulation of immune and inflammatory responses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/44\">",
"     44",
"    </a>",
"    ]. Available data suggest that interleukin (IL)-12 and IL-15 may be important in LGL leukemogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IL-12 increases the proliferation of anti-CD3 monoclonal antibody-prestimulated LGL.",
"     </li>",
"     <li>",
"      Upregulation of IL-12 messenger RNA and IL-12 receptors is observed after LGL activation.",
"     </li>",
"     <li>",
"      IL-15 stimulates LGL, mediating this activity through the beta and gamma chains of the IL-2 receptor and through a private receptor IL-15Ralpha.",
"     </li>",
"     <li>",
"      Patients with T-LGL demonstrate upregulated IL-15Ralpha mRNA levels in monocytes and CD8+ leukemic cells and increased levels of soluble IL-15Ralpha in their serum. The increase in IL-15 receptors may decrease the amount of IL-15 necessary to stimulate proliferation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gene expression profiling in patients with T cell LGL leukemia found upregulation of the following genes involved in cytotoxic function: perforin, serine proteinases (granzymes A, B, H and K), cysteine proteinases (cathepsin C, cathepsin W), calpain small subunit, and caspase-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/49\">",
"     49",
"    </a>",
"    ]. In comparison, proteolytic inhibitors such as cystatin C, A, alpha-1 antitrypsin, and metalloproteinase inhibitors were down-regulated in leukemic LGL when compared with normal peripheral blood mononuclear cells. This pattern of gene expression in leukemic LGL resembled that seen in activated cytotoxic T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3154452\">",
"    <span class=\"h2\">",
"     Role of apoptotic pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukemic LGLs are resistant to Fas-induced apoptosis, despite high levels of Fas and FasL expression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/24,50-52\">",
"     24,50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These cells display high levels of activated STAT3. Fas sensitivity could be restored when STAT3 expression was diminished [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The PI3K-AKT pathway, important in regulating the balance between cell survival and apoptosis, and capable of antagonizing the ability of Fas to initiate apoptosis, is activated in T-LGL cells, under the upstream activity of a Src family kinase [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/54\">",
"       54",
"      </a>",
"      ]. Inhibition of the PI3K-AKT pathway alone led to brisk spontaneous apoptosis of T-LGL cells.",
"     </li>",
"     <li>",
"      Sphingolipid signaling was determined to be important in survival of leukemic LGL following pathway-based microarray analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Proteasomal degradation of the Bcl-2 family member Bid mediated by IL-15 might contribute to leukemic LGL survival [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systems biology approach utilizing network modeling demonstrated that IL-15 and platelet-derived growth factor (PDGF) are the two key mediators controlling interactions among these survival pathways [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458740684\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with T cell LGL leukemia present with symptoms related to neutropenia. Fever with recurrent bacterial infections occurs in 20 to 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/9\">",
"     9",
"    </a>",
"    ]. Infections typically involve skin, oropharyngeal, and perirectal areas, but severe sepsis or pneumonia can also occur; opportunistic infections are uncommon. Approximately one-third of patients feel entirely well with no symptoms when a routine blood count reveals a cytopenia, leading to a diagnosis of T cell LGL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1,59\">",
"     1,59",
"    </a>",
"    ]. Patients with the less common T cell receptor (TCR)",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    positive variant have a similar clinical pattern to the more common TCR",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    positive cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 203 patients with T-LGL leukemia from the Mayo Clinic, 28 (14 percent) had pancytopenia at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/61\">",
"     61",
"    </a>",
"    ]. The majority of cases had decreased numbers of at least one blood cell lineage:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutropenia &mdash; Most patients with T-LGL leukemia (84 percent) present with chronic neutropenia, and about one-half have absolute neutrophil counts",
"      <span class=\"nowrap\">",
"       &lt;500/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1\">",
"       1",
"      </a>",
"      ]. Occasional patients present with adult-onset cyclic neutropenia; in one report, all three adults but none of four children with cyclic neutropenia had increased LGL counts [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link\">",
"       \"Cyclic neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia &mdash; Anemia is present in 50 percent of patients with T-LGL leukemia, with transfusion-dependent anemia in about 20 percent. In one Mayo Clinic series of patients with T-LGL leukemia, oval macrocytosis was present in 23 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/14\">",
"       14",
"      </a>",
"      ]. In a separate Mayo Clinic series of 47 adults with acquired pure red blood cell aplasia, LGL leukemia was the most common underlying cause [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/64\">",
"       64",
"      </a>",
"      ]. Several different underlying mechanisms may account for the anemia, including a high incidence of Coombs' positive autoimmune hemolytic anemia and pure red cell aplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1,4,64-68\">",
"       1,4,64-68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thrombocytopenia &mdash; Thrombocytopenia is seen in approximately 20 percent of patients, is moderate in severity, and may be associated with the presence of antiplatelet antibodies, making it difficult to distinguish from immune thrombocytopenia (ITP) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1\">",
"       1",
"      </a>",
"      ]. Splenomegaly may contribute, when present, and specific inhibition of megakaryocytic colony forming units (CFU-MK) by leukemic LGL has been reported in a patient with amegakaryocytic purpura [",
"      <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/69\">",
"       69",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"       \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Twenty to 30 percent of patients present with the typical \"B\" symptoms of lymphoma, which include one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/9,59\">",
"     9,59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unintentional weight loss &ge;10 percent of body weight within the previous six months",
"     </li>",
"     <li>",
"      Fevers of &gt;100.5&ordm;F (&gt;38&ordm;C) for &ge;2 weeks without evidence of infection",
"     </li>",
"     <li>",
"      Drenching night sweats without evidence of infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical examination reveals mild to moderate splenomegaly in 20 to 50 percent and hepatomegaly in up to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/9\">",
"     9",
"    </a>",
"    ]. Lymphadenopathy (1 to 3 percent) and skin involvement are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458740754\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic evaluation of involved tissues demonstrates infiltration with clonal LGLs of T cell lineage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/4,70\">",
"     4,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bone marrow is involved in about 90 percent of cases, with a pattern of scattered interstitial lymphocytic infiltrates. (See",
"      <a class=\"local\" href=\"#H113798352\">",
"       'Bone marrow'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Splenic involvement is almost universal, with LGL infiltration of sinuses and red pulp cords, prominent germinal centers, and plasma cell hyperplasia. (See",
"      <a class=\"local\" href=\"#H113798360\">",
"       'Spleen'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hepatic portal and sinusoidal areas are infiltrated with LGLs.",
"     </li>",
"     <li>",
"      Lymph nodes are not usually involved, but may show paracortical areas containing LGLs and plasma cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458745942\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113798345\">",
"    <span class=\"h3\">",
"     Peripheral blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute lymphocyte count in patients with T-LGL leukemia is usually modestly increased but may be normal, with a median lymphocyte count of",
"    <span class=\"nowrap\">",
"     8000/microL",
"    </span>",
"    (normal range: 1000 to",
"    <span class=\"nowrap\">",
"     4000/microL).",
"    </span>",
"    The absolute number of LGLs is increased; most patients with LGL leukemia have &gt;2000",
"    <span class=\"nowrap\">",
"     LGLs/microL,",
"    </span>",
"    with a median value of 4200",
"    <span class=\"nowrap\">",
"     LGLs/microL",
"    </span>",
"    (normal range 200 to 400",
"    <span class=\"nowrap\">",
"     LGLs/microL).",
"    </span>",
"    However, an absolute LGL count between 400 and 2000",
"    <span class=\"nowrap\">",
"     LGLs/microL",
"    </span>",
"    may be consistent with the diagnosis if the LGLs are clonal and the patient has a typical clinical presentation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    accompanying autoimmune disease. (See",
"    <a class=\"local\" href=\"#H458743514\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    LGLs are large (15 to 18 microns), measuring approximately twice the size of a normal red blood cell. LGLs are characterized by abundant cytoplasm containing fine or coarse azurophilic granules and a reniform or round nucleus with a high nuclear to cytoplasmic ratio (",
"    <a class=\"graphic graphic_picture graphicRef69027 \" href=\"UTD.htm?0/1/28\">",
"     picture 1",
"    </a>",
"    ). In approximately 5 percent of patients, cytoplasmic granules can be absent from these cells, despite a typical LGL immunophenotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113798352\">",
"    <span class=\"h3\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow can be hypocellular, normocellular, or slightly hypercellular with mild to moderate reticulin fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef81286 \" href=\"UTD.htm?13/10/13478\">",
"     picture 2",
"    </a>",
"    ). There is typically a shift in granulocyte maturation to more immature forms. The monoclonal LGLs usually account for &lt;50 percent of the nucleated cells. There is interstitial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intrasinusoidal infiltration of clonal (malignant) CD8 expressing T cells accompanied by lymphoid aggregates or nodules comprised of reactive (polyclonal) T and B cells. In one study, immunocytochemical staining of bone marrow biopsy sections showed linear arrays of intravascular CD8+, TIA-1+, or granzyme B+ lymphocytes in 67 percent of patients with T cell LGL leukemia and in none of 25 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113798360\">",
"    <span class=\"h3\">",
"     Spleen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic examination of the spleen demonstrates infiltration of the red pulp cords and sinusoids with lymphoid cells that express cytotoxic granule proteins (TIA-1, perforin, granzyme B) and do not express CD45RO or CD5. The architecture of the white pulp is typically preserved but may have expansion of the normal germinal centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458740768\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;T-LGL expansions show a mature post-thymic phenotype with a certain degree of membrane heterogeneity. The great majority of T-LGL leukemias express CD3, CD8, CD16, CD57, and the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    T cell receptor (TCR), but do not usually express CD4, CD56, or CD28 (",
"    <a class=\"graphic graphic_picture graphicRef81286 \" href=\"UTD.htm?13/10/13478\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1,72-75\">",
"     1,72-75",
"    </a>",
"    ]. Leukemic LGLs also constitutively express CD2, CD45RA, and IL-2 receptor beta (p75, CD122), but not IL-2 receptor alpha (p55, CD25). Some cells express CD4 antigen with or without coexpression of CD8. A",
"    <span class=\"nowrap\">",
"     CD4-/CD8-",
"    </span>",
"    phenotype has been rarely described. CD52 is also expressed on these cells. Killer immunoglobulin-like receptor (KIR, CD158) expression has been noted in approximately half of patients with T-LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. The uncommon",
"    <span class=\"nowrap\">",
"     CD3+/CD56+",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/79-82\">",
"     79-82",
"    </a>",
"    ] and",
"    <span class=\"nowrap\">",
"     CD3+/CD26+",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/83\">",
"     83",
"    </a>",
"    ] subtypes appear to have a more aggressive clinical behavior.",
"   </p>",
"   <p>",
"    The clonal nature of T-LGL leukemia is most easily accessed by molecular studies of the TCR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/84\">",
"     84",
"    </a>",
"    ]. The T cell beta chain variable region can be analyzed by flow cytometry. Additionally, murine monoclonal antibodies reactive against the human TCR variable region are commercially available to study the beta chain variable region (Vb) TCR repertoire. (See",
"    <a class=\"local\" href=\"#H458745436\">",
"     'Genetic features'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458745436\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of clonally rearranged T cell receptor (TCR) genes is a key factor in the diagnosis of T-LGL leukemia. Most cases are",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    variants. Less than 10 percent are",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    variants. The alpha gene is rearranged in cases expressing the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    TCR receptor, but may be germline in cases expressing the",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    TCR receptor. The analysis of TCR gene rearrangement is commonly assessed by polymerase chain reaction (PCR) analysis and less commonly by Southern blot. Clonal drift in T cell repertoire with a change in the dominant clone may be seen in approximately one-third of cases over the disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A minority of cases demonstrates numeric",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    structural chromosomal abnormalities; however, no characteristic gene abnormalities have been identified. Karyotype analysis is generally reserved for patients enrolled in clinical trials. Abnormalities involving chromosomes 7, 8, and 14 (ie, inversion, trisomy, translocation) have been described in selected patients, further demonstrating the clonal nature of this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/4,85\">",
"     4,85",
"    </a>",
"    ]. In addition, point mutations in STAT3 were found in 31 of 77 patients (40 percent) in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/29\">",
"     29",
"    </a>",
"    ]. Whether gene sequencing will play a role in the diagnosis of T-LGL in the future remains to be determined.",
"   </p>",
"   <p>",
"    Gene expression profiling of",
"    <span class=\"nowrap\">",
"     CD4-/CD8+",
"    </span>",
"    cells from 14 subjects with T-LGL leukemia have identified a number of genes whose expression was active in LGL T cells but silent in",
"    <span class=\"nowrap\">",
"     CD4-/CD8+",
"    </span>",
"    T cells from normal individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/86\">",
"     86",
"    </a>",
"    ]. The most specific finding was activation of the gene for interleukin-1 beta, confirmed by high serum levels of IL-1beta in 11 of 13 subjects with T cell LGL leukemia and in none of 13 normal controls. IL-1beta is a potent proinflammatory cytokine, and, along with tumor necrosis factor alpha, is known to have a central role in the tissue damage observed in rheumatoid arthritis, a disorder commonly associated with T cell LGL leukemia. (See",
"    <a class=\"local\" href=\"#H113797909\">",
"     'Autoimmune disorders'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathogenesis of rheumatoid arthritis\", section on 'Cytokine networks in rheumatoid arthritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458746029\">",
"    <span class=\"h2\">",
"     Serologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune abnormalities are frequently observed in patients with T-LGL leukemia (",
"    <a class=\"graphic graphic_table graphicRef73864 \" href=\"UTD.htm?15/20/15691\">",
"     table 2",
"    </a>",
"    ). Rheumatoid factor is the most common abnormality, present in approximately 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1\">",
"     1",
"    </a>",
"    ]. Antinuclear antibodies and circulating immune complexes are present in 40 and 55 percent, respectively.",
"   </p>",
"   <p>",
"    Serum protein electrophoresis shows hypergammaglobulinemia with a polyclonal pattern in about one-half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1\">",
"     1",
"    </a>",
"    ]. A monoclonal IgG gammopathy of either kappa or lambda subtype can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/14,87\">",
"     14,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458743514\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of T cell LGL leukemia is often suspected in a patient with neutropenia, recurrent infections, lymphocytosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia, commonly in the setting of rheumatoid arthritis. The diagnosis can usually be made based upon a morphologic and immunophenotypic analysis of the peripheral blood, which demonstrates increased numbers of clonal LGLs of T cell lineage (",
"    <a class=\"graphic graphic_algorithm graphicRef80765 \" href=\"UTD.htm?20/42/21167\">",
"     algorithm 1",
"    </a>",
"    ). Bone marrow aspirate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy may be required to confirm the diagnosis in some cases, especially those with low absolute numbers of circulating LGLs. Pathologic evaluation of the spleen is rarely required.",
"   </p>",
"   <p>",
"    Most patients present with a persistent peripheral blood lymphocytosis and an increased number of circulating LGLs. However, the total lymphocyte counts are normal in approximately 25 percent; in such patients, the diagnosis may be suspected only when increased numbers of LGLs are seen on careful examination of the peripheral blood smear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients with LGL leukemia have &gt;2000",
"    <span class=\"nowrap\">",
"     LGLs/microL,",
"    </span>",
"    however, an absolute LGL count between 400 and 2000",
"    <span class=\"nowrap\">",
"     LGLs/microL",
"    </span>",
"    may be consistent with the diagnosis if the LGLs are clonal and the patient has a typical clinical presentation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    accompanying autoimmune disease.",
"   </p>",
"   <p>",
"    LGL cells are identified by their morphology and their immunophenotype. They have a large size (15 to 18 microns), an abundant cytoplasm containing typical azurophilic granules, and a reniform or round nucleus (",
"    <a class=\"graphic graphic_picture graphicRef69027 \" href=\"UTD.htm?0/1/28\">",
"     picture 1",
"    </a>",
"    ). T cell LGL leukemia cells typically express CD3, CD8, CD16, CD57, and the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    T cell receptor (TCR), but do not usually express CD4, CD56, or CD28. In approximately 5 percent of patients, cytoplasmic granules can be absent from these cells, despite a typical LGL immunophenotype. Under these circumstances, LGL leukemia may be suspected because of neutropenia or lymphocytosis of uncertain cause. (See",
"    <a class=\"local\" href=\"#H458740754\">",
"     'Pathologic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458740775\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of T cell LGL leukemia includes a number of lymphomatous and leukemic conditions affecting T cells (",
"    <a class=\"graphic graphic_table graphicRef66306 \" href=\"UTD.htm?33/16/34059\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/9\">",
"     9",
"    </a>",
"    ]. In particular, T cell LGL leukemia must be differentiated from reactive LGL expansions, chronic lymphoproliferative disorders of NK cells, and aggressive NK cell leukemia. An approach has been suggested to establish the diagnosis of T cell or NK cell LGL leukemia (",
"    <a class=\"graphic graphic_algorithm graphicRef80765 \" href=\"UTD.htm?20/42/21167\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Monoclonal T cell LGL expansion has been reported following primary CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. LGL clonal expansions have also been described during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    therapy for chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Optimal molecular response seems to be correlated with LGL proliferation, raising the possibility of an aberrant immune reactivity induced by tyrosine kinase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458750509\">",
"    <span class=\"h2\">",
"     Reactive LGL expansions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the absolute number of large granular lymphocytes (LGLs) in the peripheral blood of normal subjects is 200 to",
"    <span class=\"nowrap\">",
"     400/microL.",
"    </span>",
"    Secondary benign (polyclonal) LGL expansions (ie, CD3+ cells with T cell receptor genes in germline configuration) have been reported in the setting of viral infections (eg, Epstein Barr virus, hepatitis B and C virus, HIV, cytomegalovirus), connective tissue disease, immune thrombocytopenia (ITP), non-Hodgkin lymphoma, various skin disorders, and the hemophagocytic syndrome (macrophage activation syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/1,72,94,95\">",
"     1,72,94,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7803724\">",
"    <span class=\"h2\">",
"     Felty's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Felty&rsquo;s syndrome (FS), the triad of chronic arthritis, splenomegaly, and granulocytopenia, typically occurs in patients with severe, longstanding, seropositive rheumatoid arthritis, often in association with other extra-articular manifestations. Some of these patients have proliferation of LGLs, and some patients previously diagnosed with FS would now be classified instead as having T-LGL leukemia, using current immunophenotyping techniques and molecular analyses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4247?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Felty's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The distinction between FS and T-LGL leukemia in patients with RA has generally been made based upon the determination of whether the LGL proliferation represents clonal expansion of cells, with those with polyclonality defined as having FS, and those with monoclonality as having LGL-leukemia. However, this distinction is not always clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=see_link&amp;anchor=H8862694#H8862694\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\", section on 'Felty's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7803413\">",
"    <span class=\"h2\">",
"     T cell clonopathy of unknown significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral blood of normal subjects usually contains 200 to 400 large granular lymphocytes per microL. Most patients with LGL leukemia have &gt;2000",
"    <span class=\"nowrap\">",
"     LGLs/microL;",
"    </span>",
"    however, an absolute LGL count between 400 and 2000",
"    <span class=\"nowrap\">",
"     LGLs/microL",
"    </span>",
"    may be consistent with the diagnosis if the LGLs are clonal and the patient has a typical clinical presentation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    accompanying autoimmune disease.",
"   </p>",
"   <p>",
"    Clonal or oligoclonal T cell LGL expansions have been described in patients who may be minimally symptomatic with only mild degrees of cytopenia. Such patients may represent a more benign end of the spectrum of clonal T cell LGL expansions. The term \"T cell clonopathy of unknown or undetermined significance\" has been applied to this group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/14,96\">",
"     14,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7803181\">",
"    <span class=\"h2\">",
"     Chronic lymphoproliferative disorders of NK cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphoproliferative disorder of NK cells is a provisional entity in the 2008 World Health Organization classification of mature T and NK cell neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/6\">",
"     6",
"    </a>",
"    ]. This group of disorders includes the entities also known as chronic NK cell lymphocytosis and NK cell LGL leukemia. The clinical presentation and peripheral blood morphology of patients with chronic lymphoproliferative disorders of NK cells is similar to that of patients with T cell LGL leukemia. The two may be distinguished by immunophenotype and genetic studies. NK cell disorders do not show rearrangement of the TCR genes and express CD56. In contrast, T cell LGL leukemias demonstrate clonal rearrangement of the TCR genes and typically do not express CD56. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=see_link&amp;anchor=H5#H5\">",
"     \"Natural killer (NK) cell large granular lymphocyte leukemia\", section on 'Chronic NK cell lymphocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458740782\">",
"    <span class=\"h2\">",
"     Aggressive NK cell leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive LGL leukemias have been described and typically present in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/97\">",
"     97",
"    </a>",
"    ]. All of the patients have presented with \"B\" symptoms and marked hepatosplenomegaly. Bone marrow infiltration and peripheral blood involvement by large neoplastic lymphocytes with both a CD3+ and CD56+ phenotype are observed. These patients probably have an illness similar to, if not identical to, the previously described aggressive CD3+, CD56+ variant of LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/80\">",
"     80",
"    </a>",
"    ]. The prognosis is very poor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=see_link&amp;anchor=H11#H11\">",
"     \"Natural killer (NK) cell large granular lymphocyte leukemia\", section on 'NK cell LGL leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458740789\">",
"    <span class=\"h2\">",
"     Hepatosplenic T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatosplenic T cell lymphoma (HSTL) is a neoplasm of mature",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cells that infiltrate the sinusoids of the spleen, liver, and bone marrow. HSTL is typically diagnosed in young men presenting with hepatosplenomegaly but without lymphadenopathy or peripheral blood lymphocytosis. Thrombocytopenia and anemia are common.",
"   </p>",
"   <p>",
"    Most cases of HSTL and T cell LGL leukemia express CD3 and CD16. Tumor cells in HSTL also express CD56 and the",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    TCR receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. In contrast, most cases of T cell LGL leukemia do not express CD56 and express the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    TCR receptor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4119?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458740796\">",
"    <span class=\"h2\">",
"     Post-transplant T cell lymphoproliferative disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most lymphoproliferative disorders occurring after solid organ or hematopoietic cell transplantation are of B cell origin. However, cases of T cell non-Hodgkin lymphoma have been reported post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. In one series, 3 of 24 post-transplant lymphomas were of T cell origin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/101\">",
"     101",
"    </a>",
"    ]. Pulmonary involvement, marrow infiltration, and a leukoerythroblastic reaction occurred in the majority of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/100\">",
"     100",
"    </a>",
"    ]. The phenotype is",
"    <span class=\"nowrap\">",
"     CD3+/CD8+",
"    </span>",
"    and, in one series, the CD56 antigen was expressed in two out of three cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/100\">",
"     100",
"    </a>",
"    ]. All patients displayed an aggressive clinical course. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of T cell LGL leukemia post-transplantation is no different from the diagnosis outside of the transplant setting. However, active cytomegalovirus (CMV) infection is not uncommon in the post-transplant setting and a reactive LGL expansion in the setting of CMV infection must be excluded prior to the diagnosis of T cell LGL leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458749928\">",
"    <span class=\"h2\">",
"     Aplastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is present in 50 percent of patients with T-LGL leukemia, with transfusion-dependent anemia in about 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/33/21018/abstract/61\">",
"     61",
"    </a>",
"    ]. Up to 5 percent of patients will have pancytopenia and fulfill clinical criteria for aplastic anemia. In such cases, the distinction between idiopathic aplastic anemia and T-LGL leukemia with pancytopenia may be difficult. Identification of substantial numbers of clonal T cells in the peripheral blood or bone marrow is diagnostic of T-LGL leukemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link&amp;anchor=H19#H19\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458745428\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large granular lymphocyte (LGL) leukemia is a clonal disease of the large granular lymphocyte characterized by peripheral blood and marrow lymphocytic infiltration with LGLs, splenomegaly, and cytopenias, most commonly neutropenia. LGL leukemia can be of T- or NK cell lineage. (See",
"      <a class=\"local\" href=\"#H458739477\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T cell LGL leukemia is an uncommon disorder that typically presents in the sixth decade of life. Approximately 40 percent of patients have an associated condition, most commonly rheumatoid arthritis or an autoimmune cytopenia (",
"      <a class=\"graphic graphic_table graphicRef64762 \" href=\"UTD.htm?4/2/4141\">",
"       table 1",
"      </a>",
"      ). The cause of T cell LGL leukemia is not known, but is postulated to be due to exposure to a common antigen. (See",
"      <a class=\"local\" href=\"#H113797895\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H458750948\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately one-third of patients are asymptomatic when a routine blood count reveals a cytopenia, leading to the diagnosis of T cell LGL leukemia. The most common symptoms are related to cytopenias and include fever and recurrent bacterial infections related to neutropenia. Neutropenia, anemia, and thrombocytopenia are present in approximately 85, 50, and 20 percent of patients at diagnosis, respectively. Twenty to 30 percent present with the typical \"B\" symptoms of lymphoma (ie, weight loss, fevers, night sweats). Splenomegaly is common, while lymphadenopathy and skin involvement are rare. (See",
"      <a class=\"local\" href=\"#H458740684\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pathologic evaluation of involved tissues demonstrates infiltration with clonal LGLs of T cell lineage. LGLs are large (15 to 18 microns), measuring approximately twice the size of a normal red blood cell. LGLs are characterized by abundant cytoplasm containing fine or coarse azurophilic granules and a reniform or round nucleus with a high nuclear to cytoplasmic ratio (",
"      <a class=\"graphic graphic_picture graphicRef69027 \" href=\"UTD.htm?0/1/28\">",
"       picture 1",
"      </a>",
"      ). LGLs comprise 10 to 15 percent of normal peripheral blood mononuclear cells. The absolute number of LGLs in the peripheral blood of normal subjects is 200 to",
"      <span class=\"nowrap\">",
"       400/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H113798345\">",
"       'Peripheral blood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis can usually be made based upon a morphologic and immunophenotypic analysis of the peripheral blood, which demonstrates increased numbers of clonal LGLs of T cell lineage (",
"      <a class=\"graphic graphic_algorithm graphicRef80765 \" href=\"UTD.htm?20/42/21167\">",
"       algorithm 1",
"      </a>",
"      ). Bone marrow aspirate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biopsy may be required to confirm the diagnosis in some cases, especially those with low absolute numbers of circulating LGLs. T cell LGL leukemia cells typically express CD3, CD8, CD16, CD57, and the",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      T cell receptor, but do not usually express CD4, CD56, or CD28. (See",
"      <a class=\"local\" href=\"#H458743514\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H458740768\">",
"       'Immunophenotype'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H458745436\">",
"       'Genetic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of T cell LGL leukemia includes a number of lymphomatous and leukemic conditions affecting T cells (",
"      <a class=\"graphic graphic_table graphicRef66306 \" href=\"UTD.htm?33/16/34059\">",
"       table 3",
"      </a>",
"      ). In particular, T cell LGL leukemia must be differentiated from reactive LGL expansions, chronic lymphoproliferative disorders of NK cells, and aggressive NK cell leukemia. (See",
"      <a class=\"local\" href=\"#H458740775\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/1\">",
"      Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/2\">",
"      Lamy T, Loughran TP Jr. Clinical features of large granular lymphocyte leukemia. Semin Hematol 2003; 40:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/3\">",
"      McKenna RW, Parkin J, Kersey JH, et al. Chronic lymphoproliferative disorder with unusual clinical, morphologic, ultrastructural and membrane surface marker characteristics. Am J Med 1977; 62:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/4\">",
"      Loughran TP Jr, Kadin ME, Starkebaum G, et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med 1985; 102:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/5\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/6\">",
"      Lim MS. Commentary on the WHO 2008 classification of neoplasms arising from histiocytic and other accessory cells. J Hematop 2009; 2:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/7\">",
"      Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/8\">",
"      Boeckx N, Uyttebroeck A, Langerak AW, et al. Clonal proliferation of T-Cell large granular lymphocytes. Pediatr Blood Cancer 2004; 42:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/9\">",
"      Lamy T, Loughran TP. Large Granular Lymphocyte Leukemia. Cancer Control 1998; 5:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/10\">",
"      Bareau B, Rey J, Hamidou M, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 2010; 95:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/11\">",
"      Zhang R, Shah MV, Loughran TP Jr. The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol 2010; 28:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/12\">",
"      Viny AD, Lichtin A, Pohlman B, et al. Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia. Leuk Lymphoma 2008; 49:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/13\">",
"      Howard MT, Bejanyan N, Maciejewski JP, Hsi ED. T/NK large granular lymphocyte leukemia and coexisting monoclonal B-cell lymphocytosis-like proliferations. An unrecognized and frequent association. Am J Clin Pathol 2010; 133:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/14\">",
"      Dhodapkar MV, Li CY, Lust JA, et al. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 1994; 84:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/15\">",
"      Hanada T, Ishida T, Kojima H, Tsuchiya T. Granular lymphocyte leukaemia in association with multiple myeloma. Br J Haematol 1992; 80:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/16\">",
"      Broome HE, Wang HY. A case of concomitant T-cell large granular lymphocytic leukemia and plasma cell myeloma. Clin Adv Hematol Oncol 2011; 9:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/17\">",
"      Saunthararajah Y, Molldrem JL, Rivera M, et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol 2001; 112:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/18\">",
"      Gorochov G, Debr&eacute; P, Leblond V, et al. Oligoclonal expansion of CD8+ CD57+ T cells with restricted T-cell receptor beta chain variability after bone marrow transplantation. Blood 1994; 83:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/19\">",
"      Au WY, Lam CC, Lie AK, et al. T-cell large granular lymphocyte leukemia of donor origin after allogeneic bone marrow transplantation. Am J Clin Pathol 2003; 120:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/20\">",
"      Dolstra H, Preijers F, Van de Wiel-van Kemenade E, et al. Expansion of CD8+CD57+ T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. Br J Haematol 1995; 90:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/21\">",
"      Feher O, Barilla D, Locker J, et al. T-cell large granular lymphocytic leukemia following orthotopic liver transplantation. Am J Hematol 1995; 49:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/22\">",
"      Gentile TC, Hadlock KG, Uner AH, et al. Large granular lymphocyte leukaemia occurring after renal transplantation. Br J Haematol 1998; 101:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/23\">",
"      Dearden C. Large granular lymphocytic leukaemia pathogenesis and management. Br J Haematol 2011; 152:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/24\">",
"      Yang J, Epling-Burnette PK, Painter JS, et al. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood 2008; 111:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/25\">",
"      Wlodarski MW, O'Keefe C, Howe EC, et al. Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood 2005; 106:2769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/26\">",
"      Garrido P, Ruiz-Cabello F, B&aacute;rcena P, et al. Monoclonal TCR-Vbeta13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. Blood 2007; 109:4890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/27\">",
"      Clemente MJ, Wlodarski MW, Makishima H, et al. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood 2011; 118:4384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/28\">",
"      Wlodarski MW, Nearman Z, Jankowska A, et al. Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia. J Leukoc Biol 2008; 83:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/29\">",
"      Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/30\">",
"      Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012; 120:3048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/31\">",
"      Berliner N, Horwitz M, Loughran TP Jr. Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program 2004; :63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/32\">",
"      Liles WC, Kiener PA, Ledbetter JA, et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/33\">",
"      Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med 1996; 2:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/34\">",
"      Perzova R, Loughran TP Jr. Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Br J Haematol 1997; 97:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/35\">",
"      Liu JH, Wei S, Lamy T, et al. Chronic neutropenia mediated by fas ligand. Blood 2000; 95:3219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/36\">",
"      Osuji N, Matutes E, Dearden C, Catovsky D. Pregnancy improves neutropenia in T-cell large granular lymphocyte leukaemia. Br J Haematol 2005; 128:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/37\">",
"      Sokol L, Agrawal D, Loughran TP Jr. Characterization of HTLV envelope seroreactivity in large granular lymphocyte leukemia. Leuk Res 2005; 29:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/38\">",
"      Loughran TP Jr, Hadlock KG, Perzova R, et al. Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia. Br J Haematol 1998; 101:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/39\">",
"      Loughran TP Jr, Hadlock KG, Yang Q, et al. Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes. Blood 1997; 90:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/40\">",
"      Loughran TP Jr, Coyle T, Sherman MP, et al. Detection of human T-cell leukemia/lymphoma virus, type II, in a patient with large granular lymphocyte leukemia. Blood 1992; 80:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/41\">",
"      Loughran TP Jr, Sherman MP, Ruscetti FW, et al. Prototypical HTLV-I/II infection is rare in LGL leukemia. Leuk Res 1994; 18:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/42\">",
"      Thomas A, Perzova R, Abbott L, et al. LGL leukemia and HTLV. AIDS Res Hum Retroviruses 2010; 26:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/43\">",
"      Perzova RN, Loughran TP, Dube S, et al. Lack of BLV and PTLV DNA sequences in the majority of patients with large granular lymphocyte leukaemia. Br J Haematol 2000; 109:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/44\">",
"      Nearman ZP, Wlodarski M, Jankowska AM, et al. Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol 2007; 136:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/45\">",
"      Gentile TC, Loughran TP Jr. Interleukin-12 is a costimulatory cytokine for leukemic CD3+ large granular lymphocytes. Cell Immunol 1995; 166:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/46\">",
"      Zambello R, Trentin L, Cassatella MA, et al. IL-12 is involved in the activation of CD3+ granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Br J Haematol 1996; 92:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/47\">",
"      Zambello R, Facco M, Trentin L, et al. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood 1997; 89:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/48\">",
"      Chen J, Petrus M, Bamford R, et al. Increased serum soluble IL-15R&alpha; levels in T-cell large granular lymphocyte leukemia. Blood 2012; 119:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/49\">",
"      Kothapalli R, Bailey RD, Kusmartseva I, et al. Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol 2003; 22:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/50\">",
"      Lamy T, Liu JH, Landowski TH, et al. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood 1998; 92:4771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/51\">",
"      Liu JH, Wei S, Lamy T, et al. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood 2002; 100:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/52\">",
"      Shah MV, Zhang R, Loughran TP Jr. Never say die: survival signaling in large granular lymphocyte leukemia. Clin Lymphoma Myeloma 2009; 9 Suppl 3:S244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/53\">",
"      Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001; 107:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/54\">",
"      Schade AE, Powers JJ, Wlodarski MW, Maciejewski JP. Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood 2006; 107:4834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/55\">",
"      Shah MV, Zhang R, Irby R, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008; 112:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/56\">",
"      Hodge DL, Yang J, Buschman MD, et al. Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias. Cancer Res 2009; 69:3986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/57\">",
"      Zhang R, Shah MV, Yang J, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A 2008; 105:16308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/58\">",
"      Yang J, Liu X, Nyland SB, et al. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2010; 115:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/59\">",
"      Pandolfi F, Loughran TP Jr, Starkebaum G, et al. Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer 1990; 65:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/60\">",
"      Bourgault-Rouxel AS, Loughran TP Jr, Zambello R, et al. Clinical spectrum of gammadelta+ T cell LGL leukemia: analysis of 20 cases. Leuk Res 2008; 32:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/61\">",
"      Go RS, Tefferi A, Li CY, et al. Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood 2000; 96:3644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/62\">",
"      Loughran TP Jr, Clark EA, Price TH, Hammond WP. Adult-onset cyclic neutropenia is associated with increased large granular lymphocytes. Blood 1986; 68:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/63\">",
"      Loughran TP Jr, Hammond WP 4th. Adult-onset cyclic neutropenia is a benign neoplasm associated with clonal proliferation of large granular lymphocytes. J Exp Med 1986; 164:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/64\">",
"      Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996; 87:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/65\">",
"      Dhodapkar MV, Lust JA, Phyliky RL. T-cell large granular lymphocytic leukemia and pure red cell aplasia in a patient with type I autoimmune polyendocrinopathy: response to immunosuppressive therapy. Mayo Clin Proc 1994; 69:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/66\">",
"      Kwong YL, Wong KF, Chan LC, et al. Large granular lymphocyte leukemia. A study of nine cases in a Chinese population. Am J Clin Pathol 1995; 103:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/67\">",
"      Hoffman R, Kopel S, Hsu SD, et al. T cell chronic lymphocytic leukemia: presence in bone marrow and peripheral blood of cells that suppress erythropoiesis in vitro. Blood 1978; 52:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/68\">",
"      Hara T, Mizuno Y, Nagata M, et al. Human gamma delta T-cell receptor-positive cell-mediated inhibition of erythropoiesis in vitro in a patient with type I autoimmune polyglandular syndrome and pure red blood cell aplasia. Blood 1990; 75:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/69\">",
"      Kouides PA, Rowe JM. Large granular lymphocyte leukemia presenting with both amegakaryocytic thrombocytopenic purpura and pure red cell aplasia: clinical course and response to immunosuppressive therapy. Am J Hematol 1995; 49:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/70\">",
"      Agnarsson BA, Loughran TP Jr, Starkebaum G, Kadin ME. The pathology of large granular lymphocyte leukemia. Hum Pathol 1989; 20:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/71\">",
"      Morice WG, Kurtin PJ, Tefferi A, Hanson CA. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood 2002; 99:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/72\">",
"      Oshimi K. Granular lymphocyte proliferative disorders: report of 12 cases and review of the literature. Leukemia 1988; 2:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/73\">",
"      Semenzato G, Pandolfi F, Chisesi T, et al. The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer 1987; 60:2971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/74\">",
"      Morice WG, Kurtin PJ, Leibson PJ, et al. Demonstration of aberrant T-cell and natural killer-cell antigen expression in all cases of granular lymphocytic leukaemia. Br J Haematol 2003; 120:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/75\">",
"      Bigouret V, Hoffmann T, Arlettaz L, et al. Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors. Blood 2003; 101:3198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/76\">",
"      Handgretinger R, Geiselhart A, Moris A, et al. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med 1999; 340:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/77\">",
"      Zambello R, Semenzato G. Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes. Semin Hematol 2003; 40:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/78\">",
"      Nowakowski GS, Morice WG, Phyliky RL, et al. Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia. Br J Haematol 2005; 128:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/79\">",
"      Scott CS, Richards SJ. Classification of large granular lymphocyte (LGL) and NK-associated (NKa) disorders. Blood Rev 1992; 6:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/80\">",
"      Gentile TC, Uner AH, Hutchison RE, et al. CD3+, CD56+ aggressive variant of large granular lymphocyte leukemia. Blood 1994; 84:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/81\">",
"      Matutes E, Wotherspoon AC, Parker NE, et al. Transformation of T-cell large granular lymphocyte leukaemia into a high-grade large T-cell lymphoma. Br J Haematol 2001; 115:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/82\">",
"      Alekshun TJ, Tao J, Sokol L. Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature. Am J Hematol 2007; 82:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/83\">",
"      Dang NH, Aytac U, Sato K, et al. T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. Br J Haematol 2003; 121:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/84\">",
"      Melenhorst JJ, Sorbara L, Kirby M, et al. Large granular lymphocyte leukaemia is characterized by a clonal T-cell receptor rearrangement in both memory and effector CD8(+) lymphocyte populations. Br J Haematol 2001; 112:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/85\">",
"      Wong KF, Chan JC, Liu HS, et al. Chromosomal abnormalities in T-cell large granular lymphocyte leukaemia: report of two cases and review of the literature. Br J Haematol 2002; 116:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/86\">",
"      Makishima H, Ishida F, Ito T, et al. DNA microarray analysis of T cell-type lymphoproliferative disease of granular lymphocytes. Br J Haematol 2002; 118:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/87\">",
"      Bassan R, Pronesti M, Buzzetti M, et al. Autoimmunity and B-cell dysfunction in chronic proliferative disorders of large granular lymphocytes/natural killer cells. Cancer 1989; 63:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/88\">",
"      Rossi D, Franceschetti S, Capello D, et al. Transient monoclonal expansion of CD8+/CD57+ T-cell large granular lymphocytes after primary cytomegalovirus infection. Am J Hematol 2007; 82:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/89\">",
"      Rodr&iacute;guez-Caballero A, Garc&iacute;a-Montero AC, B&aacute;rcena P, et al. Expanded cells in monoclonal TCR-alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood 2008; 112:4609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/90\">",
"      Powers JJ, Dubovsky JA, Epling-Burnette PK, et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011; 52:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/91\">",
"      Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010; 116:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/92\">",
"      Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/93\">",
"      Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009; 94:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/94\">",
"      Okuno SH, Tefferi A, Hanson CA, et al. Spectrum of diseases associated with increased proportions or absolute numbers of peripheral blood natural killer cells. Br J Haematol 1996; 93:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/95\">",
"      Imashuku S, Hibi S, Morinaga S, et al. Haemophagocytic lymphohistiocytosis in association with granular lymphocyte proliferative disorders in early childhood: characteristic bone marrow morphology. Br J Haematol 1997; 96:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/96\">",
"      Sabnani I, Tsang P. Are clonal T-cell large granular lymphocytes to blame for unexplained haematological abnormalities? Br J Haematol 2007; 136:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/97\">",
"      Macon WR, Williams ME, Greer JP, et al. Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes. Blood 1996; 87:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/98\">",
"      Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996; 88:4265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/99\">",
"      Fran&ccedil;ois A, Lesesve JF, Stamatoullas A, et al. Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. Am J Surg Pathol 1997; 21:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/100\">",
"      Hanson MN, Morrison VA, Peterson BA, et al. Posttransplant T-cell lymphoproliferative disorders--an aggressive, late complication of solid-organ transplantation. Blood 1996; 88:3626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/33/21018/abstract/101\">",
"      Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13:961.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16360 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21018=[""].join("\n");
var outline_f20_33_21018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H458745428\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458739477\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113797895\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H113797902\">",
"      Associated disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H113797909\">",
"      - Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H113797941\">",
"      - Other hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458750948\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3154436\">",
"      Role of human T-lymphotropic virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3154444\">",
"      Role of cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3154452\">",
"      Role of apoptotic pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458740684\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458740754\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458745942\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H113798345\">",
"      - Peripheral blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H113798352\">",
"      - Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H113798360\">",
"      - Spleen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458740768\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458745436\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458746029\">",
"      Serologic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458743514\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458740775\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458750509\">",
"      Reactive LGL expansions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7803724\">",
"      Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7803413\">",
"      T cell clonopathy of unknown significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7803181\">",
"      Chronic lymphoproliferative disorders of NK cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458740782\">",
"      Aggressive NK cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458740789\">",
"      Hepatosplenic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458740796\">",
"      Post-transplant T cell lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458749928\">",
"      Aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458745428\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/16360\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16360|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/42/21167\" title=\"algorithm 1\">",
"      Evaluation for LGL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16360|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/1/28\" title=\"picture 1\">",
"      Large granular lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/10/13478\" title=\"picture 2\">",
"      Bone marrow features of T-LGL leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16360|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/2/4141\" title=\"table 1\">",
"      Diseases associated with T-LGL leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/20/15691\" title=\"table 2\">",
"      Serologic findings in LGL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/16/34059\" title=\"table 3\">",
"      Differential diagnosis of T-LGL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4247?source=related_link\">",
"      Clinical manifestations and diagnosis of Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4119?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=related_link\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=related_link\">",
"      Large granular lymphocyte leukemia in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=related_link\">",
"      Natural killer (NK) cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=related_link\">",
"      Normal neutrophil development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=related_link\">",
"      Treatment of large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_33_21019="Disorders treated HCT";
var content_f20_33_21019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunodeficiency diseases which may be corrected by hematopoietic cell transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lymphocyte defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe combined immunodeficiency (multiple types)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wiskott-Aldrich syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD40 ligand deficiency (X-linked hyper IgM syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD40 deficiency (autosomal recessive hyper IgM syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X-linked lymphoproliferative disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferon gamma receptor defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NF kappa B essential modifier (NEMO) deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemophagocytic lymphohistiocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Phagocyte defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic granulomatous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocyte adhesion deficiency type 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Griscelli syndrome type 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chediak-Higashi syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21019=[""].join("\n");
var outline_f20_33_21019=null;
var title_f20_33_21020="FAB classification of MDS";
var content_f20_33_21020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    French-American-British (FAB) cooperative group criteria for myelodysplastic syndrome subtypes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Bone marrow blasts, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Peripheral blood blasts, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Auer rods",
"      </td>",
"      <td class=\"subtitle1\">",
"       Monocytes &gt;1000/&micro;L",
"      </td>",
"      <td class=\"subtitle1\">",
"       Ringed sideroblasts, &gt;15 percent of nucleated erythroid cells",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RA",
"      </td>",
"      <td>",
"       &lt;5",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &le;1",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RARS",
"      </td>",
"      <td>",
"       &lt;5",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &le;1",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RAEB",
"      </td>",
"      <td>",
"       5-20",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &lt;5",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &plusmn;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CMML",
"      </td>",
"      <td>",
"       &le;20",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &lt;5",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       &plusmn;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RAEB-T*",
"      </td>",
"      <td>",
"       21-30",
"      </td>",
"      <td>",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"      <td>",
"       &ge;5",
"      </td>",
"      <td>",
"       &plusmn;",
"      </td>",
"      <td>",
"       &plusmn;",
"      </td>",
"      <td>",
"       &plusmn;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FAB: French-American-British; RA: refractory anemia; RARS: refractory anemia with ringed sideroblasts; RAEB: refractory anemia with excess blasts; CMML: chronic myelomonocytic leukemia; RAEB-T: refractory anemia with excess blasts in transformation.",
"     <br>",
"      * Editor's note: The World Health Organization (WHO) classification considers RAEB-T to represent either an evolving acute myeloid leukemia (AML) or AML with multilineage dysplasia.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bennett, JM, Catovsky, D, Daniel, MT, et al. FAB Cooperative Group: Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189., and Greenberg, PL. The Myelodysplastic Syndromes. In: Hematology: Basic Principles and Practice, 2nd ed, Hoffman, R, Benz, E, Shattil, S (Eds), Churchill Livingstone, New York, 1994, p. 1098.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21020=[""].join("\n");
var outline_f20_33_21020=null;
var title_f20_33_21021="Clinical manifestations - Brucellosis";
var content_f20_33_21021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations - Brucellosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Literature reference",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Percent of patients reporting condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Fever",
"        <br/>",
"        (symptom)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Malaise",
"       </td>",
"       <td class=\"subtitle2\">",
"        Night perspiration",
"       </td>",
"       <td class=\"subtitle2\">",
"        Arthralgia",
"       </td>",
"       <td class=\"subtitle2\">",
"        Temperature",
"        <br/>",
"        (sign)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Hepatomegaly",
"       </td>",
"       <td class=\"subtitle2\">",
"        Splenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aygen, et al. 2002",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yinnon, et al. 1993",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Memish, et al. 2000",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Andriopoulos, et al. 2007",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shehabi, et al. 1990",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demiroglu, et al. 2007",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tasbakan, et al. 2003",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pourbagher, et al. 2006",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trujillo, et al. 1994",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buchanan, et al. 1974",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kokoglu, et al. 2006",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bosilkovski, et al. 2010",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Frequency of clinical characteristics in patients with brucellosis, as reported in the literature and in the CMJ study.",
"    <div class=\"footnotes\">",
"     ND: not determined.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bosilkovski M, Krteva L, Dimova M, et al. Human Brucellosis in Macedonia &ndash; 10 years of Clinical Experience in Endemic Region. Croat Med J 2010; 51:327. Copyright &copy; 2010 Croatian Medical Journal.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21021=[""].join("\n");
var outline_f20_33_21021=null;
var title_f20_33_21022="Thyroid hormone action part B";
var content_f20_33_21022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Mediation of thyroid hormone action",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 200px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Binding of T3 disrupts binding of co-repressor (CoR) to the thyroid hormone receptor (TR) retinoid X receptor (RXR) heterodimer, promotes binding of co-activator (CoA), and increases mRNA expression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Refetoff S, Weiss RE. Resistance to thyroid hormone. In: Molecular Genetics of Endocrine Disorders, Thakker TV (Ed), Chapman &amp; Hill, London, 1997, p.89.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21022=[""].join("\n");
var outline_f20_33_21022=null;
var title_f20_33_21023="Eval chest pain normal exam";
var content_f20_33_21023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Normal physical examination",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 465px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic approach to evaluation of pediatric patient with chest pain in whom the physical examination is normal. For details about the various conditions, see text.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Brenner, JI, Ringel, RE, Berman, MA. Cardiologic perspectives of chest pain in childhood: a referral problem? To whom? Pediatr Clin North Am 1984; 31:1241.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_33_21023=[""].join("\n");
var outline_f20_33_21023=null;
